{"PMC7235521": [["Silently and without fanfare, the virus transferred from its natural wildlife host into the first human.", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["fanfare", "TREATMENT", 21, 28], ["the virus", "PROBLEM", 30, 39], ["without", "UNCERTAINTY", 13, 20], ["virus", "OBSERVATION", 34, 39]]], ["The resulting illness was not severe or clinically distinct, because respiratory infections are so common that cough and fever afflict many citizens every winter.", [["respiratory", "ANATOMY", 69, 80], ["illness", "DISEASE", 14, 21], ["respiratory infections", "DISEASE", 69, 91], ["cough", "DISEASE", 111, 116], ["fever", "DISEASE", 121, 126], ["The resulting illness", "PROBLEM", 0, 21], ["respiratory infections", "PROBLEM", 69, 91], ["cough", "PROBLEM", 111, 116], ["fever", "PROBLEM", 121, 126], ["illness", "OBSERVATION", 14, 21], ["infections", "OBSERVATION", 81, 91]]], ["Facilitated by coughing, the virus continued on its way, passing from person to person with a basic reproductive number of between 2 and 3.", [["person", "SPECIES", 70, 76], ["person", "SPECIES", 80, 86], ["coughing", "PROBLEM", 15, 23], ["the virus", "PROBLEM", 25, 34], ["coughing", "OBSERVATION", 15, 23], ["virus", "OBSERVATION", 29, 34]]], ["Only when it reached substantial numbers of frail, elderly people did it attract medical attention.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Investigation into this latest outbreak identified a novel strain of virus from a family known to cause respiratory infection in humans and to readily infect other species of animals.", [["respiratory", "ANATOMY", 104, 115], ["respiratory infection", "DISEASE", 104, 125], ["humans", "ORGANISM", 129, 135], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["a novel strain of virus", "PROBLEM", 51, 74], ["respiratory infection in humans", "PROBLEM", 104, 135], ["infection", "OBSERVATION", 116, 125]]], ["There were no licensed antiviral drugs or vaccines specific for this strain, so public health officials had to apply the time\u2010honoured technique of quarantine, first used in Venice in 1448, to bring the outbreak under control.1", [["licensed antiviral drugs", "TREATMENT", 14, 38], ["vaccines", "TREATMENT", 42, 50], ["this strain", "PROBLEM", 64, 75], ["no", "UNCERTAINTY", 11, 13], ["antiviral drugs", "OBSERVATION", 23, 38]]]], "PMC6146581": [["IntroductionIn 1884, Waldeyer first described an annular arrangement of lymphatic tissue at the entrance of the aerodigestive tract, which he suggested plays an important part in the host immune system, including the palatine tonsils, pharyngeal tonsil, lingual tonsils and tubal tonsils 1.", [["lymphatic tissue", "ANATOMY", 72, 88], ["aerodigestive tract", "ANATOMY", 112, 131], ["immune system", "ANATOMY", 188, 201], ["palatine tonsils", "ANATOMY", 217, 233], ["pharyngeal tonsil", "ANATOMY", 235, 252], ["lingual tonsils", "ANATOMY", 254, 269], ["tubal tonsils", "ANATOMY", 274, 287], ["lymphatic tissue", "TISSUE", 72, 88], ["aerodigestive tract", "ORGAN", 112, 131], ["immune system", "ANATOMICAL_SYSTEM", 188, 201], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 217, 233], ["pharyngeal tonsil", "MULTI-TISSUE_STRUCTURE", 235, 252], ["lingual tonsils", "MULTI-TISSUE_STRUCTURE", 254, 269], ["lymphatic tissue", "PROBLEM", 72, 88], ["pharyngeal tonsil, lingual tonsils and tubal tonsils", "PROBLEM", 235, 287], ["annular", "OBSERVATION_MODIFIER", 49, 56], ["lymphatic tissue", "OBSERVATION", 72, 88], ["aerodigestive tract", "ANATOMY", 112, 131], ["palatine tonsils", "ANATOMY", 217, 233], ["pharyngeal tonsil", "ANATOMY", 235, 252], ["lingual tonsils", "ANATOMY", 254, 269], ["tubal tonsils", "ANATOMY", 274, 287]]], ["Especially the palatine as well as pharyngeal tonsils are known to play a key role in the development of the human host defense due to their location, histologic anatomy and functional capacities 2.", [["palatine", "ANATOMY", 15, 23], ["pharyngeal tonsils", "ANATOMY", 35, 53], ["palatine", "ORGAN", 15, 23], ["pharyngeal tonsils", "MULTI-TISSUE_STRUCTURE", 35, 53], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["pharyngeal tonsils", "PROBLEM", 35, 53], ["palatine", "ANATOMY", 15, 23], ["pharyngeal tonsils", "ANATOMY", 35, 53], ["functional capacities", "OBSERVATION", 174, 195]]], ["These structures harbour numerous different types of tissues, including epithelium, lymphoid follicles, blood vessels and connective tissues 34.", [["tissues", "ANATOMY", 53, 60], ["epithelium", "ANATOMY", 72, 82], ["lymphoid follicles", "ANATOMY", 84, 102], ["blood vessels", "ANATOMY", 104, 117], ["connective tissues", "ANATOMY", 122, 140], ["tissues", "TISSUE", 53, 60], ["epithelium", "TISSUE", 72, 82], ["lymphoid follicles", "MULTI-TISSUE_STRUCTURE", 84, 102], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 104, 117], ["connective tissues", "TISSUE", 122, 140], ["epithelium, lymphoid follicles, blood vessels and connective tissues", "PROBLEM", 72, 140], ["harbour", "OBSERVATION_MODIFIER", 17, 24], ["numerous", "OBSERVATION_MODIFIER", 25, 33], ["different types", "OBSERVATION_MODIFIER", 34, 49], ["tissues", "ANATOMY", 53, 60], ["epithelium", "ANATOMY_MODIFIER", 72, 82], ["lymphoid follicles", "OBSERVATION", 84, 102], ["blood vessels", "ANATOMY", 104, 117], ["connective tissues", "OBSERVATION", 122, 140]]], ["The combination of these different tissues as well as their anatomic arrangement in crypts facilitates optimised exposure and processing of antigens, which aid in evoking effective immune responses 56.", [["tissues", "ANATOMY", 35, 42], ["crypts", "ANATOMY", 84, 90], ["tissues", "TISSUE", 35, 42], ["crypts", "MULTI-TISSUE_STRUCTURE", 84, 90], ["antigens", "PROTEIN", 140, 148], ["these different tissues", "PROBLEM", 19, 42], ["different tissues", "OBSERVATION", 25, 42]]], ["The palatine as well as the pharyngeal tonsils are secondary lymphoid organs and an integral part of the mucosa associated lymphatic tissue complex 7.", [["palatine", "ANATOMY", 4, 12], ["pharyngeal tonsils", "ANATOMY", 28, 46], ["lymphoid organs", "ANATOMY", 61, 76], ["mucosa", "ANATOMY", 105, 111], ["lymphatic tissue", "ANATOMY", 123, 139], ["palatine", "ORGAN", 4, 12], ["pharyngeal tonsils", "MULTI-TISSUE_STRUCTURE", 28, 46], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 61, 76], ["mucosa", "MULTI-TISSUE_STRUCTURE", 105, 111], ["lymphatic tissue", "TISSUE", 123, 139], ["secondary lymphoid organs", "PROBLEM", 51, 76], ["the mucosa associated lymphatic tissue complex", "PROBLEM", 101, 147], ["palatine", "ANATOMY", 4, 12], ["pharyngeal tonsils", "ANATOMY", 28, 46], ["secondary lymphoid organs", "OBSERVATION", 51, 76], ["mucosa", "ANATOMY", 105, 111], ["lymphatic tissue", "OBSERVATION", 123, 139]]], ["Multiplication, differentiation and stimulation of B-lymphocytes represent one of their major functions and are essential in processing the specific immune response 8.", [["B-lymphocytes", "ANATOMY", 51, 64], ["B-lymphocytes", "CELL", 51, 64], ["B-lymphocytes", "CELL_TYPE", 51, 64]]], ["B-lymphocytes constitute more than 50% of the tonsillar lymphocyte population, in contrast to the blood and other lymphoid organs 910.", [["B-lymphocytes", "ANATOMY", 0, 13], ["tonsillar lymphocyte", "ANATOMY", 46, 66], ["blood", "ANATOMY", 98, 103], ["lymphoid organs", "ANATOMY", 114, 129], ["B-lymphocytes", "CELL", 0, 13], ["tonsillar lymphocyte population", "CELL", 46, 77], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 114, 129], ["B-lymphocytes", "CELL_TYPE", 0, 13], ["tonsillar lymphocyte population", "CELL_TYPE", 46, 77], ["B-lymphocytes", "TEST", 0, 13], ["the tonsillar lymphocyte population", "PROBLEM", 42, 77], ["lymphocytes", "ANATOMY", 2, 13], ["tonsillar", "ANATOMY", 46, 55], ["lymphocyte population", "OBSERVATION", 56, 77], ["blood", "ANATOMY", 98, 103], ["lymphoid organs", "OBSERVATION", 114, 129]]], ["The induction of the tonsillar-specific immune responses involves several distinct processes where chemokines play an integral role 11-14.", [["tonsillar", "ANATOMY", 21, 30], ["tonsillar", "ORGAN", 21, 30], ["chemokines", "PROTEIN", 99, 109], ["an integral role", "TEST", 115, 131], ["tonsillar", "ANATOMY", 21, 30]]], ["Chemokines are chemotactic cytokines, which can be classified into four subgroups depending on their arrangement of amino acids, namely CXC-, CC-, C- and CX3C-chemokines 1516.", [["amino acids", "CHEMICAL", 116, 127], ["amino acids", "CHEMICAL", 116, 127], ["amino acids", "AMINO_ACID", 116, 127], ["CXC", "GENE_OR_GENE_PRODUCT", 136, 139], ["C", "SIMPLE_CHEMICAL", 147, 148], ["Chemokines", "PROTEIN", 0, 10], ["chemotactic cytokines", "PROTEIN", 15, 36], ["CXC", "PROTEIN", 136, 139], ["CC", "PROTEIN", 142, 144], ["C", "PROTEIN", 147, 148], ["CX3C", "PROTEIN", 154, 158], ["chemokines 1516", "PROTEIN", 159, 174], ["chemotactic cytokines", "TEST", 15, 36], ["amino acids", "TEST", 116, 127], ["CXC", "TEST", 136, 139], ["CC", "TEST", 142, 144], ["C", "TEST", 147, 148], ["chemotactic cytokines", "OBSERVATION", 15, 36]]], ["CXC-chemokines, like interleukin (IL)-8 and growth-regulated peptide \u2013 alpha (GRO-alpha), are responsible for chemotaxis of neutrophils, whereas CC-chemokines, like eotaxin-1, eotaxin-2, monocyte chemotactic protein (MCP)-3, MCP-4, and RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), promote the attraction of lymphocytes, monocytes, eosinophils and basophils 17.IntroductionThe presented work investigated the importance of different chemokines, i.e. IL-8, GRO-alpha, eotaxin-1, eotaxin-2, MCP-3, MCP-4 and RANTES in tonsillar inflammatory disease and tonsil hyperplasia.Tissue samples ::: Materials and methodsThis study included 89 patients who underwent surgery at the Department of Otorhinolaryngology, Head and Neck Surgery at the University of Schleswig-Holstein, Campus Kiel, Germany, for hyperplasia of either the palatine or pharyngeal tonsil, or chronic inflammation of the palatine tonsil, defined as recurrent acute tonsillitis over a period of > 6 months.", [["neutrophils", "ANATOMY", 124, 135], ["T-cell", "ANATOMY", 278, 284], ["lymphocytes", "ANATOMY", 336, 347], ["monocytes", "ANATOMY", 349, 358], ["eosinophils", "ANATOMY", 360, 371], ["basophils", "ANATOMY", 376, 385], ["tonsillar", "ANATOMY", 544, 553], ["tonsil hyperplasia", "ANATOMY", 579, 597], ["Tissue samples", "ANATOMY", 598, 612], ["palatine", "ANATOMY", 849, 857], ["pharyngeal tonsil", "ANATOMY", 861, 878], ["palatine tonsil", "ANATOMY", 911, 926], ["CC", "CHEMICAL", 145, 147], ["tonsillar inflammatory disease", "DISEASE", 544, 574], ["tonsil hyperplasia", "DISEASE", 579, 597], ["hyperplasia", "DISEASE", 823, 834], ["inflammation of the palatine tonsil", "DISEASE", 891, 926], ["tonsillitis", "DISEASE", 955, 966], ["CXC", "GENE_OR_GENE_PRODUCT", 0, 3], ["interleukin (IL)-8", "GENE_OR_GENE_PRODUCT", 21, 39], ["growth-regulated peptide \u2013 alpha", "GENE_OR_GENE_PRODUCT", 44, 76], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 78, 87], ["neutrophils", "CELL", 124, 135], ["eotaxin-1", "GENE_OR_GENE_PRODUCT", 165, 174], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 176, 185], ["monocyte chemotactic protein (MCP)-3", "GENE_OR_GENE_PRODUCT", 187, 223], ["MCP-4", "GENE_OR_GENE_PRODUCT", 225, 230], ["RANTES", "GENE_OR_GENE_PRODUCT", 236, 242], ["T-cell", "CELL", 278, 284], ["lymphocytes", "CELL", 336, 347], ["monocytes", "CELL", 349, 358], ["eosinophils", "CELL", 360, 371], ["basophils", "CELL", 376, 385], ["IL-8", "GENE_OR_GENE_PRODUCT", 478, 482], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 484, 493], ["eotaxin-1", "GENE_OR_GENE_PRODUCT", 495, 504], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 506, 515], ["MCP-3", "GENE_OR_GENE_PRODUCT", 517, 522], ["MCP-4", "GENE_OR_GENE_PRODUCT", 524, 529], ["RANTES", "GENE_OR_GENE_PRODUCT", 534, 540], ["tonsillar inflammatory disease", "CANCER", 544, 574], ["tonsil hyperplasia", "CANCER", 579, 597], ["Tissue samples", "CANCER", 598, 612], ["patients", "ORGANISM", 661, 669], ["palatine", "ORGAN", 849, 857], ["pharyngeal tonsil", "MULTI-TISSUE_STRUCTURE", 861, 878], ["palatine tonsil", "MULTI-TISSUE_STRUCTURE", 911, 926], ["CXC", "PROTEIN", 0, 3], ["chemokines", "PROTEIN", 4, 14], ["interleukin (IL)-8", "PROTEIN", 21, 39], ["growth-regulated peptide \u2013 alpha (GRO-alpha", "PROTEIN", 44, 87], ["neutrophils", "CELL_TYPE", 124, 135], ["CC", "PROTEIN", 145, 147], ["chemokines", "PROTEIN", 148, 158], ["eotaxin-1", "PROTEIN", 165, 174], ["eotaxin", "PROTEIN", 176, 183], ["monocyte chemotactic protein (MCP)-3", "PROTEIN", 187, 223], ["MCP-4", "PROTEIN", 225, 230], ["RANTES", "PROTEIN", 236, 242], ["Regulated upon Activation, Normal T-cell Expressed and Secreted", "PROTEIN", 244, 307], ["lymphocytes", "CELL_TYPE", 336, 347], ["monocytes", "CELL_TYPE", 349, 358], ["eosinophils", "CELL_TYPE", 360, 371], ["basophils", "CELL_TYPE", 376, 385], ["chemokines", "PROTEIN", 461, 471], ["IL-8", "PROTEIN", 478, 482], ["GRO", "PROTEIN", 484, 487], ["eotaxin", "PROTEIN", 495, 502], ["eotaxin", "PROTEIN", 506, 513], ["MCP-3", "PROTEIN", 517, 522], ["MCP-4", "PROTEIN", 524, 529], ["RANTES", "PROTEIN", 534, 540], ["patients", "SPECIES", 661, 669], ["CXC", "TEST", 0, 3], ["chemokines", "TEST", 4, 14], ["interleukin (IL)", "TEST", 21, 37], ["growth", "TEST", 44, 50], ["alpha (GRO-alpha)", "TEST", 71, 88], ["neutrophils", "TEST", 124, 135], ["CC", "TEST", 145, 147], ["chemokines", "TEST", 148, 158], ["eotaxin", "TEST", 165, 172], ["eotaxin", "TEST", 176, 183], ["monocyte chemotactic protein", "TEST", 187, 215], ["MCP", "TEST", 217, 220], ["MCP", "TEST", 225, 228], ["monocytes", "TEST", 349, 358], ["eosinophils", "TEST", 360, 371], ["basophils", "TEST", 376, 385], ["different chemokines", "TREATMENT", 451, 471], ["IL", "TEST", 478, 480], ["GRO", "TEST", 484, 487], ["eotaxin", "TEST", 495, 502], ["eotaxin", "TEST", 506, 513], ["MCP", "TEST", 517, 520], ["MCP", "TEST", 524, 527], ["tonsillar inflammatory disease", "PROBLEM", 544, 574], ["tonsil hyperplasia", "PROBLEM", 579, 597], ["Tissue samples", "TEST", 598, 612], ["This study", "TEST", 638, 648], ["surgery", "TREATMENT", 684, 691], ["Head and Neck Surgery", "TREATMENT", 734, 755], ["hyperplasia of either the palatine or pharyngeal tonsil", "PROBLEM", 823, 878], ["chronic inflammation of the palatine tonsil", "PROBLEM", 883, 926], ["recurrent acute tonsillitis", "PROBLEM", 939, 966], ["responsible for", "UNCERTAINTY", 94, 109], ["tonsillar", "ANATOMY", 544, 553], ["inflammatory disease", "OBSERVATION", 554, 574], ["tonsil", "ANATOMY", 579, 585], ["hyperplasia", "OBSERVATION", 586, 597], ["Head", "ANATOMY", 734, 738], ["Neck", "ANATOMY", 743, 747], ["hyperplasia", "OBSERVATION", 823, 834], ["palatine", "ANATOMY", 849, 857], ["pharyngeal tonsil", "ANATOMY", 861, 878], ["chronic", "OBSERVATION_MODIFIER", 883, 890], ["inflammation", "OBSERVATION", 891, 903], ["palatine tonsil", "ANATOMY", 911, 926], ["recurrent", "OBSERVATION_MODIFIER", 939, 948], ["acute", "OBSERVATION_MODIFIER", 949, 954], ["tonsillitis", "OBSERVATION", 955, 966]]], ["Samples were retrieved during surgery after written patient consent was obtained, in accordance with the ethical commission of the Christian-Albrechts-University of Kiel, subjected to the 1975 Helsinki Declaration.", [["Samples", "ANATOMY", 0, 7], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Samples", "TEST", 0, 7]]], ["Tissue samples were divided into four subgroups, based on origin, patient past medical history, clinical presentation and histologic diagnosis established by certified pathologists of the University of Schleswig-Holstein, Campus Kiel.", [["Tissue samples", "ANATOMY", 0, 14], ["Tissue samples", "CANCER", 0, 14], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["Tissue samples", "TEST", 0, 14]]], ["The subgroups included 21 hyperplastic palatine tonsils, 25 adenoids, 16 chronic inflammatory palatine tonsils and 27 chronic inflammatory palatine tonsils with histologic signs of acute inflammation as per presence of cryptal ulcerations and leukocyte infiltration.", [["hyperplastic palatine tonsils", "ANATOMY", 26, 55], ["adenoids", "ANATOMY", 60, 68], ["palatine tonsils", "ANATOMY", 94, 110], ["palatine tonsils", "ANATOMY", 139, 155], ["cryptal", "ANATOMY", 219, 226], ["leukocyte", "ANATOMY", 243, 252], ["adenoids", "DISEASE", 60, 68], ["inflammation", "DISEASE", 187, 199], ["ulcerations", "DISEASE", 227, 238], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 39, 55], ["adenoids", "ORGAN", 60, 68], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 94, 110], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 139, 155], ["ulcerations", "PATHOLOGICAL_FORMATION", 227, 238], ["leukocyte", "CELL", 243, 252], ["21 hyperplastic palatine tonsils", "PROBLEM", 23, 55], ["16 chronic inflammatory palatine tonsils", "PROBLEM", 70, 110], ["27 chronic inflammatory palatine tonsils", "PROBLEM", 115, 155], ["acute inflammation", "PROBLEM", 181, 199], ["cryptal ulcerations", "PROBLEM", 219, 238], ["leukocyte infiltration", "PROBLEM", 243, 265], ["hyperplastic", "OBSERVATION_MODIFIER", 26, 38], ["palatine tonsils", "ANATOMY", 39, 55], ["25 adenoids", "OBSERVATION_MODIFIER", 57, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["palatine tonsils", "ANATOMY", 94, 110], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["inflammatory", "OBSERVATION_MODIFIER", 126, 138], ["palatine tonsils", "ANATOMY", 139, 155], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["inflammation", "OBSERVATION", 187, 199], ["cryptal", "OBSERVATION_MODIFIER", 219, 226], ["ulcerations", "OBSERVATION", 227, 238], ["leukocyte infiltration", "OBSERVATION", 243, 265]]], ["At the time of procedure, the median of age for each subgroup was 6, 5, 26, and 7, respectively.", [["procedure", "TREATMENT", 15, 24]]], ["Immediately after collection, samples were frozen in liquid nitrogen, and stored at -80\u00b0C for further processing.RNA isolation ::: Materials and methodsFrozen tissue samples were ground by mortar, and 1 ml of TRIzol\u2122 reagent (Gibco, Ingolstadt, Germany) was applied upon 200 mg of tissue.", [["samples", "ANATOMY", 30, 37], ["tissue samples", "ANATOMY", 159, 173], ["tissue", "ANATOMY", 281, 287], ["nitrogen", "CHEMICAL", 60, 68], ["tissue samples", "TISSUE", 159, 173], ["tissue", "TISSUE", 281, 287], ["collection", "TEST", 18, 28], ["samples", "TEST", 30, 37], ["liquid nitrogen", "TREATMENT", 53, 68], ["TRIzol\u2122 reagent", "TREATMENT", 209, 224], ["Gibco", "TREATMENT", 226, 231]]], ["Total RNA was isolated following the manufacturer\u2019s instructions.", [["Total RNA", "TREATMENT", 0, 9]]], ["After determination of the RNA content using the UVICON-931 UV-spectralphotometer (Kontron, Hamburg, Germany), samples of total RNA were adjusted to 1.0 \u03bcg for first strand cDNA synthesis.", [["samples", "ANATOMY", 111, 118], ["total RNA", "RNA", 122, 131], ["the UVICON", "TEST", 45, 55], ["total RNA", "TREATMENT", 122, 131], ["first strand cDNA synthesis", "TREATMENT", 160, 187]]], ["Quality assessment of the RNA was conducted using a 1% agarose ethidium-bromide stained gel electrophoresis.Reverse transcription ::: Materials and methods1.0 \u03bcg RNA was heat-denatured (65\u00b0C, 10 min), chilled on ice, and subjected to random hexadeoxynucleotide primed reverse transcription using the first strand cDNA synthesis kit (Pharmacia, Freiburg, Germany).", [["agarose", "CHEMICAL", 55, 62], ["ethidium-bromide", "CHEMICAL", 63, 79], ["hexadeoxynucleotide", "CHEMICAL", 241, 260], ["ethidium-bromide", "CHEMICAL", 63, 79], ["agarose ethidium-bromide", "SIMPLE_CHEMICAL", 55, 79], ["Quality assessment", "TEST", 0, 18], ["a 1% agarose ethidium", "TREATMENT", 50, 71], ["bromide stained gel electrophoresis", "TREATMENT", 72, 107], ["methods", "TEST", 148, 155], ["random hexadeoxynucleotide", "TREATMENT", 234, 260]]], ["Reverse transcription (final volume 15 \u03bcl) was conducted at 37\u00b0C for 60 min in the presence of 0.2 \u03bcM of random hexanucleotide primer and 40 U RNase inhibitor (RNAsin, Gibco, Germany).", [["U RNase", "GENE_OR_GENE_PRODUCT", 141, 148], ["random hexanucleotide primer", "TREATMENT", 105, 133], ["40 U RNase inhibitor", "TREATMENT", 138, 158]]], ["Following synthesis of the completed first strand cDNA the resulting RNA-cDNA double-stranded helix was heat-denatured (95\u00b0C, 5 min) to provide cDNA as a template for polymerisation.Primers ::: Materials and methodsWe used the following oligonucleotides for high-stringency PCR reaction as listed below.", [["first strand cDNA", "DNA", 37, 54], ["cDNA double-stranded helix", "DNA", 73, 99], ["cDNA", "DNA", 144, 148], ["the resulting RNA", "TREATMENT", 55, 72], ["cDNA double-stranded helix", "TREATMENT", 73, 99], ["cDNA", "TREATMENT", 144, 148], ["polymerisation", "PROBLEM", 167, 181], ["the following oligonucleotides", "TREATMENT", 223, 253], ["high-stringency PCR reaction", "PROBLEM", 258, 286]]], ["Glutaraldehyde-3-phosphate-dehydrogenase (G3PDH) was used to compare expression of the genes mentioned below:Primers ::: Materials and methodsRANTES sense: 5\u2019-CAT CCT CATT GCT ACT GCC CTC TG-3\u2019, RANTES antisense: 5\u2019-TAA CTG CTG CTC GTC GTG GTC-3\u2019; Eotaxin-1 sense: 5\u2019-CAT CCT CAT TGC TAC TGC CCT CTG-3\u2019, Eotaxin-1 antisense: 5\u2019-CGG GTT CAC GCC ATT CTC CT-3\u2019; Eotaxin-2 sense: 5\u2019-CAC ATC ATC CCT ACG GGC TCT-3\u2019; Eotaxin-2 antisense: 5\u2019-GGT TGC CAG GAT ATC TCT GGA CAG GG-3\u2019; MCP-3 sense: 5\u2019-GAG CTA CAG AAG GAC CAC CAG T-3\u2019, MCP-3 antisense: 5\u2019-AAG TCC TGG ACC CAC TTC TG-3\u2019; MCP-4 sense: 5\u2019-TCA TCT TTC CAC AAT AAC ATA TTT A-3\u2019, MCP-4 antisense: 5\u2019-GTT TAT TTG AGT ATT GCT GAT CTT T-3\u2019; IL-8 sense: 5\u2019-CTT TCA GAG ACA GCA GAG CAC-3\u2019, IL-8 antisense: 5\u2019-ACT GTG AGG TAA GAT GGT GGC-3\u2019; GRO-alpha sense: 5\u2019-TGA ACT GCG CTG CCA GTG C-3\u2019, GRO-alpha antisense; G3PDH sense: 5\u2019-CATCCTCATTGCTACTGCCCTCTG-3\u2019, G3PDH antisense: 5\u2019- ATGAGCCCCAGCCTTCTCCAT-3\u2019.Polymerase chain reaction (PCR) ::: Materials and methodsReverse transcribed cDNA products (0.2 5\u03bcl) were incubated in 50 \u03bcl reaction mixture containing 0.2 \u03bcM 5\u2019-3\u2019 sequence specific sense oligonucleotide primers, 0.2 \u03bcM of 3\u2019-5\u2019 corresponding antisense oligonucleotide primers, 200 \u03bcM dNTP\u2019s, 1.5 mM MgCl2, 5.0 \u03bcl 10x PCR-buffer, and 2.5 U Taq-polymerase (Gibco, Ingolstadt, Germany).", [["Glutaraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["NTP", "CHEMICAL", 1235, 1238], ["MgCl2", "CHEMICAL", 1249, 1254], ["Glutaraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["MgCl2", "CHEMICAL", 1249, 1254], ["Glutaraldehyde-3-phosphate-dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 40], ["G3PDH", "GENE_OR_GENE_PRODUCT", 42, 47], ["Eotaxin-1", "GENE_OR_GENE_PRODUCT", 248, 257], ["Eotaxin-1", "GENE_OR_GENE_PRODUCT", 304, 313], ["Eotaxin-2", "GENE_OR_GENE_PRODUCT", 359, 368], ["Eotaxin-2", "GENE_OR_GENE_PRODUCT", 411, 420], ["MCP-3", "GENE_OR_GENE_PRODUCT", 474, 479], ["MCP-3", "GENE_OR_GENE_PRODUCT", 524, 529], ["MCP-4", "GENE_OR_GENE_PRODUCT", 575, 580], ["MCP-4", "GENE_OR_GENE_PRODUCT", 629, 634], ["IL-8", "GENE_OR_GENE_PRODUCT", 687, 691], ["IL-8", "GENE_OR_GENE_PRODUCT", 734, 738], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 785, 794], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 835, 844], ["G3PDH", "GENE_OR_GENE_PRODUCT", 856, 861], ["G3PDH", "GENE_OR_GENE_PRODUCT", 901, 906], ["MgCl2", "SIMPLE_CHEMICAL", 1249, 1254], ["Glutaraldehyde-3-phosphate-dehydrogenase", "PROTEIN", 0, 40], ["G3PDH", "PROTEIN", 42, 47], ["RANTES antisense: 5\u2019-TAA", "DNA", 195, 219], ["Eotaxin-1", "DNA", 248, 257], ["Eotaxin", "DNA", 304, 311], ["Eotaxin-2", "DNA", 359, 368], ["Eotaxin-2 antisense: 5\u2019-GGT", "DNA", 411, 438], ["MCP", "DNA", 474, 477], ["MCP", "DNA", 524, 527], ["MCP-4", "DNA", 575, 580], ["MCP", "DNA", 629, 632], ["GRO", "DNA", 785, 788], ["GRO", "DNA", 835, 838], ["alpha antisense", "DNA", 839, 854], ["G3PDH", "DNA", 856, 861], ["cDNA products", "DNA", 1024, 1037], ["Glutaraldehyde", "TREATMENT", 0, 14], ["phosphate-dehydrogenase (G3PDH)", "TREATMENT", 17, 48], ["Materials", "TEST", 121, 130], ["methodsRANTES", "TEST", 135, 148], ["sense", "TEST", 149, 154], ["CAT CCT CATT GCT", "TEST", 159, 175], ["ACT", "TEST", 176, 179], ["GCC", "TEST", 180, 183], ["CTC", "TEST", 184, 187], ["TG", "TEST", 188, 190], ["antisense", "TEST", 202, 211], ["TAA", "TEST", 216, 219], ["CTG", "TEST", 220, 223], ["CTG", "TEST", 224, 227], ["CTC", "TEST", 228, 231], ["GTC", "TEST", 232, 235], ["GTG", "TEST", 236, 239], ["GTC", "TEST", 240, 243], ["Eotaxin", "TEST", 248, 255], ["CAT CCT", "TEST", 268, 275], ["CAT", "TEST", 276, 279], ["TGC", "TEST", 280, 283], ["TGC", "TEST", 288, 291], ["CTG", "TEST", 296, 299], ["Eotaxin", "TEST", 304, 311], ["antisense", "TEST", 314, 323], ["CGG", "TEST", 328, 331], ["GTT", "TEST", 332, 335], ["CAC", "TEST", 336, 339], ["GCC", "TEST", 340, 343], ["CTC", "TEST", 348, 351], ["CT", "TEST", 352, 354], ["Eotaxin", "TEST", 359, 366], ["sense", "TEST", 369, 374], ["CAC", "TEST", 379, 382], ["CCT", "TEST", 391, 394], ["ACG", "TEST", 395, 398], ["GGC", "TEST", 399, 402], ["TCT", "TEST", 403, 406], ["Eotaxin", "TEST", 411, 418], ["antisense", "TEST", 421, 430], ["GGT", "TEST", 435, 438], ["TGC", "TEST", 439, 442], ["CAG", "TEST", 443, 446], ["GAT", "TEST", 447, 450], ["TCT", "TEST", 455, 458], ["GGA", "TEST", 459, 462], ["CAG", "TEST", 463, 466], ["GG", "TEST", 467, 469], ["\u2019", "TEST", 471, 472], ["MCP", "TEST", 474, 477], ["sense", "TEST", 480, 485], ["CTA", "TEST", 494, 497], ["CAG", "TEST", 498, 501], ["AAG", "TEST", 502, 505], ["GAC", "TEST", 506, 509], ["CAC", "TEST", 510, 513], ["CAG", "TEST", 514, 517], ["T", "TEST", 518, 519], ["\u2019", "TEST", 521, 522], ["MCP", "TEST", 524, 527], ["antisense", "TEST", 530, 539], ["AAG", "TEST", 544, 547], ["TGG", "TEST", 552, 555], ["CAC", "TEST", 560, 563], ["TTC", "TEST", 564, 567], ["TG", "TEST", 568, 570], ["\u2019", "TEST", 572, 573], ["MCP", "TEST", 575, 578], ["sense", "TEST", 581, 586], ["TCA", "TEST", 591, 594], ["TCT", "TEST", 595, 598], ["TTC", "TEST", 599, 602], ["CAC", "TEST", 603, 606], ["AAT", "TEST", 607, 610], ["AAC", "TEST", 611, 614], ["ATA", "TEST", 615, 618], ["TTT", "TEST", 619, 622], ["A", "TEST", 623, 624], ["MCP", "TEST", 629, 632], ["antisense", "TEST", 635, 644], ["GTT", "TEST", 649, 652], ["TAT", "TEST", 653, 656], ["TTG", "TEST", 657, 660], ["AGT", "TEST", 661, 664], ["GCT", "TEST", 669, 672], ["GAT", "TEST", 673, 676], ["CTT", "TEST", 677, 680], ["T", "TEST", 681, 682], ["\u2019", "TEST", 684, 685], ["IL", "TEST", 687, 689], ["sense", "TEST", 692, 697], ["CTT", "TEST", 702, 705], ["TCA", "TEST", 706, 709], ["GAG", "TEST", 710, 713], ["ACA", "TEST", 714, 717], ["GCA", "TEST", 718, 721], ["GAG", "TEST", 722, 725], ["CAC", "TEST", 726, 729], ["IL", "TEST", 734, 736], ["antisense", "TEST", 739, 748], ["ACT", "TEST", 753, 756], ["GTG", "TEST", 757, 760], ["AGG", "TEST", 761, 764], ["TAA", "TEST", 765, 768], ["GAT", "TEST", 769, 772], ["GGT", "TEST", 773, 776], ["GGC", "TEST", 777, 780], ["\u2019", "TEST", 782, 783], ["GRO", "TEST", 785, 788], ["TGA", "TEST", 805, 808], ["GCG", "TEST", 813, 816], ["CTG", "TEST", 817, 820], ["CCA", "TEST", 821, 824], ["GTG", "TEST", 825, 828], ["C", "TEST", 829, 830], ["\u2019", "TEST", 832, 833], ["GRO", "TEST", 835, 838], ["sense", "TEST", 862, 867], ["CATCCTCATTGCTACTGCCCTCTG", "TEST", 872, 896], ["ATGAGCCCCAGCCTTCTCCAT", "TEST", 922, 943], ["Polymerase chain reaction", "PROBLEM", 947, 972], ["methodsReverse transcribed cDNA products", "TREATMENT", 997, 1037], ["oligonucleotide primers", "TEST", 1137, 1160], ["antisense oligonucleotide primers", "TREATMENT", 1192, 1225], ["MgCl2", "TEST", 1249, 1254], ["PCR", "TEST", 1267, 1270]]], ["The reaction mixture was covered with a mineral oil layer (Applied Biosystem, Weiterstadt, Germany) to prevent evaporation.", [["The reaction mixture", "TREATMENT", 0, 20], ["a mineral oil layer", "TREATMENT", 38, 57]]], ["The PCR was conducted in a Biometra T3 thermocycler.", [["The PCR", "TEST", 0, 7], ["a Biometra T3 thermocycler", "TREATMENT", 25, 51]]], ["Following initial denaturation (3 min at 95\u00b0C), high stringency PCR was run for 34 cycles (94\u00b0C for 75 sec, 60\u00b0C for 30 sec, and 72\u00b0C for 2 min) with an increased annealing temperature of 67\u00b0C in the first two cycles, to amplify the RANTES, Eotaxin-1, Eotaxin-2 and G3PDH cDNA.", [["C", "GENE_OR_GENE_PRODUCT", 191, 192], ["RANTES", "GENE_OR_GENE_PRODUCT", 233, 239], ["Eotaxin-1", "GENE_OR_GENE_PRODUCT", 241, 250], ["Eotaxin-2", "GENE_OR_GENE_PRODUCT", 252, 261], ["G3PDH", "GENE_OR_GENE_PRODUCT", 266, 271], ["RANTES", "PROTEIN", 233, 239], ["Eotaxin-1, Eotaxin-2", "DNA", 241, 261], ["G3PDH cDNA", "DNA", 266, 276], ["initial denaturation", "PROBLEM", 10, 30], ["high stringency PCR", "PROBLEM", 48, 67], ["an increased annealing temperature", "PROBLEM", 150, 184], ["the RANTES", "TREATMENT", 229, 239], ["Eotaxin", "TREATMENT", 241, 248], ["Eotaxin", "TREATMENT", 252, 259]]], ["In case of the other chemokines, the PCR parameters were modified to a 40 cycles of 95\u00b0C for 60 sec, 60\u00b0C for 30 sec, and 72\u00b0C for 2 min, with an increased annealing temperature of 68\u00b0 to 60\u00b0 over the first 8 cycles.", [["chemokines", "PROTEIN", 21, 31], ["the PCR parameters", "TEST", 33, 51], ["an increased annealing temperature", "PROBLEM", 143, 177]]], ["After PCR, all samples were subjected to ethidium-bromide stained 1.5% agarose gel electrophoresis.Densitometry ::: Materials and methodsThe amplicons were evaluated in quantity using Herolab E.A.S.Y. Win32 software (Herolab, Wiesloch, Germany).", [["samples", "ANATOMY", 15, 22], ["ethidium-bromide", "CHEMICAL", 41, 57], ["ethidium-bromide", "CHEMICAL", 41, 57], ["ethidium-bromide", "SIMPLE_CHEMICAL", 41, 57], ["agarose", "SIMPLE_CHEMICAL", 71, 78], ["PCR", "TEST", 6, 9], ["all samples", "TEST", 11, 22], ["ethidium", "TEST", 41, 49], ["bromide", "TREATMENT", 50, 57], ["agarose gel electrophoresis", "TEST", 71, 98], ["Densitometry", "TEST", 99, 111], ["The amplicons", "TREATMENT", 137, 150]]], ["At first, G3PDH bands were compared among each other, in order to assess relative sample signal strength.", [["G3PDH", "GENE_OR_GENE_PRODUCT", 10, 15], ["G3PDH bands", "PROTEIN", 10, 21], ["G3PDH bands", "PROBLEM", 10, 21]]], ["Subsequently, all other signals of the chemokine bands were adjusted to the relative strength by division through the G3PDH band signal.Statistical analysis ::: Materials and methodsAll densitometric data obtained from the SQRT-PCR were analysed using SPSS 9.0 (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA).", [["G3PDH", "GENE_OR_GENE_PRODUCT", 118, 123], ["chemokine bands", "PROTEIN", 39, 54], ["SQRT", "DNA", 223, 227], ["the chemokine bands", "TREATMENT", 35, 54], ["the G3PDH band signal", "TEST", 114, 135], ["All densitometric data", "TEST", 182, 204], ["the SQRT-PCR", "TEST", 219, 231], ["SPSS", "TEST", 252, 256]]], ["All data assembled in this study were tested for normal distribution using the Kolmogoroff-Smirnov test.", [["All data", "TEST", 0, 8], ["this study", "TEST", 22, 32], ["the Kolmogoroff-Smirnov test", "TEST", 75, 103]]], ["Expression profiles of each chemokine were analysed among each group using simple block variance analysis and Kruskal-Wallis test for normally and non-normally distributed data, respectively.", [["chemokine", "PROTEIN", 28, 37], ["simple block variance analysis", "TEST", 75, 105], ["Kruskal-Wallis test", "TEST", 110, 129]]], ["A p-value < 0.05 was considered significant, and a p-value < 0.01 was considered highly significant.RANTES and Eotaxin ::: ResultsRelative RANTES total-mRNA expression showed a median of 1.37 for tonsil hyperplasia 1.58 for adenoids, 1.32 for chronic tonsillitis and 1.56 for acute tonsillitis (Table I, Fig. 1A).", [["tonsil hyperplasia", "ANATOMY", 196, 214], ["adenoids", "ANATOMY", 224, 232], ["tonsil hyperplasia", "DISEASE", 196, 214], ["adenoids", "DISEASE", 224, 232], ["tonsillitis", "DISEASE", 251, 262], ["tonsillitis", "DISEASE", 282, 293], ["RANTES", "GENE_OR_GENE_PRODUCT", 100, 106], ["Eotaxin", "GENE_OR_GENE_PRODUCT", 111, 118], ["RANTES", "GENE_OR_GENE_PRODUCT", 139, 145], ["tonsil", "ORGAN", 196, 202], ["adenoids", "ORGAN", 224, 232], ["RANTES", "PROTEIN", 100, 106], ["Eotaxin", "PROTEIN", 111, 118], ["RANTES", "PROTEIN", 139, 145], ["A p-value", "TEST", 0, 9], ["a p-value", "TEST", 49, 58], ["mRNA expression", "TEST", 152, 167], ["tonsil hyperplasia", "PROBLEM", 196, 214], ["adenoids", "PROBLEM", 224, 232], ["chronic tonsillitis", "PROBLEM", 243, 262], ["acute tonsillitis", "PROBLEM", 276, 293], ["tonsil", "ANATOMY", 196, 202], ["hyperplasia", "OBSERVATION", 203, 214], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["tonsillitis", "OBSERVATION", 251, 262], ["acute", "OBSERVATION_MODIFIER", 276, 281], ["tonsillitis", "OBSERVATION", 282, 293]]], ["As shown in Table II and Fig. 1B, relative mRNA expression for eotaxin-2 was 1.02 in tonsillar hyperplasia (median value), 1.34 for adenoids, 1.16 for chronic tonsillitis and 1.16 for acute tonsillitis.", [["tonsillar hyperplasia", "ANATOMY", 85, 106], ["adenoids", "ANATOMY", 132, 140], ["tonsillar hyperplasia", "DISEASE", 85, 106], ["adenoids", "DISEASE", 132, 140], ["chronic tonsillitis", "DISEASE", 151, 170], ["tonsillitis", "DISEASE", 190, 201], ["1B", "GENE_OR_GENE_PRODUCT", 30, 32], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 63, 72], ["tonsillar hyperplasia", "PATHOLOGICAL_FORMATION", 85, 106], ["adenoids", "ORGAN", 132, 140], ["eotaxin", "PROTEIN", 63, 70], ["eotaxin", "TEST", 63, 70], ["tonsillar hyperplasia", "PROBLEM", 85, 106], ["adenoids", "PROBLEM", 132, 140], ["chronic tonsillitis", "PROBLEM", 151, 170], ["acute tonsillitis", "PROBLEM", 184, 201], ["tonsillar", "ANATOMY", 85, 94], ["hyperplasia", "OBSERVATION", 95, 106], ["chronic", "OBSERVATION_MODIFIER", 151, 158], ["tonsillitis", "OBSERVATION", 159, 170], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["tonsillitis", "OBSERVATION", 190, 201]]], ["A significant overexpression of eotaxin-2 was observed in adenoids compared to patients with chronic tonsillitis (p < 0.05).IL-8 and GRO-alpha ::: ResultsRelative expression of IL-8 are shown in Table III and Figure 2A.", [["adenoids", "ANATOMY", 58, 66], ["tonsillitis", "DISEASE", 101, 112], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 32, 41], ["adenoids", "ORGAN", 58, 66], ["patients", "ORGANISM", 79, 87], ["IL-8", "GENE_OR_GENE_PRODUCT", 124, 128], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 133, 142], ["IL-8", "GENE_OR_GENE_PRODUCT", 177, 181], ["eotaxin", "PROTEIN", 32, 39], ["IL", "PROTEIN", 124, 126], ["GRO", "PROTEIN", 133, 136], ["IL-8", "PROTEIN", 177, 181], ["patients", "SPECIES", 79, 87], ["eotaxin-2", "TREATMENT", 32, 41], ["adenoids", "PROBLEM", 58, 66], ["chronic tonsillitis", "PROBLEM", 93, 112], ["IL", "TEST", 124, 126], ["IL", "TEST", 177, 179], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["overexpression", "OBSERVATION_MODIFIER", 14, 28], ["eotaxin", "OBSERVATION", 32, 39], ["adenoids", "ANATOMY", 58, 66], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["tonsillitis", "OBSERVATION", 101, 112]]], ["A relative IL-8-mRNA expression was found to be a median of 1.12 in tonsillar hyperplasia, 1.97 for adenoids, 1.82 for chronic tonsillitis and 1.41 for acute tonsillitis.", [["tonsillar hyperplasia", "ANATOMY", 68, 89], ["adenoids", "ANATOMY", 100, 108], ["tonsillar hyperplasia", "DISEASE", 68, 89], ["adenoids", "DISEASE", 100, 108], ["tonsillitis", "DISEASE", 127, 138], ["tonsillitis", "DISEASE", 158, 169], ["IL-8-mRNA", "GENE_OR_GENE_PRODUCT", 11, 20], ["tonsillar hyperplasia", "PATHOLOGICAL_FORMATION", 68, 89], ["adenoids", "ORGAN", 100, 108], ["IL", "PROTEIN", 11, 13], ["tonsillar hyperplasia", "PROBLEM", 68, 89], ["adenoids", "TEST", 100, 108], ["chronic tonsillitis", "PROBLEM", 119, 138], ["acute tonsillitis", "PROBLEM", 152, 169], ["tonsillar", "ANATOMY", 68, 77], ["hyperplasia", "OBSERVATION", 78, 89], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["tonsillitis", "OBSERVATION", 127, 138], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["tonsillitis", "OBSERVATION", 158, 169]]], ["IL-8 was significantly overexpressed in patients with chronic inflammatory tonsillar disease (with and without acute inflammation) compared to tonsil hyperplasia.", [["tonsillar", "ANATOMY", 75, 84], ["tonsil hyperplasia", "ANATOMY", 143, 161], ["inflammatory tonsillar disease", "DISEASE", 62, 92], ["inflammation", "DISEASE", 117, 129], ["tonsil hyperplasia", "DISEASE", 143, 161], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 40, 48], ["tonsillar", "ORGAN", 75, 84], ["tonsil hyperplasia", "CANCER", 143, 161], ["IL-8", "PROTEIN", 0, 4], ["patients", "SPECIES", 40, 48], ["IL", "TEST", 0, 2], ["chronic inflammatory tonsillar disease", "PROBLEM", 54, 92], ["acute inflammation", "PROBLEM", 111, 129], ["tonsil hyperplasia", "PROBLEM", 143, 161], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["inflammatory tonsillar disease", "OBSERVATION", 62, 92], ["without", "UNCERTAINTY", 103, 110], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["inflammation", "OBSERVATION", 117, 129], ["tonsil", "ANATOMY", 143, 149], ["hyperplasia", "OBSERVATION", 150, 161]]], ["Relative GRO-alpha mRNA expression levels are shown in Table IV and Figure 2B.", [["GRO-alpha", "GENE_OR_GENE_PRODUCT", 9, 18], ["GRO", "PROTEIN", 9, 12], ["Relative GRO-alpha mRNA expression levels", "TEST", 0, 41], ["alpha mRNA", "OBSERVATION", 13, 23]]], ["Median values were 0.84 for tonsillar hyperplasia, 1.07 for adenoids, 0.60 for chronic tonsillitis and 0.55 for acute tonsillits.IL-8 and GRO-alpha ::: ResultsAll other examined cytokines were not significantly expressed in the groups analysed.DiscussionWaldeyer\u2019s tonsillar ring acts as the first line of immune defence against microbes, entering the body nasally or orally.", [["tonsillar hyperplasia", "ANATOMY", 28, 49], ["adenoids", "ANATOMY", 60, 68], ["tonsillar ring", "ANATOMY", 265, 279], ["body", "ANATOMY", 352, 356], ["tonsillar hyperplasia", "DISEASE", 28, 49], ["adenoids", "DISEASE", 60, 68], ["tonsillitis", "DISEASE", 87, 98], ["tonsillar hyperplasia", "PATHOLOGICAL_FORMATION", 28, 49], ["adenoids", "ORGAN", 60, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 129, 133], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 138, 147], ["body", "ORGANISM_SUBDIVISION", 352, 356], ["IL", "PROTEIN", 129, 131], ["GRO", "PROTEIN", 138, 141], ["cytokines", "PROTEIN", 178, 187], ["Median values", "TEST", 0, 13], ["tonsillar hyperplasia", "PROBLEM", 28, 49], ["adenoids", "TEST", 60, 68], ["chronic tonsillitis", "PROBLEM", 79, 98], ["acute tonsillits", "PROBLEM", 112, 128], ["IL", "TEST", 129, 131], ["tonsillar ring acts", "TREATMENT", 265, 284], ["immune defence", "TREATMENT", 306, 320], ["tonsillar", "ANATOMY", 28, 37], ["hyperplasia", "OBSERVATION", 38, 49], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["tonsillitis", "OBSERVATION", 87, 98], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["tonsillits", "OBSERVATION", 118, 128], ["cytokines", "OBSERVATION", 178, 187], ["tonsillar", "ANATOMY", 265, 274], ["body", "ANATOMY_MODIFIER", 352, 356]]], ["Especially in children, the immunogenic properties of the palatine tonsils are of particular importance.", [["palatine tonsils", "ANATOMY", 58, 74], ["children", "ORGANISM", 14, 22], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 58, 74], ["children", "SPECIES", 14, 22], ["palatine tonsils", "ANATOMY", 58, 74]]], ["Chemokines are small signalling proteins, whose expression in various tissues is variably regulated during immune responses as well as acute and chronic infection.", [["tissues", "ANATOMY", 70, 77], ["infection", "DISEASE", 153, 162], ["tissues", "TISSUE", 70, 77], ["Chemokines", "PROTEIN", 0, 10], ["small signalling proteins", "PROTEIN", 15, 40], ["small signalling proteins", "PROBLEM", 15, 40], ["acute and chronic infection", "PROBLEM", 135, 162], ["small", "OBSERVATION_MODIFIER", 15, 20], ["signalling proteins", "OBSERVATION", 21, 40], ["various tissues", "OBSERVATION_MODIFIER", 62, 77], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["chronic", "OBSERVATION_MODIFIER", 145, 152], ["infection", "OBSERVATION", 153, 162]]], ["Previous studies have suggested a functional role for chemokines in hepatitis, colitis, pancreatitis, asthma and various malignancies as well as acute and chronic infections of the upper aerodigestive tract 18-23.", [["malignancies", "ANATOMY", 121, 133], ["upper aerodigestive tract", "ANATOMY", 181, 206], ["hepatitis", "DISEASE", 68, 77], ["colitis", "DISEASE", 79, 86], ["pancreatitis", "DISEASE", 88, 100], ["asthma", "DISEASE", 102, 108], ["malignancies", "DISEASE", 121, 133], ["infections", "DISEASE", 163, 173], ["malignancies", "CANCER", 121, 133], ["upper aerodigestive tract", "ORGANISM_SUBDIVISION", 181, 206], ["chemokines", "PROTEIN", 54, 64], ["Previous studies", "TEST", 0, 16], ["chemokines in hepatitis", "PROBLEM", 54, 77], ["colitis", "PROBLEM", 79, 86], ["pancreatitis", "PROBLEM", 88, 100], ["asthma", "PROBLEM", 102, 108], ["various malignancies", "PROBLEM", 113, 133], ["acute and chronic infections of the upper aerodigestive tract", "PROBLEM", 145, 206], ["hepatitis", "OBSERVATION", 68, 77], ["colitis", "OBSERVATION", 79, 86], ["pancreatitis", "OBSERVATION", 88, 100], ["asthma", "OBSERVATION", 102, 108], ["various", "OBSERVATION_MODIFIER", 113, 120], ["malignancies", "OBSERVATION", 121, 133], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["infections", "OBSERVATION", 163, 173], ["upper", "ANATOMY_MODIFIER", 181, 186], ["aerodigestive tract", "ANATOMY", 187, 206]]], ["Most chemokines are only produced and secreted upon appropriate stimulation of cells by bacterial or viral products 24.", [["cells", "ANATOMY", 79, 84], ["cells", "CELL", 79, 84], ["chemokines", "PROTEIN", 5, 15], ["bacterial or viral products", "TREATMENT", 88, 115]]], ["In cases of acute and chronically infected tonsils, accumulation of certain subsets of chemokines and neutrophilic dynamics has been observed 25.DiscussionIL-8 has been described to be very potent in neutrophil activation and migration 2627.", [["tonsils", "ANATOMY", 43, 50], ["neutrophil", "ANATOMY", 200, 210], ["acute and chronically infected tonsils", "DISEASE", 12, 50], ["DiscussionIL-8", "CHEMICAL", 145, 159], ["tonsils", "ORGAN", 43, 50], ["DiscussionIL-8", "GENE_OR_GENE_PRODUCT", 145, 159], ["neutrophil", "CELL", 200, 210], ["chemokines", "PROTEIN", 87, 97], ["DiscussionIL-8", "PROTEIN", 145, 159], ["neutrophil", "CELL_TYPE", 200, 210], ["acute and chronically infected tonsils", "PROBLEM", 12, 50], ["neutrophilic dynamics", "TEST", 102, 123], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["chronically", "OBSERVATION_MODIFIER", 22, 33], ["infected tonsils", "OBSERVATION", 34, 50], ["certain", "OBSERVATION_MODIFIER", 68, 75], ["subsets", "OBSERVATION_MODIFIER", 76, 83], ["chemokines", "OBSERVATION_MODIFIER", 87, 97], ["neutrophilic dynamics", "OBSERVATION", 102, 123], ["neutrophil activation", "OBSERVATION", 200, 221]]], ["Our data shows significant overexpression of IL-8 in chronic inflammatory tonsillar disease.", [["tonsillar", "ANATOMY", 74, 83], ["tonsillar disease", "DISEASE", 74, 91], ["IL-8", "GENE_OR_GENE_PRODUCT", 45, 49], ["tonsillar", "ORGAN", 74, 83], ["IL-8", "PROTEIN", 45, 49], ["Our data", "TEST", 0, 8], ["significant overexpression of IL", "PROBLEM", 15, 47], ["chronic inflammatory tonsillar disease", "PROBLEM", 53, 91], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["overexpression", "OBSERVATION_MODIFIER", 27, 41], ["IL", "OBSERVATION_MODIFIER", 45, 47], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["inflammatory tonsillar disease", "OBSERVATION", 61, 91]]], ["Since IL-8 expression has been reported to be effectively stimulated by TNF-\u03b1 und IL-1\u03b1 for neutrophil chemotaxis as well as activity, our data suggests that a Th1 response is predominatly involved in the pathogenesis of chronic tonsillitis.DiscussionBoth IL-8 and GRO-\u03b1 are known to be synthesised by neutrophils and fibroblasts in response to various stimuli 2829.", [["neutrophil", "ANATOMY", 92, 102], ["neutrophils", "ANATOMY", 302, 313], ["fibroblasts", "ANATOMY", 318, 329], ["tonsillitis", "DISEASE", 229, 240], ["IL-8", "GENE_OR_GENE_PRODUCT", 6, 10], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 82, 87], ["neutrophil", "CELL", 92, 102], ["Th1", "GENE_OR_GENE_PRODUCT", 160, 163], ["IL-8", "GENE_OR_GENE_PRODUCT", 256, 260], ["GRO-\u03b1", "GENE_OR_GENE_PRODUCT", 265, 270], ["neutrophils", "CELL", 302, 313], ["fibroblasts", "CELL", 318, 329], ["IL-8", "PROTEIN", 6, 10], ["TNF", "PROTEIN", 72, 75], ["IL-1\u03b1", "PROTEIN", 82, 87], ["IL-8", "PROTEIN", 256, 260], ["GRO", "PROTEIN", 265, 268], ["\u03b1", "PROTEIN", 269, 270], ["neutrophils", "CELL_TYPE", 302, 313], ["fibroblasts", "CELL_TYPE", 318, 329], ["TNF-\u03b1 und IL", "TEST", 72, 84], ["neutrophil chemotaxis", "PROBLEM", 92, 113], ["our data", "TEST", 135, 143], ["a Th1 response", "PROBLEM", 158, 172], ["chronic tonsillitis", "PROBLEM", 221, 240], ["neutrophils", "TEST", 302, 313], ["various stimuli", "TEST", 345, 360], ["chronic", "OBSERVATION_MODIFIER", 221, 228], ["tonsillitis", "OBSERVATION", 229, 240]]], ["In vitro, IL-1\u03b2 and TNF-\u03b1 seem to be potent stimulators of chemokine production, whereas IFN-\u03b3 inhibits their production 18.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 10, 15], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 89, 94], ["IL-1\u03b2", "PROTEIN", 10, 15], ["TNF", "PROTEIN", 20, 23], ["chemokine", "PROTEIN", 59, 68], ["IFN", "PROTEIN", 89, 92], ["\u03b3", "PROTEIN", 93, 94], ["IL", "TEST", 10, 12], ["TNF", "TEST", 20, 23], ["chemokine production", "PROBLEM", 59, 79], ["IFN", "TEST", 89, 92]]], ["GRO-alpha is further produced by endothelial cells, fibroblasts and monocytes after stimulation with lipopolysaccharide, IL-1 or TNF-\u03b1 in vitro.", [["endothelial cells", "ANATOMY", 33, 50], ["fibroblasts", "ANATOMY", 52, 63], ["monocytes", "ANATOMY", 68, 77], ["lipopolysaccharide", "CHEMICAL", 101, 119], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 0, 9], ["endothelial cells", "CELL", 33, 50], ["fibroblasts", "CELL", 52, 63], ["monocytes", "CELL", 68, 77], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 101, 119], ["IL-1", "GENE_OR_GENE_PRODUCT", 121, 125], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 129, 134], ["GRO-alpha", "PROTEIN", 0, 9], ["endothelial cells", "CELL_TYPE", 33, 50], ["fibroblasts", "CELL_TYPE", 52, 63], ["monocytes", "CELL_TYPE", 68, 77], ["TNF", "PROTEIN", 129, 132], ["monocytes", "TEST", 68, 77], ["stimulation", "TEST", 84, 95], ["lipopolysaccharide", "TREATMENT", 101, 119], ["IL", "TEST", 121, 123], ["TNF", "TEST", 129, 132], ["endothelial cells", "OBSERVATION", 33, 50]]], ["In addition, it induces neutrophil accumulation and chemotaxis 29.", [["neutrophil", "ANATOMY", 24, 34], ["neutrophil", "CELL", 24, 34], ["neutrophil", "CELL_TYPE", 24, 34], ["neutrophil accumulation", "PROBLEM", 24, 47], ["chemotaxis", "TEST", 52, 62], ["neutrophil accumulation", "OBSERVATION", 24, 47]]], ["In our data however, GRO-alpha was not significantly overexpressed in chronic tonsillar diseases.DiscussionTonsillar hyperplasia appears to be a result of increased proliferation of lymphoid tissue predominantly triggered by bacterial infections.", [["tonsillar", "ANATOMY", 78, 87], ["Tonsillar hyperplasia", "ANATOMY", 107, 128], ["lymphoid tissue", "ANATOMY", 182, 197], ["tonsillar diseases", "DISEASE", 78, 96], ["Tonsillar hyperplasia", "DISEASE", 107, 128], ["bacterial infections", "DISEASE", 225, 245], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 21, 30], ["tonsillar", "ORGAN", 78, 87], ["lymphoid tissue", "TISSUE", 182, 197], ["GRO", "PROTEIN", 21, 24], ["GRO-alpha", "TEST", 21, 30], ["chronic tonsillar diseases", "PROBLEM", 70, 96], ["Tonsillar hyperplasia", "PROBLEM", 107, 128], ["increased proliferation of lymphoid tissue", "PROBLEM", 155, 197], ["bacterial infections", "PROBLEM", 225, 245], ["not", "UNCERTAINTY", 35, 38], ["significantly overexpressed", "OBSERVATION_MODIFIER", 39, 66], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["tonsillar", "ANATOMY", 78, 87], ["diseases", "OBSERVATION", 88, 96], ["Tonsillar", "ANATOMY", 107, 116], ["hyperplasia", "OBSERVATION", 117, 128], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["proliferation", "OBSERVATION", 165, 178], ["lymphoid tissue", "OBSERVATION", 182, 197], ["bacterial", "OBSERVATION_MODIFIER", 225, 234], ["infections", "OBSERVATION", 235, 245]]], ["Previously, tonsil size has been shown to be directly proportional to the mean bacterial load 30.", [["tonsil", "ANATOMY", 12, 18], ["tonsil", "ORGAN", 12, 18], ["the mean bacterial load", "TEST", 70, 93], ["tonsil", "ANATOMY", 12, 18], ["size", "OBSERVATION_MODIFIER", 19, 23], ["mean bacterial load", "OBSERVATION", 74, 93]]], ["The kind of bacteria found in hyperplastic tonsils does not seem to greatly differ from those in recurrently active infected tonsils.", [["hyperplastic tonsils", "ANATOMY", 30, 50], ["tonsils", "ANATOMY", 125, 132], ["hyperplastic tonsils", "ORGAN", 30, 50], ["tonsils", "ORGAN", 125, 132], ["bacteria", "PROBLEM", 12, 20], ["hyperplastic tonsils", "PROBLEM", 30, 50], ["recurrently active infected tonsils", "PROBLEM", 97, 132], ["bacteria", "OBSERVATION", 12, 20], ["hyperplastic tonsils", "OBSERVATION", 30, 50], ["active", "OBSERVATION_MODIFIER", 109, 115], ["infected tonsils", "OBSERVATION", 116, 132]]], ["However, Haemophilus infection, besides Staphylococcus aureus and Streptococcus pyogenes appears to be more common in tonsillar hyperplasia 30.", [["tonsillar hyperplasia", "ANATOMY", 118, 139], ["Haemophilus infection", "DISEASE", 9, 30], ["Staphylococcus aureus", "DISEASE", 40, 61], ["Streptococcus pyogenes", "DISEASE", 66, 88], ["tonsillar hyperplasia", "DISEASE", 118, 139], ["Haemophilus infection", "ORGANISM", 9, 30], ["Staphylococcus aureus", "ORGANISM", 40, 61], ["Streptococcus pyogenes", "ORGANISM", 66, 88], ["tonsillar hyperplasia", "CANCER", 118, 139], ["Staphylococcus aureus", "SPECIES", 40, 61], ["Streptococcus pyogenes", "SPECIES", 66, 88], ["Staphylococcus aureus", "SPECIES", 40, 61], ["Streptococcus pyogenes", "SPECIES", 66, 88], ["Haemophilus infection", "PROBLEM", 9, 30], ["Staphylococcus aureus", "PROBLEM", 40, 61], ["Streptococcus pyogenes", "PROBLEM", 66, 88], ["tonsillar hyperplasia", "PROBLEM", 118, 139], ["Haemophilus", "OBSERVATION_MODIFIER", 9, 20], ["infection", "OBSERVATION", 21, 30], ["Staphylococcus aureus", "OBSERVATION", 40, 61], ["Streptococcus pyogenes", "OBSERVATION", 66, 88], ["tonsillar", "ANATOMY", 118, 127], ["hyperplasia", "OBSERVATION", 128, 139]]], ["Our investigations demonstrate that hyperplastic tonsillitis is characterised by an acute inflammatory chemokine pattern as IL-8 expression on mRNA levels correlates with the presence of actively infected tissue.", [["hyperplastic tonsillitis", "ANATOMY", 36, 60], ["tissue", "ANATOMY", 205, 211], ["tonsillitis", "DISEASE", 49, 60], ["IL-8", "GENE_OR_GENE_PRODUCT", 124, 128], ["tissue", "TISSUE", 205, 211], ["IL-8", "PROTEIN", 124, 128], ["Our investigations", "TEST", 0, 18], ["hyperplastic tonsillitis", "PROBLEM", 36, 60], ["an acute inflammatory chemokine pattern", "PROBLEM", 81, 120], ["IL", "TEST", 124, 126], ["mRNA levels", "TEST", 143, 154], ["actively infected tissue", "PROBLEM", 187, 211], ["hyperplastic", "OBSERVATION_MODIFIER", 36, 48], ["tonsillitis", "OBSERVATION", 49, 60], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["chemokine pattern", "OBSERVATION", 103, 120], ["actively", "OBSERVATION_MODIFIER", 187, 195], ["infected tissue", "OBSERVATION", 196, 211]]], ["IL-8 expression was significantly elevated in acutely infected tissue compared to hyperplastic tonsils (p < 0.01), and in adenoids and chronic tonsillitis compared to hyperplastic tonsils (p < 0.05).", [["tissue", "ANATOMY", 63, 69], ["hyperplastic tonsils", "ANATOMY", 82, 102], ["adenoids", "ANATOMY", 122, 130], ["hyperplastic tonsils", "ANATOMY", 167, 187], ["tonsillitis", "DISEASE", 143, 154], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue", "TISSUE", 63, 69], ["tonsils", "ORGAN", 95, 102], ["adenoids", "ORGAN", 122, 130], ["tonsils", "ORGAN", 180, 187], ["IL-8", "PROTEIN", 0, 4], ["IL", "TEST", 0, 2], ["significantly elevated", "PROBLEM", 20, 42], ["acutely infected tissue", "PROBLEM", 46, 69], ["hyperplastic tonsils", "PROBLEM", 82, 102], ["adenoids", "PROBLEM", 122, 130], ["chronic tonsillitis", "PROBLEM", 135, 154], ["hyperplastic tonsils", "PROBLEM", 167, 187], ["elevated", "OBSERVATION_MODIFIER", 34, 42], ["acutely", "OBSERVATION_MODIFIER", 46, 53], ["infected tissue", "OBSERVATION", 54, 69], ["hyperplastic", "OBSERVATION_MODIFIER", 82, 94], ["tonsils", "ANATOMY", 95, 102], ["adenoids", "ANATOMY", 122, 130], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["tonsillitis", "OBSERVATION", 143, 154], ["hyperplastic tonsils", "OBSERVATION", 167, 187]]], ["Therefore, as IL-8 is an acute phase chemokine expressed in chronic tonsillitis, this suggests an inflammatory process in the pathogenesis of chronic tonsillitis.", [["tonsillitis", "DISEASE", 68, 79], ["tonsillitis", "DISEASE", 150, 161], ["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-8", "PROTEIN", 14, 18], ["acute phase chemokine", "PROTEIN", 25, 46], ["an acute phase chemokine", "PROBLEM", 22, 46], ["chronic tonsillitis", "PROBLEM", 60, 79], ["an inflammatory process", "PROBLEM", 95, 118], ["chronic tonsillitis", "PROBLEM", 142, 161], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["tonsillitis", "OBSERVATION", 68, 79], ["inflammatory", "OBSERVATION", 98, 110], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["tonsillitis", "OBSERVATION", 150, 161]]], ["An elevation of IL-8 in acute infections has been described previously 3132, and therefore anticipated for tonsillar disease.", [["tonsillar", "ANATOMY", 107, 116], ["acute infections", "DISEASE", 24, 40], ["tonsillar disease", "DISEASE", 107, 124], ["IL-8", "GENE_OR_GENE_PRODUCT", 16, 20], ["tonsillar disease", "CANCER", 107, 124], ["IL-8", "PROTEIN", 16, 20], ["An elevation of IL", "PROBLEM", 0, 18], ["acute infections", "PROBLEM", 24, 40], ["tonsillar disease", "PROBLEM", 107, 124], ["elevation", "OBSERVATION_MODIFIER", 3, 12], ["IL", "OBSERVATION_MODIFIER", 16, 18], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["infections", "OBSERVATION", 30, 40], ["tonsillar", "ANATOMY", 107, 116], ["disease", "OBSERVATION", 117, 124]]], ["However there have been studies showing an equal expression of IL-8 in hyperplastic tonsils and chronic tonsillitis 33.", [["hyperplastic tonsils", "ANATOMY", 71, 91], ["tonsillitis", "DISEASE", 104, 115], ["IL-8", "GENE_OR_GENE_PRODUCT", 63, 67], ["tonsils", "ORGAN", 84, 91], ["IL-8", "PROTEIN", 63, 67], ["studies", "TEST", 24, 31], ["IL", "TEST", 63, 65], ["hyperplastic tonsils", "PROBLEM", 71, 91], ["chronic tonsillitis", "PROBLEM", 96, 115], ["equal", "OBSERVATION_MODIFIER", 43, 48], ["expression", "OBSERVATION_MODIFIER", 49, 59], ["hyperplastic tonsils", "ANATOMY", 71, 91], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["tonsillitis", "OBSERVATION", 104, 115]]], ["Another reason for a high expression of this chemokine in chronic and hyperplastic disease could be its additional extensive effect on cell proliferation 34.DiscussionA similar result would have been expected for the expression of GRO-alpha, since this chemokine also plays an important role in host immune defence by conveying chemotaxis and activation of neutrophils, similar to IL-8.", [["hyperplastic disease", "ANATOMY", 70, 90], ["cell", "ANATOMY", 135, 139], ["neutrophils", "ANATOMY", 357, 368], ["hyperplastic disease", "DISEASE", 70, 90], ["hyperplastic disease", "CANCER", 70, 90], ["cell", "CELL", 135, 139], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 231, 240], ["neutrophils", "CELL", 357, 368], ["IL-8", "GENE_OR_GENE_PRODUCT", 381, 385], ["chemokine", "PROTEIN", 45, 54], ["GRO-alpha", "PROTEIN", 231, 240], ["chemokine", "PROTEIN", 253, 262], ["neutrophils", "CELL_TYPE", 357, 368], ["IL-8", "PROTEIN", 381, 385], ["this chemokine in chronic and hyperplastic disease", "PROBLEM", 40, 90], ["cell proliferation", "TEST", 135, 153], ["neutrophils", "TEST", 357, 368], ["IL", "TEST", 381, 383], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["hyperplastic", "OBSERVATION", 70, 82], ["extensive", "OBSERVATION_MODIFIER", 115, 124], ["cell proliferation", "OBSERVATION", 135, 153]]], ["However, in our data, mRNA expression levels of GRO-alpha were not significantly elevated in acute nor chronic tonsillitis compared to tonsillar hyperplasia.DiscussionMCP 1-4, RANTES, eotaxin, eotaxin-2 und eotaxin-3 are CC-chemokines.", [["tonsillar hyperplasia", "ANATOMY", 135, 156], ["tonsillitis", "DISEASE", 111, 122], ["tonsillar hyperplasia", "DISEASE", 135, 156], ["CC", "CHEMICAL", 221, 223], ["GRO-alpha", "GENE_OR_GENE_PRODUCT", 48, 57], ["tonsillar hyperplasia", "PATHOLOGICAL_FORMATION", 135, 156], ["1-4", "GENE_OR_GENE_PRODUCT", 171, 174], ["RANTES", "GENE_OR_GENE_PRODUCT", 176, 182], ["eotaxin", "GENE_OR_GENE_PRODUCT", 184, 191], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 193, 202], ["eotaxin-3", "GENE_OR_GENE_PRODUCT", 207, 216], ["GRO", "PROTEIN", 48, 51], ["RANTES", "PROTEIN", 176, 182], ["eotaxin", "PROTEIN", 184, 191], ["eotaxin", "PROTEIN", 193, 200], ["eotaxin", "PROTEIN", 207, 214], ["CC", "PROTEIN", 221, 223], ["chemokines", "PROTEIN", 224, 234], ["mRNA expression levels", "TEST", 22, 44], ["GRO-alpha", "TEST", 48, 57], ["significantly elevated", "PROBLEM", 67, 89], ["acute nor chronic tonsillitis", "PROBLEM", 93, 122], ["tonsillar hyperplasia", "PROBLEM", 135, 156], ["DiscussionMCP", "TEST", 157, 170], ["eotaxin", "TREATMENT", 184, 191], ["eotaxin", "TREATMENT", 193, 200], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["tonsillitis", "OBSERVATION", 111, 122], ["tonsillar", "ANATOMY", 135, 144], ["hyperplasia", "OBSERVATION", 145, 156]]], ["RANTES is a selective attractant for T-cell and monocytes migration 35.", [["T-cell", "ANATOMY", 37, 43], ["monocytes", "ANATOMY", 48, 57], ["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["T-cell", "CELL", 37, 43], ["monocytes", "CELL", 48, 57], ["RANTES", "PROTEIN", 0, 6], ["T-cell", "CELL_TYPE", 37, 43], ["monocytes", "CELL_TYPE", 48, 57], ["a selective attractant", "TREATMENT", 10, 32], ["T-cell and monocytes migration", "TREATMENT", 37, 67]]], ["Proinflammatory cytokines, such as TNF-\u03b1 or IL-1\u03b1, have been described to be some of the most potent stimulators of RANTES expression.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 44, 49], ["RANTES", "GENE_OR_GENE_PRODUCT", 116, 122], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["TNF", "PROTEIN", 35, 38], ["IL-1\u03b1", "PROTEIN", 44, 49], ["RANTES", "PROTEIN", 116, 122], ["Proinflammatory cytokines", "TEST", 0, 25], ["TNF", "TEST", 35, 38], ["cytokines", "OBSERVATION", 16, 25]]], ["Furthermore, a combination of TNF-\u03b1 and INF-c strongly stimulate production of RANTES 36.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["INF-c", "GENE_OR_GENE_PRODUCT", 40, 45], ["RANTES", "GENE_OR_GENE_PRODUCT", 79, 85], ["TNF", "PROTEIN", 30, 33], ["INF", "PROTEIN", 40, 43], ["RANTES 36", "PROTEIN", 79, 88], ["TNF", "TEST", 30, 33], ["INF", "TREATMENT", 40, 43], ["RANTES", "TEST", 79, 85]]], ["Another important function of RANTES is its ability to enhance the mucosal as well as systemic humoral production of antibodies, via an elevation of the production of IFN-c-, IL-2-, IL-5-and IL-6, and further an induction of co-stimulatory molecules as well as expression of cytokine receptors for CD 4+T cells 37.DiscussionIn our data, RANTES expression was evident in all subgroups analysed with no significant differences in relative mRNA expression levels within these groups.DiscussionEotaxin-2 is also described to be a potent chemoattractor for eosinophils in vitro and in vivo3839.", [["mucosal", "ANATOMY", 67, 74], ["CD 4+T cells", "ANATOMY", 298, 310], ["eosinophils", "ANATOMY", 552, 563], ["RANTES", "GENE_OR_GENE_PRODUCT", 30, 36], ["mucosal", "PATHOLOGICAL_FORMATION", 67, 74], ["IFN-c-", "GENE_OR_GENE_PRODUCT", 167, 173], ["IL-2", "GENE_OR_GENE_PRODUCT", 175, 179], ["IL-5", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-6", "GENE_OR_GENE_PRODUCT", 191, 195], ["RANTES", "GENE_OR_GENE_PRODUCT", 337, 343], ["DiscussionEotaxin-2", "GENE_OR_GENE_PRODUCT", 480, 499], ["eosinophils", "CELL", 552, 563], ["RANTES", "PROTEIN", 30, 36], ["antibodies", "PROTEIN", 117, 127], ["IFN", "PROTEIN", 167, 170], ["IL-6", "PROTEIN", 191, 195], ["co-stimulatory molecules", "PROTEIN", 225, 249], ["cytokine receptors", "PROTEIN", 275, 293], ["RANTES", "PROTEIN", 337, 343], ["eosinophils", "CELL_TYPE", 552, 563], ["systemic humoral production of antibodies", "PROBLEM", 86, 127], ["an elevation", "PROBLEM", 133, 145], ["IFN", "TEST", 167, 170], ["c-", "TEST", 171, 173], ["IL", "TEST", 175, 177], ["IL", "TEST", 182, 184], ["an induction of co-stimulatory molecules", "TREATMENT", 209, 249], ["cytokine receptors", "TEST", 275, 293], ["CD", "TEST", 298, 300], ["T cells", "TEST", 303, 310], ["relative mRNA expression levels", "PROBLEM", 428, 459], ["eosinophils in vitro", "TREATMENT", 552, 572], ["mucosal", "ANATOMY", 67, 74], ["elevation", "OBSERVATION", 136, 145], ["mRNA expression", "OBSERVATION", 437, 452]]], ["In eosinophils, eotaxin-2 causes a dose-dependent increase of the production of free radicals, mobilisation of intracellular calcium and upregulation of CD11b 40.DiscussionEotaxin-2 expression was evident in all analysed subgroups with a significant upregulation in adenoids, suggesting an involvement of Th2- immune responses as eotaxin-2 which is known to play a crucial role in the pathogenesis of atopic diseases involving Th 2- cell activation 41.", [["eosinophils", "ANATOMY", 3, 14], ["intracellular", "ANATOMY", 111, 124], ["adenoids", "ANATOMY", 266, 274], ["Th 2- cell", "ANATOMY", 427, 437], ["calcium", "CHEMICAL", 125, 132], ["atopic diseases", "DISEASE", 401, 416], ["calcium", "CHEMICAL", 125, 132], ["eosinophils", "CELL", 3, 14], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 16, 25], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["CD11b 40", "GENE_OR_GENE_PRODUCT", 153, 161], ["DiscussionEotaxin-2", "GENE_OR_GENE_PRODUCT", 162, 181], ["adenoids", "ORGAN", 266, 274], ["Th2", "GENE_OR_GENE_PRODUCT", 305, 308], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 330, 339], ["Th 2- cell", "CELL", 427, 437], ["eosinophils", "CELL_TYPE", 3, 14], ["eotaxin", "PROTEIN", 16, 23], ["CD11b 40", "PROTEIN", 153, 161], ["eotaxin", "PROTEIN", 330, 337], ["eosinophils", "TEST", 3, 14], ["eotaxin", "TREATMENT", 16, 23], ["free radicals", "TREATMENT", 80, 93], ["intracellular calcium", "TREATMENT", 111, 132], ["CD11b", "TEST", 153, 158], ["a significant upregulation in adenoids", "PROBLEM", 236, 274], ["eotaxin", "TREATMENT", 330, 337], ["atopic diseases", "PROBLEM", 401, 416], ["significant", "OBSERVATION_MODIFIER", 238, 249], ["upregulation", "OBSERVATION", 250, 262], ["adenoids", "OBSERVATION", 266, 274], ["atopic diseases", "OBSERVATION", 401, 416]]], ["Significant upregulation of eotaxin-2 has been observed in bronchial asthma 42 and allergic rhinitis 43.", [["bronchial", "ANATOMY", 59, 68], ["bronchial asthma", "DISEASE", 59, 75], ["allergic rhinitis", "DISEASE", 83, 100], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 28, 37], ["eotaxin", "PROTEIN", 28, 35], ["Significant upregulation of eotaxin", "TREATMENT", 0, 35], ["bronchial asthma", "PROBLEM", 59, 75], ["allergic rhinitis", "PROBLEM", 83, 100], ["upregulation", "OBSERVATION", 12, 24], ["eotaxin", "OBSERVATION", 28, 35], ["bronchial", "ANATOMY", 59, 68], ["asthma", "OBSERVATION", 69, 75], ["allergic rhinitis", "OBSERVATION", 83, 100]]], ["However, the significance of eotaxin-2 expression in lymphatic tissue of the Waldeyer\u2019s tonsillar ring still largely remains uncertain, like their role in the maturation of the adaptive immune system in the mucosa of the upper aerodigestive tract.", [["lymphatic tissue", "ANATOMY", 53, 69], ["Waldeyer\u2019s tonsillar ring", "ANATOMY", 77, 102], ["immune system", "ANATOMY", 186, 199], ["mucosa", "ANATOMY", 207, 213], ["upper aerodigestive tract", "ANATOMY", 221, 246], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 29, 38], ["lymphatic tissue", "TISSUE", 53, 69], ["tonsillar ring", "MULTI-TISSUE_STRUCTURE", 88, 102], ["immune system", "ANATOMICAL_SYSTEM", 186, 199], ["mucosa", "MULTI-TISSUE_STRUCTURE", 207, 213], ["upper aerodigestive", "ORGANISM_SUBDIVISION", 221, 240], ["tract", "ORGANISM_SUBDIVISION", 241, 246], ["eotaxin", "PROTEIN", 29, 36], ["eotaxin", "TREATMENT", 29, 36], ["eotaxin", "OBSERVATION", 29, 36], ["lymphatic tissue", "ANATOMY", 53, 69], ["tonsillar", "ANATOMY", 88, 97], ["ring", "ANATOMY_MODIFIER", 98, 102], ["mucosa", "ANATOMY", 207, 213], ["upper", "ANATOMY_MODIFIER", 221, 226], ["aerodigestive tract", "ANATOMY", 227, 246]]], ["However, it is remarkable that eotaxin-2 as well as RANTES are constitutively expressed in the mucosa of the gastrointestinal tract, an organ with distinctive antigen contact, such as Waldeyer`s tonsilar ring 4445.DiscussionTo further evaluate the role of the chemokines analysed in the function of the lymphatic tissue of the Waldeyer\u2019s tonsillar ring, it is essential to evaluate their expression on protein level to examine alterations through potential post-transcriptional splicing.", [["mucosa", "ANATOMY", 95, 101], ["gastrointestinal tract", "ANATOMY", 109, 131], ["organ", "ANATOMY", 136, 141], ["lymphatic tissue", "ANATOMY", 303, 319], ["Waldeyer\u2019s tonsillar ring", "ANATOMY", 327, 352], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 31, 40], ["RANTES", "GENE_OR_GENE_PRODUCT", 52, 58], ["mucosa", "MULTI-TISSUE_STRUCTURE", 95, 101], ["gastrointestinal tract", "ORGAN", 109, 131], ["organ", "ORGAN", 136, 141], ["antigen", "GENE_OR_GENE_PRODUCT", 159, 166], ["lymphatic tissue", "TISSUE", 303, 319], ["Waldeyer\u2019s tonsillar ring", "TISSUE", 327, 352], ["eotaxin", "PROTEIN", 31, 38], ["RANTES", "PROTEIN", 52, 58], ["chemokines", "PROTEIN", 260, 270], ["eotaxin-2", "TREATMENT", 31, 40], ["the chemokines", "TEST", 256, 270], ["protein level", "TEST", 402, 415], ["potential post-transcriptional splicing", "TREATMENT", 447, 486], ["mucosa", "ANATOMY", 95, 101], ["gastrointestinal tract", "ANATOMY", 109, 131], ["organ", "ANATOMY", 136, 141], ["lymphatic tissue", "ANATOMY", 303, 319], ["tonsillar ring", "ANATOMY", 338, 352], ["transcriptional splicing", "OBSERVATION", 462, 486]]], ["Also, immunohistochemical studies would be of interest to evaluate their expression in relation to certain cell populations.", [["cell", "ANATOMY", 107, 111], ["cell populations", "CELL", 107, 123], ["immunohistochemical studies", "TEST", 6, 33], ["certain cell populations", "TREATMENT", 99, 123], ["certain cell populations", "OBSERVATION", 99, 123]]], ["These studies would greatly aid in understanding the pathophysiology of tonsillar disease, from which patients could benefit in the future.ConclusionsThe presented data suggest that the majority of diseases related to adenoid formation are mediated via an eotaxin-2 expression, whereas chronic inflammatory tonsillitis is associated with IL-8 upregulation.", [["tonsillar", "ANATOMY", 72, 81], ["adenoid", "ANATOMY", 218, 225], ["tonsillar disease", "DISEASE", 72, 89], ["tonsillitis", "DISEASE", 307, 318], ["tonsillar", "ORGAN", 72, 81], ["patients", "ORGANISM", 102, 110], ["adenoid", "ORGAN", 218, 225], ["eotaxin-2", "GENE_OR_GENE_PRODUCT", 256, 265], ["IL-8", "GENE_OR_GENE_PRODUCT", 338, 342], ["eotaxin", "PROTEIN", 256, 263], ["IL", "PROTEIN", 338, 340], ["patients", "SPECIES", 102, 110], ["These studies", "TEST", 0, 13], ["tonsillar disease", "PROBLEM", 72, 89], ["diseases", "PROBLEM", 198, 206], ["adenoid formation", "PROBLEM", 218, 235], ["an eotaxin", "TREATMENT", 253, 263], ["chronic inflammatory tonsillitis", "PROBLEM", 286, 318], ["IL-8 upregulation", "TREATMENT", 338, 355], ["tonsillar", "ANATOMY", 72, 81], ["disease", "OBSERVATION", 82, 89], ["diseases", "OBSERVATION", 198, 206], ["adenoid", "OBSERVATION", 218, 225], ["chronic", "OBSERVATION_MODIFIER", 286, 293], ["inflammatory", "OBSERVATION_MODIFIER", 294, 306], ["tonsillitis", "OBSERVATION", 307, 318]]], ["Thus, these data imply that adenoids are related to a Th-2 response, and chronic inflammatory tonsillitis to a Th-1 based immune response.", [["adenoids", "ANATOMY", 28, 36], ["adenoids", "DISEASE", 28, 36], ["tonsillitis", "DISEASE", 94, 105], ["adenoids", "ORGAN", 28, 36], ["Th-2", "GENE_OR_GENE_PRODUCT", 54, 58], ["Th-1", "GENE_OR_GENE_PRODUCT", 111, 115], ["adenoids", "PROBLEM", 28, 36], ["chronic inflammatory tonsillitis", "PROBLEM", 73, 105], ["adenoids", "OBSERVATION", 28, 36], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["tonsillitis", "OBSERVATION", 94, 105]]]], "ede3e68d78272c42ca9dfe80d79c589076ae7178": [["2 HCQ is widely used to treat dermatologic and rheumatologic diseases and it has been described as one of the main drugs triggering acute generalized exanthematous pustulosis (AGEP).", [["HCQ", "CHEMICAL", 2, 5], ["dermatologic and rheumatologic diseases", "DISEASE", 30, 69], ["exanthematous pustulosis", "DISEASE", 150, 174], ["AGEP", "DISEASE", 176, 180], ["HCQ", "CHEMICAL", 2, 5], ["HCQ", "SIMPLE_CHEMICAL", 2, 5], ["dermatologic and rheumatologic diseases", "PROBLEM", 30, 69], ["acute generalized exanthematous pustulosis", "PROBLEM", 132, 174], ["rheumatologic", "OBSERVATION", 47, 60], ["main", "OBSERVATION_MODIFIER", 110, 114], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["generalized", "OBSERVATION_MODIFIER", 138, 149], ["exanthematous", "OBSERVATION_MODIFIER", 150, 163], ["pustulosis", "OBSERVATION", 164, 174]]], ["3, 4 Only one single case of AGEP induced by HIV post-exposure prophylaxis with Lopinavir/Ritonavir has been reported.", [["AGEP", "DISEASE", 29, 33], ["Lopinavir", "CHEMICAL", 80, 89], ["Ritonavir", "CHEMICAL", 90, 99], ["Lopinavir", "CHEMICAL", 80, 89], ["Ritonavir", "CHEMICAL", 90, 99], ["AGEP", "CANCER", 29, 33], ["HIV", "ORGANISM", 45, 48], ["Lopinavir", "SIMPLE_CHEMICAL", 80, 89], ["Ritonavir", "SIMPLE_CHEMICAL", 90, 99], ["HIV", "SPECIES", 45, 48], ["HIV", "SPECIES", 45, 48], ["AGEP", "PROBLEM", 29, 33], ["HIV post-exposure prophylaxis", "TREATMENT", 45, 74], ["Lopinavir", "TREATMENT", 80, 89], ["Ritonavir", "TREATMENT", 90, 99]]], ["5 A 70-year-old Italian woman with no personal/family history of psoriasis was admitted to our clinic for the rapid onset of a diffuse, pruritic pustular eruption.", [["pustular", "ANATOMY", 145, 153], ["psoriasis", "DISEASE", 65, 74], ["pustular eruption", "DISEASE", 145, 162], ["woman", "ORGANISM", 24, 29], ["woman", "SPECIES", 24, 29], ["psoriasis", "PROBLEM", 65, 74], ["a diffuse, pruritic pustular eruption", "PROBLEM", 125, 162], ["psoriasis", "OBSERVATION", 65, 74], ["diffuse", "OBSERVATION_MODIFIER", 127, 134], ["pruritic", "OBSERVATION_MODIFIER", 136, 144], ["pustular", "OBSERVATION_MODIFIER", 145, 153], ["eruption", "OBSERVATION", 154, 162]]], ["Three weeks before she had been treated for SARS-CoV-2 pneumonia with Lopinavir/Ritonavir 200/50mg 2 tables and HCQ 200 mg bid for 10 days with a good response.", [["SARS-CoV-2 pneumonia", "DISEASE", 44, 64], ["Lopinavir", "CHEMICAL", 70, 79], ["Ritonavir", "CHEMICAL", 80, 89], ["HCQ", "CHEMICAL", 112, 115], ["Lopinavir", "CHEMICAL", 70, 79], ["Ritonavir", "CHEMICAL", 80, 89], ["HCQ", "CHEMICAL", 112, 115], ["Lopinavir", "SIMPLE_CHEMICAL", 70, 79], ["Ritonavir", "SIMPLE_CHEMICAL", 80, 89], ["HCQ", "SIMPLE_CHEMICAL", 112, 115], ["CoV-", "SPECIES", 49, 53], ["SARS-CoV-2", "SPECIES", 44, 54], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["pneumonia", "PROBLEM", 55, 64], ["Lopinavir", "TREATMENT", 70, 79], ["Ritonavir", "TREATMENT", 80, 89], ["HCQ", "TREATMENT", 112, 115], ["pneumonia", "OBSERVATION", 55, 64]]], ["Three days after the withdrawal of the treatment she referred the onset of a skin eruption on the upper arms, rapidly spreading to the trunk.", [["skin", "ANATOMY", 77, 81], ["trunk", "ANATOMY", 135, 140], ["skin eruption", "DISEASE", 77, 90], ["skin", "ORGAN", 77, 81], ["upper arms", "ORGANISM_SUBDIVISION", 98, 108], ["trunk", "ORGANISM_SUBDIVISION", 135, 140], ["the treatment", "TREATMENT", 35, 48], ["a skin eruption", "PROBLEM", 75, 90], ["skin", "ANATOMY", 77, 81], ["eruption", "OBSERVATION", 82, 90], ["upper", "ANATOMY_MODIFIER", 98, 103], ["arms", "ANATOMY", 104, 108], ["trunk", "ANATOMY", 135, 140]]], ["She consulted her primary care physician and began treatment with oral prednisone 0.3 mg/Kg daily.", [["oral", "ANATOMY", 66, 70], ["prednisone", "CHEMICAL", 71, 81], ["prednisone", "CHEMICAL", 71, 81], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["prednisone", "SIMPLE_CHEMICAL", 71, 81], ["oral prednisone", "TREATMENT", 66, 81]]]], "PMC7292029": [["IntroductionThe global pandemic of COVID-19 (a disease caused by a novel coronavirus, SARS-CoV-2) has caused drastic changes in the structure of people's daily routines in many countries around the world, including the way we purchase food.", [["COVID-19", "CHEMICAL", 35, 43], ["coronavirus", "DISEASE", 73, 84], ["SARS", "DISEASE", 86, 90], ["COVID-19", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 86, 96], ["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["COVID-19", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 86, 94], ["COVID", "TEST", 35, 40], ["a disease", "PROBLEM", 45, 54], ["a novel coronavirus", "PROBLEM", 65, 84], ["SARS", "PROBLEM", 86, 90], ["drastic changes", "PROBLEM", 109, 124], ["global", "OBSERVATION_MODIFIER", 16, 22], ["pandemic", "OBSERVATION_MODIFIER", 23, 31], ["drastic", "OBSERVATION_MODIFIER", 109, 116]]], ["Many regions and countries have \u201clocked down\u201d to prevent the spread of the virus, including first Wuhan in China, and countries such as the USA, UK, Germany, India, Poland, and New Zealand.", [["the virus", "PROBLEM", 71, 80], ["virus", "OBSERVATION", 75, 80]]], ["During these lockdown periods, people are only allowed to leave their homes if strictly necessary\u2014e.g., for essential work, exercise, medical care, or to purchase groceries or supplies.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37]]], ["Although these lockdowns were initially declared to last for a matter of weeks, Ferguson et al. (2020) suggest that lockdowns may need to be implemented regularly for over a year, in order to manage the burden of COVID-19 on health services.IntroductionThis opinion paper evaluates the emerging and likely consequences of these lockdowns on consumer grocery purchasing habits and their implications for food retail as of early April of 2020, with a particular focus on New Zealand as a case study.", [["COVID", "DISEASE", 213, 218], ["COVID", "TEST", 213, 218], ["a case study", "TEST", 484, 496]]], ["However, in the weeks before the lockdown was announced, many individuals began to panic buy and stock-pile products such as water, gloves, carbohydrate-rich staples (e.g., bread, pasta), canned food, hand sanitizer, and even toilet paper (Mao, 2020).Consumer Behavior Prior To LockdownPanic buying is a common response at times of fear and uncertainty, and can be seen as rational (e.g., stockpiling essential goods that are in limited supply) or irrational (e.g., stockpiling non-essential products that are not in limited supply; Sterman and Dogan, 2015).", [["hand", "ANATOMY", 201, 205], ["panic", "DISEASE", 83, 88], ["carbohydrate", "CHEMICAL", 140, 152], ["bread", "ORGANISM_SUBDIVISION", 173, 178], ["pasta", "ORGANISM_SUBDIVISION", 180, 185], ["hand", "ORGANISM_SUBDIVISION", 201, 205], ["stock-pile products", "TREATMENT", 97, 116], ["gloves", "TREATMENT", 132, 138], ["carbohydrate-rich staples", "TREATMENT", 140, 165], ["hand sanitizer", "TREATMENT", 201, 215], ["irrational (e.g., stockpiling non-essential products", "PROBLEM", 448, 500], ["staples", "OBSERVATION", 158, 165]]], ["Even though supply chains were operating as normal, the panic buying itself caused shortages of many products on the supermarket shelves.", [["panic", "DISEASE", 56, 61], ["chains", "OBSERVATION_MODIFIER", 19, 25], ["normal", "OBSERVATION", 44, 50]]], ["Given that people are especially influenced by the behavior of their peers at times of uncertainty (Sherif, 1936; Pickett and Gardner, 2005; Smith et al., 2007), seeing others engage in panic buying likely exacerbated the situation.", [["panic", "DISEASE", 186, 191], ["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17]]], ["The recent cases of panic buying were not novel\u2014during the SARS epidemic, misinformation and rumors spread via the internet and SMS communications were also linked to waves of panic buying (e.g., Ding, 2009).Consumers' Shifting Grocery Shopping ExperienceFollowing the outbreak of a global pandemic of COVID-19, the retail experience has dramatically changed for the foreseeable future.", [["panic", "DISEASE", 20, 25], ["SARS", "DISEASE", 59, 63], ["panic", "DISEASE", 176, 181], ["COVID-19", "CHEMICAL", 302, 310], ["panic buying", "PROBLEM", 20, 32], ["the SARS epidemic", "PROBLEM", 55, 72], ["panic buying", "PROBLEM", 176, 188]]], ["Supermarkets in New Zealand, Europe, Australia, the USA, and the UK have introduced changes to reduce panic buying and to minimize the spread of COVID-19 while shopping, although these changes vary considerably from store to store.", [["panic", "DISEASE", 102, 107], ["panic buying", "TREATMENT", 102, 114], ["COVID", "TEST", 145, 150], ["New", "OBSERVATION_MODIFIER", 16, 19], ["Zealand", "OBSERVATION_MODIFIER", 20, 27]]], ["Some of the more common measures are described below.Consumers' Shifting Grocery Shopping ExperienceSupermarkets have placed a temporary limit for their customers of buying two or three similar items per shopping visit, reduced their opening hours, and asked people to \u201cshop normal\u201d (Coles, 2020; Countdown, 2020a; nzherald.co.nz, 2020), in order to mitigate the effects of panic buying.Consumers' Shifting Grocery Shopping ExperienceTo minimize the spread of the virus, shoppers are required to maintain a distance from other customers and staff of 1.5\u20132 m (Australian Government Department of Health, 2020; New Zealand Government, 2020).", [["panic", "DISEASE", 374, 379], ["people", "SPECIES", 259, 265], ["panic buying", "PROBLEM", 374, 386], ["more common", "OBSERVATION_MODIFIER", 12, 23]]], ["Customers have been asked to shop alone, and once stores have reached the maximum safe capacity, people are only allowed to enter the supermarket on a \u201cone in, one out\u201d basis, with floor-markings at checkouts directing customers to maintain their distance (New World, 2020; Waitrose, 2020).", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["Other supermarkets have closed deli counters and salad bars to avoid close contact with their customers (World Economic Forum, 2020).Consumers' Shifting Grocery Shopping ExperienceLike other viral diseases, there is the possibility that food shoppers might contract COVID-19 by simply touching a surface or object that has the virus on it (CDC, 2020).", [["surface", "ANATOMY", 296, 303], ["viral diseases", "DISEASE", 191, 205], ["COVID-19", "CHEMICAL", 266, 274], ["COVID-19", "CHEMICAL", 266, 274], ["surface", "CELLULAR_COMPONENT", 296, 303], ["other viral diseases", "PROBLEM", 185, 205], ["the virus", "PROBLEM", 323, 332], ["viral diseases", "OBSERVATION", 191, 205]]], ["Supermarkets are now providing wipes for cleaning trolley/basket handles and hand sanitizing units, which are placed around the store (New World, 2020; Tesco, 2020).Consumers' Shifting Grocery Shopping ExperienceTo buy groceries, consumers usually touch cash or credit cards.", [["hand", "ANATOMY", 77, 81], ["cleaning trolley/basket handles", "TREATMENT", 41, 72], ["hand sanitizing units", "TREATMENT", 77, 98]]], ["Supermarkets are advising their customers to pay in a cashless or contactless way (e.g., using payWave or Tap & Go) to minimize the handling of cash (New World, 2020; Waitrose, 2020) and reduce the chance of the virus spreading through this means (Seymour et al., 2020).", [["Tap", "TREATMENT", 106, 109], ["the virus spreading", "PROBLEM", 208, 227]]], ["Under time constraints, most people will not have time to process product information, and rely more heavily on heuristics such as brand name, price, product images, and color-coded labels to make their food choices (Nowlis, 1995; Schulte-Mecklenbeck et al., 2013; Bialkova et al., 2020).", [["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35]]], ["Suri and Monroe (2003) show that motivation to find information also plays a role, such that when under time pressure, people motivated to process information rely on these heuristics more than those who are not motivated.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125]]], ["Under the current shopping conditions, the use of these heuristics is likely to increase.", [["likely to", "UNCERTAINTY", 70, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88]]], ["As a result, consumers under time constraints are predicted to choose high price and high-quality brands over low-quality and low-price brands, and products with enhanced features (Bialkova et al., 2020) over more basic products.Demand for Online Shopping ::: Implications of Constraints on The Shopping ProcessSince the lockdown, supermarkets have created systems to more safely deliver groceries\u2014e.g., in New Zealand, New World Supermarket introduced contactless deliveries for people who ordered online (New World, 2020).", [["people", "ORGANISM", 480, 486], ["people", "SPECIES", 480, 486]]], ["However, demand for online shopping has dramatically increased, similar to what happened during the SARS epidemic (e.g., Kee and Wan, 2004; Forster and Ya, 2005), and this demand has exceeded the capacity of supermarkets in many countries.", [["SARS", "DISEASE", 100, 104], ["dramatically", "OBSERVATION_MODIFIER", 40, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["As such, many supermarkets are restricting this service to those particularly in need (e.g., people over 70 years of age, people with chronic illness, people who are in self-isolation, people with disabilities; Countdown, 2020a).", [["chronic illness", "DISEASE", 134, 149], ["people", "ORGANISM", 93, 99], ["people", "ORGANISM", 151, 157], ["people", "ORGANISM", 185, 191], ["people", "SPECIES", 93, 99], ["people", "SPECIES", 122, 128], ["people", "SPECIES", 151, 157], ["people", "SPECIES", 185, 191]]], ["It is likely that due to these restrictions, many consumers will not have a positive experience and will not be satisfied with the service.", [["likely that due to", "UNCERTAINTY", 6, 24]]], ["No New Zealand supermarket is currently offering a \u2018live customer support chat' to provide customers with immediate help with accessing their services.", [["New", "OBSERVATION_MODIFIER", 3, 6], ["Zealand", "OBSERVATION", 7, 14]]], ["However, to cope with this increased demand, many retail shops are expanding their online capabilities\u2014e.g., Countdown has just launched the first national e-store supermarket (Countdown, 2020b).Grocery Expenditures ::: Implications of Constraints on The Shopping ProcessDuring the Great Recession of 2008, consumer spending on supermarket foods increased (Cha et al., 2015), while spending on many other product categories decreased.", [["this increased demand", "PROBLEM", 22, 43], ["decreased", "OBSERVATION_MODIFIER", 424, 433]]], ["This trend is likely to be visible in the expected recession due to COVID-19, as opportunities to spend at other outlets are greatly restricted.", [["COVID", "TEST", 68, 73], ["likely to be", "UNCERTAINTY", 14, 26], ["recession", "OBSERVATION", 51, 60]]], ["Disruptions in the supply change may cause supply limitations and a further increase in prices.", [["Disruptions in the supply change", "PROBLEM", 0, 32], ["a further increase in prices", "PROBLEM", 66, 94], ["increase", "OBSERVATION_MODIFIER", 76, 84]]], ["However, supermarket spending will likely vary depending on the income (support) that consumers have available during and after the pandemic.DiscussionGenerally, people purchase according to food habits and liking (Sproesser et al., 2018).", [["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168]]], ["Under the new shopping conditions of the COVID-19 pandemic, food choices will depend heavily on product availability and restrictions on how many products consumers can buy.", [["the COVID", "TREATMENT", 37, 46]]], ["We can expect that consumers will predominantly use simple heuristics such as brand and price, particularly with products for which they usually spend time looking at labels and packaging at the point of sale.", [["simple heuristics", "TREATMENT", 52, 69]]], ["Although people will continue to make purchases in line with their individual taste preferences, habits, and health beliefs, given the present restrictions on the availability of some food products, they may need to sometimes buy unfamiliar brands.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["some food products", "TREATMENT", 179, 197]]], ["Easily-recognized, well-established brands (where available) should therefore have an advantage over newer and less prominent brands.DiscussionTo be competitive, food companies will need to deliver a customer-centric experience that make it enjoyable for people to go to the supermarket, without compromising staff or customer safety.", [["people", "ORGANISM", 255, 261], ["people", "SPECIES", 255, 261]]], ["Supermarkets will also need to fine-tune their online delivery services to maintain consumers' trust and confidence in the face of elevated demand.", [["online delivery services", "TREATMENT", 47, 71], ["elevated demand", "PROBLEM", 131, 146], ["elevated", "OBSERVATION", 131, 139]]]], "346b3ccd9b1bdd7dbe3fab3ee41884b97284383b": [["NF-\u03baB and STAT3 signaling mainly had known to regulate several biological interactions; development, proliferation, differentiation as well as cancer and inflammation (He & Karin, 2011) .", [["cancer", "ANATOMY", 143, 149], ["cancer", "DISEASE", 143, 149], ["inflammation", "DISEASE", 154, 166], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["STAT3", "GENE_OR_GENE_PRODUCT", 10, 15], ["cancer", "CANCER", 143, 149], ["NF-\u03baB", "PROTEIN", 0, 5], ["STAT3", "PROTEIN", 10, 15], ["cancer", "PROBLEM", 143, 149], ["inflammation", "PROBLEM", 154, 166], ["proliferation", "OBSERVATION", 101, 114], ["cancer", "OBSERVATION", 143, 149], ["inflammation", "OBSERVATION", 154, 166]]], ["In perspectives of inflammatory action, NF-\u03baB acts on a family of inducible transcription factors that regulate a lot of genes associated with individual functional processes in inflammation in innate immune cells, including macrophages (Oeckinghaus & Ghosh, 2009 ).", [["immune cells", "ANATOMY", 201, 213], ["macrophages", "ANATOMY", 225, 236], ["inflammation", "DISEASE", 178, 190], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["innate immune cells", "CELL", 194, 213], ["macrophages", "CELL", 225, 236], ["NF-\u03baB", "PROTEIN", 40, 45], ["transcription factors", "PROTEIN", 76, 97], ["innate immune cells", "CELL_TYPE", 194, 213], ["macrophages", "CELL_TYPE", 225, 236], ["inflammatory action", "PROBLEM", 19, 38], ["inducible transcription factors", "PROBLEM", 66, 97], ["individual functional processes", "PROBLEM", 143, 174], ["inflammation in innate immune cells", "PROBLEM", 178, 213], ["inflammatory", "OBSERVATION", 19, 31], ["inflammation", "OBSERVATION", 178, 190], ["innate immune cells", "OBSERVATION", 194, 213], ["macrophages", "ANATOMY", 225, 236]]], ["In addition, STAT3 is involved in a family of cytoplasmic protein with SH2 (Src Homology-2) domains.", [["cytoplasmic", "ANATOMY", 46, 57], ["STAT3", "GENE_OR_GENE_PRODUCT", 13, 18], ["cytoplasmic", "ORGANISM_SUBSTANCE", 46, 57], ["SH2", "GENE_OR_GENE_PRODUCT", 71, 74], ["Src Homology-2", "GENE_OR_GENE_PRODUCT", 76, 90], ["STAT3", "PROTEIN", 13, 18], ["cytoplasmic protein", "PROTEIN", 46, 65], ["SH2", "PROTEIN", 71, 74], ["Src Homology-2) domains", "PROTEIN", 76, 99], ["SH2 (Src Homology", "TREATMENT", 71, 88]]]], "83e7619e70e57e3f10a6c84229e6d69011f894ee": [["IntroductionHuman noroviruses (NoVs) infections are considered a significant public health problem, which cause more than 50% of non-bacterial gastroenteritis characterized by fever, vomiting and frequent episodes of diarrhea, especially in adults and children (Ahmed et al. 2014; Kaplan et al. 1982) .", [["noroviruses (NoVs) infections", "DISEASE", 18, 47], ["gastroenteritis", "DISEASE", 143, 158], ["fever", "DISEASE", 176, 181], ["vomiting", "DISEASE", 183, 191], ["diarrhea", "DISEASE", 217, 225], ["IntroductionHuman noroviruses", "ORGANISM", 0, 29], ["children", "ORGANISM", 252, 260], ["children", "SPECIES", 252, 260], ["IntroductionHuman noroviruses (NoVs) infections", "PROBLEM", 0, 47], ["non-bacterial gastroenteritis", "PROBLEM", 129, 158], ["fever", "PROBLEM", 176, 181], ["vomiting", "PROBLEM", 183, 191], ["diarrhea", "PROBLEM", 217, 225], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["non-bacterial", "OBSERVATION_MODIFIER", 129, 142], ["gastroenteritis", "OBSERVATION", 143, 158], ["fever", "OBSERVATION", 176, 181], ["diarrhea", "OBSERVATION", 217, 225]]], ["NoVs are divided into 5 genogroups designated GI through to GV and subdivided into 9 and 22 genotypes, which were first linked to human disease in 1972 (Kroneman et al. 2013; Zheng et al. 2006) .", [["human disease", "DISEASE", 130, 143], ["NoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GI", "CANCER", 46, 48], ["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135]]], ["From the mid-1990s, Genogroup II, genotype 4 (GII.4) NoV have predominantly occored as outbreaks, which emergence with new variants every two or three years (Ramani et al. 2014) .", [["NoV", "ORGANISM", 53, 56], ["mid", "ANATOMY_MODIFIER", 9, 12], ["predominantly occored", "OBSERVATION_MODIFIER", 62, 83]]], ["However, since the emergence of the novel Genogroup II, genotype 17 (GII.17) Kawasaki_2014 strain, a new pandemic strain has become predominant in the world.", [["Genogroup II", "PROTEIN", 42, 54], ["genotype", "TEST", 56, 64], ["Kawasaki_2014 strain", "PROBLEM", 77, 97], ["a new pandemic strain", "PROBLEM", 99, 120], ["new", "OBSERVATION_MODIFIER", 101, 104], ["predominant", "OBSERVATION_MODIFIER", 132, 143]]], ["The novel GII.17 not only caused NoVs outbreaks but also spread sporadically with cases reported in China (Shanghai, Taiwan) and USA during the winter of 2014_2015 Lee et al. 2015; Parra and Green 2015) .", [["NoVs", "PATHOLOGICAL_FORMATION", 33, 37], ["NoVs outbreaks", "PROBLEM", 33, 47], ["GII", "OBSERVATION", 10, 13], ["outbreaks", "OBSERVATION", 38, 47]]], ["These epidemiological surveys indicated that NoV GII.17 is becoming an important etiological agent of gastroenteritis.IntroductionNoVs belongs to the family of Caliciviridae and are nonenveloped, single-stranded, positive-sense ribonucleic acid (RNA) viruses.", [["gastroenteritis", "DISEASE", 102, 117], ["ribonucleic acid", "CHEMICAL", 228, 244], ["NoV GII", "ORGANISM", 45, 52], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 160, 173], ["nonenveloped, single-stranded, positive-sense ribonucleic acid", "RNA", 182, 244], ["NoV GII", "SPECIES", 45, 52], ["These epidemiological surveys", "TEST", 0, 29], ["gastroenteritis", "PROBLEM", 102, 117], ["Caliciviridae", "TREATMENT", 160, 173], ["sense ribonucleic acid (RNA) viruses", "PROBLEM", 222, 258], ["gastroenteritis", "OBSERVATION", 102, 117]]], ["The genomes are 7.4-7.7 kb in size and are typically organized into three open reading frames (ORFs).", [["open reading frames", "DNA", 74, 93], ["ORFs", "DNA", 95, 99], ["7.4-7.7 kb", "OBSERVATION_MODIFIER", 16, 26], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["The ORF1 encodes nonstructural proteins, such as the RNA dependent RNA polymerase (RdRp), while the structural proteins, such as the major and minor capsid protein (VP1 and VP2), are encoded by ORF2 and ORF3, respectively (Glass et al. 2009 ).", [["ORF1", "GENE_OR_GENE_PRODUCT", 4, 8], ["RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 53, 81], ["RdRp", "GENE_OR_GENE_PRODUCT", 83, 87], ["VP1", "GENE_OR_GENE_PRODUCT", 165, 168], ["VP2", "GENE_OR_GENE_PRODUCT", 173, 176], ["ORF2", "GENE_OR_GENE_PRODUCT", 194, 198], ["ORF3", "GENE_OR_GENE_PRODUCT", 203, 207], ["ORF1", "DNA", 4, 8], ["nonstructural proteins", "PROTEIN", 17, 39], ["RNA dependent RNA polymerase", "PROTEIN", 53, 81], ["RdRp", "PROTEIN", 83, 87], ["structural proteins", "PROTEIN", 100, 119], ["major and minor capsid protein", "PROTEIN", 133, 163], ["VP1", "PROTEIN", 165, 168], ["VP2", "PROTEIN", 173, 176], ["ORF2", "DNA", 194, 198], ["ORF3", "DNA", 203, 207], ["The ORF1 encodes nonstructural proteins", "PROBLEM", 0, 39], ["the RNA dependent RNA polymerase", "PROBLEM", 49, 81], ["VP1", "TEST", 165, 168], ["VP2", "TEST", 173, 176], ["nonstructural proteins", "OBSERVATION", 17, 39]]], ["VP1 is a 60 KDa protein that can be divided into a shell domain (S domain) and a protruding domain (P domain).", [["VP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP1", "PROTEIN", 0, 3], ["60 KDa protein", "PROTEIN", 9, 23], ["shell domain", "PROTEIN", 51, 63], ["S domain", "PROTEIN", 65, 73], ["protruding domain", "PROTEIN", 81, 98], ["P domain", "PROTEIN", 100, 108], ["VP1", "TEST", 0, 3], ["a 60 KDa protein", "TEST", 7, 23], ["a protruding domain (P domain)", "TREATMENT", 79, 109]]], ["The S domain forms a scaffold surrounding the viral RNA and is responsible for the shell structure of the capsid, whereas the P domain contains neutralizing epitopes and binds to the histo-blood group antigens (HBGAs) receptors, responsible for the genetic variability, builds the viral spikes and facilitates cell attachment (Debbink et al. 2012; Prasad et al. 1999; Tan and Jiang 2005) .", [["cell", "ANATOMY", 310, 314], ["histo-blood group antigens", "GENE_OR_GENE_PRODUCT", 183, 209], ["HBGAs", "GENE_OR_GENE_PRODUCT", 211, 216], ["cell", "CELL", 310, 314], ["S domain", "PROTEIN", 4, 12], ["viral RNA", "RNA", 46, 55], ["capsid", "PROTEIN", 106, 112], ["P domain", "PROTEIN", 126, 134], ["neutralizing epitopes", "PROTEIN", 144, 165], ["histo-blood group antigens (HBGAs) receptors", "PROTEIN", 183, 227], ["a scaffold surrounding the viral RNA", "PROBLEM", 19, 55], ["the capsid", "PROBLEM", 102, 112], ["neutralizing epitopes", "PROBLEM", 144, 165], ["the genetic variability", "PROBLEM", 245, 268], ["the viral spikes", "PROBLEM", 277, 293], ["viral RNA", "OBSERVATION", 46, 55], ["responsible for", "UNCERTAINTY", 63, 78], ["shell structure", "OBSERVATION", 83, 98], ["capsid", "OBSERVATION", 106, 112], ["neutralizing epitopes", "OBSERVATION", 144, 165], ["viral spikes", "OBSERVATION", 281, 293]]], ["VP2, a minor capsid protein, exhibit multiple functions, which are observed to stabilize and promote expression of VP1 (Lin et al. 2014) .IntroductionThe most recent outbreak of NoV GII.17 strain has been sweeping all over the world; however, there are no available vaccines or specific treatments.", [["VP2", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP1", "GENE_OR_GENE_PRODUCT", 115, 118], ["NoV GII", "ORGANISM", 178, 185], ["VP2", "PROTEIN", 0, 3], ["minor capsid protein", "PROTEIN", 7, 27], ["VP1", "PROTEIN", 115, 118], ["NoV GII", "SPECIES", 178, 185], ["VP2", "TEST", 0, 3], ["a minor capsid protein", "PROBLEM", 5, 27], ["available vaccines", "TREATMENT", 256, 274], ["specific treatments", "TREATMENT", 278, 297], ["capsid protein", "OBSERVATION", 13, 27], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["functions", "OBSERVATION", 46, 55], ["sweeping", "OBSERVATION_MODIFIER", 205, 213]]], ["Due to the lack of a permissive cell culture system or available animal models, the main capsid protein VP1 that forms the virus like particles (VLPs) has been assembled and used as a NoVs vaccine candidates in preclinical and clinical studies (Lucero et al. 2017) .", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["VP1", "GENE_OR_GENE_PRODUCT", 104, 107], ["VLPs", "GENE_OR_GENE_PRODUCT", 145, 149], ["capsid protein VP1", "PROTEIN", 89, 107], ["VLPs", "PROTEIN", 145, 149], ["a permissive cell culture system", "PROBLEM", 19, 51], ["the main capsid protein VP1", "TEST", 80, 107], ["the virus like particles", "PROBLEM", 119, 143], ["a NoVs vaccine", "TREATMENT", 182, 196], ["clinical studies", "TEST", 227, 243], ["protein VP1", "OBSERVATION", 96, 107]]], ["VLPs have shown high immunogenicity, safety and promising results as human enteroviruses vaccines, such as enterovirus 71 (EV71), coxsackievirus A16 (CA16), and enterovirus D68 (EV-D68) (Dai et al. 2018; Zhang et al. 2015 Zhang et al. , 2016 .IntroductionIn the present study, we constructed the GII.17 VP1, which was expressed using the recombinant baculovirus expression system in sf9 cells, which lead to the formation of VLPs that are morphologically and antigenically similar to the true virions.", [["sf9 cells", "ANATOMY", 383, 392], ["virions", "ANATOMY", 493, 500], ["EV-D68", "CHEMICAL", 178, 184], ["VLPs", "ORGANISM", 0, 4], ["human", "ORGANISM", 69, 74], ["enteroviruses", "ORGANISM", 75, 88], ["enterovirus 71", "ORGANISM", 107, 121], ["EV71", "ORGANISM", 123, 127], ["coxsackievirus A16", "ORGANISM", 130, 148], ["CA16", "ORGANISM", 150, 154], ["enterovirus D68", "ORGANISM", 161, 176], ["EV-D68", "ORGANISM", 178, 184], ["GII.17 VP1", "ORGANISM", 296, 306], ["baculovirus", "ORGANISM", 350, 361], ["sf9 cells", "CELL", 383, 392], ["VLPs", "ORGANISM", 425, 429], ["GII.17 VP1", "DNA", 296, 306], ["sf9 cells", "CELL_LINE", 383, 392], ["human", "SPECIES", 69, 74], ["coxsackievirus A16", "SPECIES", 130, 148], ["human", "SPECIES", 69, 74], ["enterovirus 71", "SPECIES", 107, 121], ["EV71", "SPECIES", 123, 127], ["coxsackievirus A16", "SPECIES", 130, 148], ["CA16", "SPECIES", 150, 154], ["enterovirus D68 (EV-D68", "SPECIES", 161, 184], ["baculovirus", "SPECIES", 350, 361], ["VLPs", "TREATMENT", 0, 4], ["high immunogenicity", "PROBLEM", 16, 35], ["human enteroviruses vaccines", "TREATMENT", 69, 97], ["enterovirus", "TEST", 107, 118], ["EV71", "TEST", 123, 127], ["coxsackievirus", "PROBLEM", 130, 144], ["CA16", "TEST", 150, 154], ["enterovirus", "PROBLEM", 161, 172], ["the recombinant baculovirus expression system", "TREATMENT", 334, 379], ["the formation of VLPs", "PROBLEM", 408, 429], ["high immunogenicity", "OBSERVATION_MODIFIER", 16, 35], ["sf9 cells", "OBSERVATION", 383, 392], ["VLPs", "OBSERVATION", 425, 429], ["true virions", "OBSERVATION", 488, 500]]], ["Our results showed that GII.17 VLPs could be readily produced in the baculovirus/insect cell system and these VLPs could induce potent neutralizing antibody responses and provided effective protection.Construction of baculovirus expression vectorsThe full-length capsid protein VP1 coding sequence (Genbank number, KT992785) was optimized based on insect cell expression and synthesized by Sangon Biotech (Shanghai, China) with flanked by BamHI and Xba l sites at its 5 0 and 3 0 ends, respectively.", [["cell", "ANATOMY", 88, 92], ["cell", "ANATOMY", 355, 359], ["VLPs", "ORGANISM", 31, 35], ["baculovirus", "ORGANISM", 69, 80], ["insect cell", "CELL", 81, 92], ["VLPs", "ORGANISM", 110, 114], ["baculovirus", "ORGANISM", 217, 228], ["insect cell", "CELL", 348, 359], ["BamHI", "GENE_OR_GENE_PRODUCT", 439, 444], ["Xba", "GENE_OR_GENE_PRODUCT", 449, 452], ["baculovirus expression vectors", "DNA", 217, 247], ["full-length capsid protein VP1 coding sequence", "DNA", 251, 297], ["BamHI and Xba l sites", "DNA", 439, 460], ["5 0 and 3 0 ends", "DNA", 468, 484], ["baculovirus", "SPECIES", 69, 80], ["baculovirus", "SPECIES", 217, 228], ["GII", "PROBLEM", 24, 27], ["the baculovirus/insect cell system", "TREATMENT", 65, 99], ["these VLPs", "TREATMENT", 104, 114], ["potent neutralizing antibody responses", "PROBLEM", 128, 166], ["baculovirus expression vectors", "TREATMENT", 217, 247], ["BamHI and Xba l sites", "TREATMENT", 439, 460], ["GII", "OBSERVATION", 24, 27], ["insect cell", "OBSERVATION", 81, 92], ["potent", "OBSERVATION_MODIFIER", 128, 134], ["neutralizing antibody", "OBSERVATION", 135, 156]]], ["The optimized gene was cloned into the pFastBac-Dual-EGFP vector (our laboratory construction previously), named pFastBac-Dual-EGFP-VP1 (GII.17).", [["pFastBac", "GENE_OR_GENE_PRODUCT", 39, 47], ["EGFP", "GENE_OR_GENE_PRODUCT", 53, 57], ["pFastBac", "GENE_OR_GENE_PRODUCT", 113, 121], ["pFastBac-Dual-EGFP vector", "DNA", 39, 64], ["pFastBac-Dual-EGFP-VP1", "DNA", 113, 135], ["GII", "DNA", 137, 140]]], ["Subsequently, the pFASTBac-Dual-EGFP-VP1 (GII.17) vector purified plasmid DNA was transformed into DH10Bac TM E. coli for transposition into the bacmid.", [["plasmid", "ANATOMY", 66, 73], ["EGFP", "GENE_OR_GENE_PRODUCT", 32, 36], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DH10Bac TM E. coli", "ORGANISM", 99, 117], ["pFASTBac-Dual-EGFP-VP1", "DNA", 18, 40], ["GII", "PROTEIN", 42, 45], ["vector purified plasmid DNA", "DNA", 50, 77], ["E. coli", "SPECIES", 110, 117], ["E. coli", "SPECIES", 110, 117], ["the pFASTBac", "TEST", 14, 26], ["vector purified plasmid DNA", "TREATMENT", 50, 77], ["DH10Bac TM E. coli", "TREATMENT", 99, 117], ["transposition into the bacmid", "TREATMENT", 122, 151], ["coli", "OBSERVATION", 113, 117]]], ["Finally, the correct recombinant bacmid DNA was transfected into sf9 insect cells to produce recombinant baculovirus.Production and purification of NoV GII.17 VLPsAfter 96 h of transfection (green fluorescence reached its optimal point), the budded virus was released into the medium and collected the medium, the P1 viral stock.", [["cells", "ANATOMY", 76, 81], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["sf9 insect cells", "CELL", 65, 81], ["baculovirus", "ORGANISM", 105, 116], ["NoV GII", "ORGANISM", 148, 155], ["recombinant bacmid DNA", "DNA", 21, 43], ["sf9 insect cells", "CELL_LINE", 65, 81], ["NoV GII", "PROTEIN", 148, 155], ["baculovirus", "SPECIES", 105, 116], ["NoV GII", "SPECIES", 148, 155], ["the correct recombinant bacmid DNA", "TREATMENT", 9, 43], ["recombinant baculovirus", "TREATMENT", 93, 116], ["transfection (green fluorescence", "PROBLEM", 177, 209], ["the budded virus", "PROBLEM", 238, 254], ["recombinant baculovirus", "OBSERVATION", 93, 116], ["virus", "OBSERVATION", 249, 254], ["viral stock", "OBSERVATION", 317, 328]]], ["Amplified baculoviral was stocked until P5 viral stock and collected cells.Production and purification of NoV GII.17 VLPsCells were washed and lysed in a phosphate buffer solution (PBS) using ultrasound.", [["cells", "ANATOMY", 69, 74], ["Cells", "ANATOMY", 121, 126], ["phosphate", "CHEMICAL", 154, 163], ["phosphate", "CHEMICAL", 154, 163], ["cells", "CELL", 69, 74], ["NoV GII", "ORGANISM", 106, 113], ["VLPs", "ORGANISM", 117, 121], ["Cells", "CELL", 121, 126], ["phosphate buffer solution", "SIMPLE_CHEMICAL", 154, 179], ["NoV GII", "PROTEIN", 106, 113], ["NoV GII", "SPECIES", 106, 113], ["Amplified baculoviral", "TREATMENT", 0, 21], ["Cells", "TEST", 121, 126], ["a phosphate buffer solution", "TREATMENT", 152, 179], ["ultrasound", "TEST", 192, 202]]], ["The lysates were supplemented with 0.5 mol/L NaCl and 10% (W/V) PEG 8000 was mixed for 6 h, and subsequently centrifuged at 10,0009g for 30 min.", [["lysates", "ANATOMY", 4, 11], ["NaCl", "CHEMICAL", 45, 49], ["PEG 8000", "CHEMICAL", 64, 72], ["NaCl", "CHEMICAL", 45, 49], ["PEG", "CHEMICAL", 64, 67], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["The lysates", "TREATMENT", 0, 11], ["0.5 mol/L NaCl", "TREATMENT", 35, 49], ["PEG", "TREATMENT", 64, 67]]], ["The resultant precipitates were loaded onto a 20% sucrose cushion, and subjected to 10-50% sucrose gradients for ultracentrifugation at 40,0009g for 6 h.", [["sucrose", "CHEMICAL", 50, 57], ["sucrose", "CHEMICAL", 91, 98], ["sucrose", "CHEMICAL", 50, 57], ["sucrose", "CHEMICAL", 91, 98], ["sucrose", "SIMPLE_CHEMICAL", 91, 98], ["a 20% sucrose cushion", "TREATMENT", 44, 65], ["ultracentrifugation", "TREATMENT", 113, 132]]], ["The uninfected sf9 cells were subjected to the same treatments as the negative control.", [["sf9 cells", "ANATOMY", 15, 24], ["sf9 cells", "CELL", 15, 24], ["uninfected sf9 cells", "CELL_LINE", 4, 24], ["The uninfected sf9 cells", "PROBLEM", 0, 24], ["uninfected", "OBSERVATION_MODIFIER", 4, 14], ["sf9 cells", "OBSERVATION", 15, 24]]], ["The final purified proteins were dialyzed with physiological saline at 4\u00b0C overnight and used for immunization experiments.Production and purification of NoV GII.17 VLPsElectron microscopy Purified GII.17 VLPs was negatively stained with 0.5% aqueous uranyl acetate, and observed by transmission electron microscopy with Tecnai G2 Spirit at 120 V (Thermo, USA).Mouse immunizationMice were purchased from Kunming Medical University (Yunnan, China).", [["aqueous uranyl acetate", "CHEMICAL", 243, 265], ["uranyl acetate", "CHEMICAL", 251, 265], ["saline", "SIMPLE_CHEMICAL", 61, 67], ["NoV GII", "ORGANISM", 154, 161], ["VLPs", "ORGANISM", 205, 209], ["aqueous uranyl acetate", "SIMPLE_CHEMICAL", 243, 265], ["Mouse", "ORGANISM", 361, 366], ["NoV GII", "PROTEIN", 154, 161], ["Mouse", "SPECIES", 361, 366], ["NoV GII", "SPECIES", 154, 161], ["Mouse", "SPECIES", 361, 366], ["physiological saline", "TREATMENT", 47, 67], ["immunization experiments", "TREATMENT", 98, 122], ["0.5% aqueous uranyl acetate", "TREATMENT", 238, 265], ["Mouse immunizationMice", "TREATMENT", 361, 383], ["GII", "OBSERVATION", 198, 201]]], ["All animal studies were approved by the Institutional Animal Care and Use Committee at the Kunming University of Science and Technology.Mouse immunizationGII.17 VLPs or the negative control antigen were adsorbed to the aluminum hydroxide adjuvant with 1:1 by vortexing to a final volume of 100 lL containing 50 lg of GII.17 VLPs for each injection.", [["aluminum hydroxide", "CHEMICAL", 219, 237], ["aluminum hydroxide", "CHEMICAL", 219, 237], ["Mouse", "ORGANISM", 136, 141], ["immunizationGII.17 VLPs", "ORGANISM", 142, 165], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 219, 237], ["VLPs", "ORGANISM", 324, 328], ["Mouse", "SPECIES", 136, 141], ["Mouse", "SPECIES", 136, 141], ["All animal studies", "TEST", 0, 18], ["Mouse immunizationGII.17 VLPs", "TREATMENT", 136, 165], ["the aluminum hydroxide adjuvant", "TREATMENT", 215, 246], ["a final volume", "TEST", 272, 286], ["each injection", "TREATMENT", 333, 347]]], ["Groups of 6 female BALB/c mice (6-8 weeks old) were intraperitoneally (i.p.) injected with antigen mixtures at weeks 0 and 4.", [["intraperitoneally", "ANATOMY", 52, 69], ["BALB/c mice", "ORGANISM", 19, 30], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30]]], ["Blood samples were collected from each immunized mouse after the final immunization, and placed at 37\u00b0C for 2 h and 4\u00b0C for overnight.Serum antibody measurement assayNoV GII.17 specific antibodies in immunized mice serums were detected by indirect ELISA assays.", [["Blood samples", "ANATOMY", 0, 13], ["Serum", "ANATOMY", 134, 139], ["serums", "ANATOMY", 215, 221], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["mouse", "ORGANISM", 49, 54], ["Serum", "ORGANISM_SUBSTANCE", 134, 139], ["mice", "ORGANISM", 210, 214], ["serums", "ORGANISM_SUBSTANCE", 215, 221], ["Serum antibody", "PROTEIN", 134, 148], ["17 specific antibodies", "PROTEIN", 174, 196], ["mouse", "SPECIES", 49, 54], ["mice", "SPECIES", 210, 214], ["mouse", "SPECIES", 49, 54], ["NoV GII", "SPECIES", 166, 173], ["mice", "SPECIES", 210, 214], ["Blood samples", "TEST", 0, 13], ["the final immunization", "TREATMENT", 61, 83], ["Serum antibody measurement", "TEST", 134, 160], ["specific antibodies", "TEST", 177, 196], ["immunized mice serums", "TEST", 200, 221], ["indirect ELISA assays", "TEST", 239, 260]]], ["96-well plates were coated with 0.1 lg (100 lL)/well of GII.17 VLPs at 4\u00b0C overnight, followed by blockade with 5% milk diluted in PBS containing 0.05% Tween-20 (PBS-T) at 37\u00b0C for 1 h.", [["milk", "ANATOMY", 115, 119], ["Tween-20", "CHEMICAL", 152, 160], ["Tween-20", "CHEMICAL", 152, 160], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["Tween-20", "SIMPLE_CHEMICAL", 152, 160], ["PBS-T", "SIMPLE_CHEMICAL", 162, 167], ["GII", "PROBLEM", 56, 59], ["blockade", "TREATMENT", 98, 106], ["5% milk diluted in PBS", "TREATMENT", 112, 134]]], ["Subsequently, they were incubated at 37\u00b0C for 2 h with 100 lL/well of serum samples in which individual serum samples were diluted in series in PBS-T.", [["serum samples", "ANATOMY", 70, 83], ["serum samples", "ANATOMY", 104, 117], ["serum samples", "ORGANISM_SUBSTANCE", 70, 83], ["serum samples", "ORGANISM_SUBSTANCE", 104, 117], ["serum samples", "TEST", 70, 83], ["individual serum samples", "TEST", 93, 117]]], ["Finally, incubation with goat anti-mouse IgG HPR (Abcam, Ab6789, UK) at 37\u00b0C for 1 h.", [["goat", "ORGANISM", 25, 29], ["Abcam", "GENE_OR_GENE_PRODUCT", 50, 55], ["goat anti-mouse IgG HPR", "PROTEIN", 25, 48], ["Abcam", "PROTEIN", 50, 55], ["Ab6789", "PROTEIN", 57, 63], ["goat", "SPECIES", 25, 29], ["anti-mouse", "SPECIES", 30, 40], ["goat", "SPECIES", 25, 29], ["goat anti-mouse IgG HPR", "TEST", 25, 48]]], ["Between each step, the plates were washed three times with PBS-T.", [["the plates", "TREATMENT", 19, 29]]], ["The absorbance was measured at 450 nm using a microplate reader (Thermo, USA).Western blot assayCollected mouse sera were used to determine their reactivates on VP1 protein.", [["sera", "ANATOMY", 112, 116], ["mouse", "ORGANISM", 106, 111], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["VP1", "GENE_OR_GENE_PRODUCT", 161, 164], ["VP1 protein", "PROTEIN", 161, 172], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 106, 111], ["The absorbance", "TEST", 0, 14], ["VP1 protein", "TEST", 161, 172], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["In brief, the VLPs proteins separated by SDS-PAGE were transferred to a PVDF membrane and detected using mouse anti-GII.17 VLPs serum at a dilution of 1:20,000 in PBS-T and then HRP conjugated goat anti-rabbit IgG polyclonal antibody was added at 1:10,000 in an enzyme buffer.", [["PVDF membrane", "ANATOMY", 72, 85], ["serum", "ANATOMY", 128, 133], ["PVDF", "CHEMICAL", 72, 76], ["VLPs", "ORGANISM", 14, 18], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["mouse", "ORGANISM", 105, 110], ["anti-GII", "GENE_OR_GENE_PRODUCT", 111, 119], ["VLPs", "ORGANISM", 123, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["HRP", "SIMPLE_CHEMICAL", 178, 181], ["goat", "ORGANISM", 193, 197], ["VLPs proteins", "PROTEIN", 14, 27], ["mouse anti-GII", "PROTEIN", 105, 119], ["HRP conjugated goat anti-rabbit IgG polyclonal antibody", "PROTEIN", 178, 233], ["mouse", "SPECIES", 105, 110], ["goat", "SPECIES", 193, 197], ["anti-rabbit", "SPECIES", 198, 209], ["mouse", "SPECIES", 105, 110], ["goat", "SPECIES", 193, 197], ["anti-rabbit", "SPECIES", 198, 209], ["the VLPs proteins", "TEST", 10, 27], ["a PVDF membrane", "TREATMENT", 70, 85], ["mouse anti-GII", "TREATMENT", 105, 119], ["VLPs serum", "TEST", 123, 133], ["a dilution", "TEST", 137, 147], ["PBS", "TEST", 163, 166], ["T", "TEST", 167, 168], ["HRP conjugated goat anti-rabbit IgG polyclonal antibody", "TREATMENT", 178, 233], ["an enzyme buffer", "TREATMENT", 259, 275]]], ["The membrane was developed after a subsequent three times of wash using PBS-T with DAB.GII.17 VLPs-HBGAs binding assay in vitroFor the in vitro VLPs-HBGA binding assay, the eighty-four saliva samples collected from blood type A, B, AB and O individuals were used.", [["membrane", "ANATOMY", 4, 12], ["samples", "ANATOMY", 192, 199], ["blood", "ANATOMY", 215, 220], ["DAB", "CHEMICAL", 83, 86], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["DAB", "SIMPLE_CHEMICAL", 83, 86], ["HBGAs", "GENE_OR_GENE_PRODUCT", 99, 104], ["VLPs", "ORGANISM", 144, 148], ["HBGA", "SIMPLE_CHEMICAL", 149, 153], ["saliva", "ORGANISM", 185, 191], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["B", "CELL", 229, 230], ["AB", "CELL", 232, 234], ["O individuals", "CELL", 239, 252], ["HBGAs", "PROTEIN", 99, 104], ["HBGA", "PROTEIN", 149, 153], ["PBS", "TREATMENT", 72, 75], ["the in vitro VLPs", "TEST", 131, 148], ["HBGA binding assay", "TEST", 149, 167], ["saliva samples", "TEST", 185, 199], ["blood type", "TEST", 215, 225], ["membrane", "OBSERVATION_MODIFIER", 4, 12]]], ["The protocol for the GII.17 VLPs saliva HBGAs binding assay was conducted based on previously description Marionneau et al. 2005) .", [["VLPs", "ORGANISM", 28, 32], ["saliva", "ORGANISM_SUBSTANCE", 33, 39], ["The protocol", "TREATMENT", 0, 12], ["binding assay", "TEST", 46, 59]]], ["Briefly, human saliva with known ABO antigens was boiled for 10 min and diluted at 1:1000 in PBS, added into 96-well plates (100 lL/well) and incubated at 4\u00b0C for overnight.", [["saliva", "ANATOMY", 15, 21], ["human", "ORGANISM", 9, 14], ["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["ABO antigens", "GENE_OR_GENE_PRODUCT", 33, 45], ["ABO antigens", "PROTEIN", 33, 45], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["known ABO antigens", "TREATMENT", 27, 45]]], ["After which, it was by blocked with 5% milk diluted in PBS-T at 37\u00b0C for 1 h.", [["milk", "ANATOMY", 39, 43], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["PBS-T", "SIMPLE_CHEMICAL", 55, 60], ["37\u00b0C", "SIMPLE_CHEMICAL", 64, 68]]], ["GII.17 VLP at 0.1 lg (100 lL)/well was incubated at 37\u00b0C for 2 h, followed by dilution of serum samples; 1:1000 PBS-T at 37\u00b0C for 2 h with 100 lL/well.", [["serum samples", "ANATOMY", 90, 103], ["serum samples", "ORGANISM_SUBSTANCE", 90, 103], ["GII", "TEST", 0, 3], ["VLP", "TEST", 7, 10], ["serum samples", "TEST", 90, 103]]], ["At last, samples were incubated with goat anti-mouse IgG HPR (Abcam, Ab6789, UK) at 37\u00b0C for 1 h.", [["samples", "ANATOMY", 9, 16], ["goat", "ORGANISM", 37, 41], ["Abcam", "GENE_OR_GENE_PRODUCT", 62, 67], ["goat anti-mouse IgG HPR", "PROTEIN", 37, 60], ["Abcam", "PROTEIN", 62, 67], ["Ab6789", "PROTEIN", 69, 75], ["goat", "SPECIES", 37, 41], ["anti-mouse", "SPECIES", 42, 52], ["goat", "SPECIES", 37, 41], ["samples", "TEST", 9, 16], ["goat anti-mouse IgG HPR", "TEST", 37, 60], ["Abcam", "TEST", 62, 67], ["Ab", "TEST", 69, 71]]], ["Between each step, the plates were washed three times with PBS-T.", [["the plates", "TREATMENT", 19, 29]]], ["The absorbance was measured at 450 nm using a microplate reader.", [["The absorbance", "TEST", 0, 14], ["a microplate reader", "TREATMENT", 44, 63], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["At the same time, we used PBS-T without sera as a negative control.GII.17 VLPs-HBGAs binding blockade assayThe blocking activity of sera against GII.17 VLPs was determined by an in vitro VLPs-HBGAs binding blockade assay.", [["sera", "ANATOMY", 40, 44], ["sera", "ANATOMY", 132, 136], ["sera", "ORGANISM_SUBSTANCE", 40, 44], ["HBGAs", "GENE_OR_GENE_PRODUCT", 79, 84], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["VLPs", "ORGANISM", 152, 156], ["VLPs", "ORGANISM", 187, 191], ["HBGAs", "SIMPLE_CHEMICAL", 192, 197], ["HBGAs", "PROTEIN", 79, 84], ["PBS", "TEST", 26, 29], ["sera", "TREATMENT", 40, 44], ["GII", "TEST", 67, 70], ["VLPs", "TEST", 74, 78], ["HBGAs binding blockade", "TREATMENT", 79, 101], ["GII", "PROBLEM", 145, 148], ["an in vitro VLPs", "TREATMENT", 175, 191]]], ["The protocol was performed practically at the same as the in vitro VLPs-HBGA binding assay except for serum dilution and antibody.", [["serum", "ANATOMY", 102, 107], ["VLPs", "ORGANISM", 67, 71], ["HBGA", "SIMPLE_CHEMICAL", 72, 76], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["HBGA", "PROTEIN", 72, 76], ["The protocol", "TREATMENT", 0, 12], ["HBGA binding assay", "TEST", 72, 90], ["serum dilution", "TEST", 102, 116], ["antibody", "TEST", 121, 129]]], ["Since GII.17 VLPs exhibited the strongest affinity to blood type AB salivary HBGAs, a blood type A saliva sample was selected for the blockade assay.", [["blood", "ANATOMY", 54, 59], ["salivary HBGAs", "ANATOMY", 68, 82], ["blood", "ANATOMY", 86, 91], ["sample", "ANATOMY", 106, 112], ["GII.17 VLPs", "ORGANISM", 6, 17], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["salivary HBGAs", "ORGANISM_SUBSTANCE", 68, 82], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["saliva", "ORGANISM_SUBSTANCE", 99, 105], ["GII", "TEST", 6, 9], ["a blood type A saliva sample", "TEST", 84, 112], ["the blockade assay", "TEST", 130, 148]]], ["For all reagents, sera dilutions and reaction times were optimized, and we conducted saliva-VLPs blocking assays using the mouse sera.", [["sera", "ANATOMY", 18, 22], ["sera", "ANATOMY", 129, 133], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["saliva", "ORGANISM_SUBSTANCE", 85, 91], ["VLPs", "ORGANISM", 92, 96], ["mouse", "ORGANISM", 123, 128], ["sera", "ORGANISM_SUBSTANCE", 129, 133], ["mouse", "SPECIES", 123, 128], ["mouse", "SPECIES", 123, 128], ["all reagents", "TREATMENT", 4, 16], ["sera dilutions", "TEST", 18, 32], ["the mouse sera", "TREATMENT", 119, 133]]], ["The 96-well microplates were added to purified VLPs containing VLPs mice serum at 37\u00b0C for 1 h, and diluted rabbit anti-GII.17-P domain monoclonal antibodies (Taizhou SCIVAC Bio-Tech CO., Ltd) were added.", [["serum", "ANATOMY", 73, 78], ["VLPs", "ORGANISM", 47, 51], ["VLPs", "ORGANISM", 63, 67], ["mice", "ORGANISM", 68, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["rabbit", "ORGANISM", 108, 114], ["anti-GII", "GENE_OR_GENE_PRODUCT", 115, 123], ["Ltd", "GENE_OR_GENE_PRODUCT", 188, 191], ["anti-GII", "PROTEIN", 115, 123], ["17-P domain monoclonal antibodies", "PROTEIN", 124, 157], ["Ltd", "PROTEIN", 188, 191], ["mice", "SPECIES", 68, 72], ["rabbit", "SPECIES", 108, 114], ["mice", "SPECIES", 68, 72], ["rabbit", "SPECIES", 108, 114], ["The 96-well microplates", "TREATMENT", 0, 23], ["purified VLPs", "TREATMENT", 38, 51], ["VLPs mice serum", "TREATMENT", 63, 78], ["diluted rabbit anti-GII", "TREATMENT", 100, 123], ["domain monoclonal antibodies", "TEST", 129, 157]]], ["Wells added with VLPs that did not contain VLPs in the mice serum were selected as controls.", [["serum", "ANATOMY", 60, 65], ["VLPs", "ORGANISM", 17, 21], ["VLPs", "ORGANISM", 43, 47], ["mice", "ORGANISM", 55, 59], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["VLPs", "TREATMENT", 17, 21], ["VLPs", "TREATMENT", 43, 47]]], ["The blocking index was calculated in % as (mean OD without VLP sera-mean OD with VLP sera)/mean OD without VLP sera 9 100% (Huo et al. 2016b ).Statistical analysis of dataStatistical analyses were performed using Graphpad Prism v5 software.", [["sera", "ANATOMY", 85, 89], ["The blocking index", "TEST", 0, 18], ["VLP", "TEST", 59, 62], ["VLP sera", "TEST", 81, 89], ["VLP sera", "TEST", 107, 115], ["Statistical analysis", "TEST", 143, 163], ["dataStatistical analyses", "TEST", 167, 191]]], ["Antibody titers or OD values between groups were compared by Student's twotailed t-test.Expression and characterization of NoV GII.17 VLPs in sf9 cellsIn order to confirm the expression of GII.17 VP1 protein in sf9 cells, EGFP and VP1 genes were cloned together into a pFastBac-Dual vector under the control of pH and p10 promoters, respectively (Fig. 1a) .", [["sf9 cells", "ANATOMY", 142, 151], ["sf9 cells", "ANATOMY", 211, 220], ["NoV GII", "ORGANISM", 123, 130], ["VLPs", "ORGANISM", 134, 138], ["sf9 cells", "CELL", 142, 151], ["GII", "GENE_OR_GENE_PRODUCT", 189, 192], ["VP1", "GENE_OR_GENE_PRODUCT", 196, 199], ["sf9 cells", "CELL", 211, 220], ["EGFP", "GENE_OR_GENE_PRODUCT", 222, 226], ["VP1", "GENE_OR_GENE_PRODUCT", 231, 234], ["pFastBac", "GENE_OR_GENE_PRODUCT", 269, 277], ["p10", "GENE_OR_GENE_PRODUCT", 318, 321], ["NoV GII", "PROTEIN", 123, 130], ["sf9 cells", "CELL_LINE", 142, 151], ["17 VP1 protein", "PROTEIN", 193, 207], ["sf9 cells", "CELL_LINE", 211, 220], ["EGFP and VP1 genes", "DNA", 222, 240], ["pFastBac-Dual vector", "DNA", 269, 289], ["pH and p10 promoters", "DNA", 311, 331], ["NoV GII", "SPECIES", 123, 130], ["Antibody titers", "TEST", 0, 15], ["OD values", "TEST", 19, 28], ["GII", "PROBLEM", 189, 192], ["VP1 protein", "TEST", 196, 207], ["EGFP", "TEST", 222, 226], ["VP1 genes", "TREATMENT", 231, 240], ["a pFastBac-Dual vector", "TREATMENT", 267, 289], ["pH and p10 promoters", "TREATMENT", 311, 331], ["sf9 cells", "OBSERVATION", 142, 151], ["sf9 cells", "OBSERVATION", 211, 220], ["VP1 genes", "OBSERVATION", 231, 240]]], ["We used for the recombinant baculovirus was a Bac-to-Bac baculovirus expression system and subsequently used it to infect insect cells.", [["cells", "ANATOMY", 129, 134], ["baculovirus", "ORGANISM", 28, 39], ["baculovirus", "ORGANISM", 57, 68], ["insect cells", "CELL", 122, 134], ["insect cells", "CELL_TYPE", 122, 134], ["baculovirus", "SPECIES", 28, 39], ["Bac baculovirus", "SPECIES", 53, 68], ["the recombinant baculovirus", "TREATMENT", 12, 39], ["a Bac-to-Bac baculovirus expression system", "TREATMENT", 44, 86]]], ["When green fluorescence reached its optimal level under the fluorescence microscope, we collected the cells.", [["cells", "ANATOMY", 102, 107], ["cells", "CELL", 102, 107], ["green fluorescence", "TEST", 5, 23], ["the fluorescence microscope", "TEST", 56, 83]]], ["Sucrose gradient ultracentrifugation was used to purify the VP1 revealed by SDS-PAGE and the results, which corresponds to the full-length VP1 protein of -58 KDa (Fig. 1b) .", [["Sucrose", "CHEMICAL", 0, 7], ["Sucrose", "SIMPLE_CHEMICAL", 0, 7], ["VP1", "PROTEIN", 60, 63], ["VP1 protein", "PROTEIN", 139, 150], ["58 KDa", "PROTEIN", 155, 161], ["Fig. 1b", "PROTEIN", 163, 170], ["Sucrose gradient ultracentrifugation", "TREATMENT", 0, 36], ["the VP1", "TEST", 56, 63], ["length VP1 protein", "TEST", 132, 150]]], ["The purity and integrity of VLPs were showed by transmission electron microscopy (Fig. 1c) .", [["VLPs", "ORGANISM", 28, 32], ["integrity of VLPs", "TEST", 15, 32], ["transmission electron microscopy", "TEST", 48, 80], ["VLPs", "ANATOMY", 28, 32]]], ["It should be noted that smaller, larger and full VLPs (about 35 nm) were observed.Specificity of the antibody response following immunizationTo determine the immunogenicity, GII.17 VLPs was used to i.p. immunize BALB/c mice three times after four weeks.", [["VLPs", "ORGANISM", 181, 185], ["BALB/c mice", "ORGANISM", 212, 223], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 219, 223], ["smaller, larger and full VLPs", "PROBLEM", 24, 53], ["the antibody response", "PROBLEM", 97, 118], ["immunizationTo", "TREATMENT", 129, 143], ["GII", "PROBLEM", 174, 177], ["smaller", "OBSERVATION_MODIFIER", 24, 31], ["larger", "OBSERVATION_MODIFIER", 33, 39], ["full VLPs", "OBSERVATION_MODIFIER", 44, 53]]], ["Another group of mice were injected with PBS as a control.", [["mice", "ORGANISM", 17, 21], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["PBS", "TREATMENT", 41, 44]]], ["Serum samples were collected 2 weeks after the final immunization and were subjected to ELISA analysis for antibody measurement.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples", "TEST", 0, 13], ["the final immunization", "TEST", 43, 65], ["ELISA analysis", "TEST", 88, 102], ["antibody measurement", "TEST", 107, 127]]], ["All sera from VLPs immunized mice exhibited high binding affinities towards GII.17 VLPs, whereas the control group did not exhibit significant reactivity (serum 1:20,000 dilution) (Fig. 2a) .", [["sera", "ANATOMY", 4, 8], ["serum", "ANATOMY", 155, 160], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["VLPs", "ORGANISM", 14, 18], ["mice", "ORGANISM", 29, 33], ["VLPs", "ORGANISM", 83, 87], ["serum", "ORGANISM_SUBSTANCE", 155, 160], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["All sera", "TEST", 0, 8], ["high binding affinities", "PROBLEM", 44, 67], ["significant reactivity", "PROBLEM", 131, 153], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["reactivity", "OBSERVATION", 143, 153]]], ["As showed in (Fig. 2b ) Western blot analysis confirmed theAssembled VLPs bind to salivary HBGAsAn in vitro VLP-HBGA binding assay was used to characterize the binding profiles of GII.17 capsid protein assembled VLPs.", [["salivary", "ANATOMY", 82, 90], ["VLP", "ORGANISM", 108, 111], ["HBGA", "GENE_OR_GENE_PRODUCT", 112, 116], ["HBGA", "PROTEIN", 112, 116], ["17 capsid protein assembled VLPs", "PROTEIN", 184, 216], ["Western blot analysis", "TEST", 24, 45], ["salivary HBGAsAn", "TEST", 82, 98], ["vitro VLP", "TREATMENT", 102, 111], ["HBGA binding assay", "TEST", 112, 130]]], ["As shown in Fig. 3 , VLPs bound to blood type A, B and AB salivary HBGAs, respectively, while weak binding was observed onto type O salivary HBGA.Assembled VLPs bind to salivary HBGAsThe capacity of VLPs immunized mouse sera to block GII.17 VLPs saliva binding As we known, the protective function of anti-NoV serum antibodies correlates with their capacity to block NoV VLPs binding to HBGAs, therefore, the serum antibody-blocking assay was conducted to test the NoV neutralization (Atmar et al. 2011; Reeck et al. 2010; Tan and Jiang 2011) .", [["blood type A", "ANATOMY", 35, 47], ["salivary HBGAs", "ANATOMY", 58, 72], ["salivary", "ANATOMY", 132, 140], ["salivary HBGAs", "ANATOMY", 169, 183], ["sera", "ANATOMY", 220, 224], ["serum", "ANATOMY", 310, 315], ["serum", "ANATOMY", 409, 414], ["VLPs", "ORGANISM", 21, 25], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["A", "GENE_OR_GENE_PRODUCT", 46, 47], ["B", "GENE_OR_GENE_PRODUCT", 49, 50], ["VLPs", "ORGANISM", 156, 160], ["VLPs", "ORGANISM", 199, 203], ["mouse", "ORGANISM", 214, 219], ["sera", "ORGANISM_SUBSTANCE", 220, 224], ["VLPs", "ORGANISM", 241, 245], ["saliva", "ORGANISM_SUBSTANCE", 246, 252], ["anti-NoV", "ORGANISM", 301, 309], ["serum", "ORGANISM_SUBSTANCE", 310, 315], ["NoV VLPs", "ORGANISM", 367, 375], ["HBGAs", "GENE_OR_GENE_PRODUCT", 387, 392], ["serum", "ORGANISM_SUBSTANCE", 409, 414], ["NoV", "ORGANISM", 465, 468], ["anti-NoV serum antibodies", "PROTEIN", 301, 326], ["NoV VLPs", "PROTEIN", 367, 375], ["HBGAs", "PROTEIN", 387, 392], ["serum antibody", "PROTEIN", 409, 423], ["mouse", "SPECIES", 214, 219], ["mouse", "SPECIES", 214, 219], ["NoV", "SPECIES", 367, 370], ["AB salivary HBGAs", "TEST", 55, 72], ["weak binding", "PROBLEM", 94, 106], ["salivary HBGAs", "TEST", 169, 183], ["VLPs", "TREATMENT", 199, 203], ["anti-NoV serum antibodies", "TEST", 301, 326], ["their capacity", "PROBLEM", 343, 357], ["the serum antibody", "TEST", 405, 423], ["blocking assay", "TEST", 424, 438], ["VLPs", "OBSERVATION", 156, 160]]], ["We collected the saliva HBGAs, including A, B and O antigens and they have therefore been used in the blockade assay.", [["saliva", "ORGANISM_SUBSTANCE", 17, 23], ["HBGAs", "SIMPLE_CHEMICAL", 24, 29], ["B", "GENE_OR_GENE_PRODUCT", 44, 45], ["O antigens", "GENE_OR_GENE_PRODUCT", 50, 60], ["A, B and O antigens", "PROTEIN", 41, 60], ["the saliva HBGAs", "TEST", 13, 29]]], ["We used rabbit sera against the GII.17 P domain as antibodies in our study.", [["sera", "ANATOMY", 15, 19], ["rabbit", "ORGANISM", 8, 14], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["GII.17 P domain", "PROTEIN", 32, 47], ["antibodies", "PROTEIN", 51, 61], ["rabbit", "SPECIES", 8, 14], ["rabbit", "SPECIES", 8, 14], ["rabbit sera", "TREATMENT", 8, 19], ["our study", "TEST", 65, 74]]], ["Saliva samples collected from a blood type AB individual was used in the in vitro VLPs-HBGA binding blockade assay which represented the highest binding signal.", [["Saliva samples", "ANATOMY", 0, 14], ["blood", "ANATOMY", 32, 37], ["Saliva samples", "ORGANISM_SUBSTANCE", 0, 14], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["VLPs", "ORGANISM", 82, 86], ["HBGA", "SIMPLE_CHEMICAL", 87, 91], ["HBGA", "PROTEIN", 87, 91], ["Saliva samples", "TEST", 0, 14], ["a blood type AB individual", "TEST", 30, 56], ["the in vitro VLPs", "TEST", 69, 86], ["HBGA binding blockade assay", "TEST", 87, 114], ["highest binding", "OBSERVATION", 137, 152]]], ["As was shown in Fig. 4 , the Characterization of binding profiles of GII.17 VLPs to blood type A, B and AB salivary HBGAs, respectively.", [["blood", "ANATOMY", 84, 89], ["salivary", "ANATOMY", 107, 115], ["VLPs", "ORGANISM", 76, 80], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["B", "CELL", 98, 99], ["GII", "PROBLEM", 69, 72], ["AB salivary HBGAs", "TEST", 104, 121]]], ["VLPs at 0.1 lg/ lL were used.", [["VLPs", "ORGANISM", 0, 4], ["VLPs", "TREATMENT", 0, 4]]], ["NC negative control blocking indices were higher for antisera from blood type AB.", [["blood", "ANATOMY", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 67, 72]]], ["Addition of serum against GII.17 VLPs blocked the binding of GII.17-VP1 capsid protein assembled VLPs to salivary HBGAs.Discussion and conclusionNoVs are the major causes of acute non-bacterial gastroenteritis the worldwide, especially in children.", [["serum", "ANATOMY", 12, 17], ["gastroenteritis", "DISEASE", 194, 209], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["VLPs", "ORGANISM", 33, 37], ["children", "ORGANISM", 239, 247], ["17-VP1 capsid protein", "PROTEIN", 65, 86], ["children", "SPECIES", 239, 247], ["VP1 capsid protein", "TREATMENT", 68, 86], ["salivary HBGAs", "TEST", 105, 119], ["acute non-bacterial gastroenteritis", "PROBLEM", 174, 209], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["non-bacterial", "OBSERVATION_MODIFIER", 180, 193], ["gastroenteritis", "OBSERVATION", 194, 209]]], ["As NoV GII.4 has rapidly evolved that produced new strains that replaced previous strains every 2 or 3 years, the recent outbreak of NoV GII.17 has sweept all over the world.", [["NoV GII.4", "ORGANISM", 3, 12], ["NoV GII", "ORGANISM", 133, 140], ["NoV GII.4", "SPECIES", 3, 12], ["NoV GII", "SPECIES", 133, 140], ["new strains", "PROBLEM", 47, 58], ["new", "OBSERVATION_MODIFIER", 47, 50], ["strains", "OBSERVATION", 51, 58]]], ["Thus, it is urgent to formulate an effective and rapid NoV GII.17 vaccine.", [["NoV GII", "ORGANISM", 55, 62], ["NoV", "SPECIES", 55, 58]]], ["In our study, we showed that the insect cell expressed GII.17 VLPs is a promising vaccine.Discussion and conclusionThe NoVs capsid protein is divided into two domains: S domain, forming the core of the viruslike particle, and the P domain, mainly involved in receptor binding (Prasad et al. 1999) .", [["cell", "ANATOMY", 40, 44], ["insect cell", "CELL", 33, 44], ["GII.17 VLPs", "ORGANISM", 55, 66], ["NoVs", "GENE_OR_GENE_PRODUCT", 119, 123], ["GII.17 VLPs", "PROTEIN", 55, 66], ["NoVs capsid protein", "PROTEIN", 119, 138], ["S domain", "PROTEIN", 168, 176], ["viruslike particle", "PROTEIN", 202, 220], ["P domain", "PROTEIN", 230, 238], ["our study", "TEST", 3, 12], ["a promising vaccine", "TREATMENT", 70, 89]]], ["By comparing the avidity of IgG from mice immunized against VLPs and P particles, the results suggested that there is a significantly higher avidity for VLPs in immunized mice; moreover, it showed that immunization route and adjuvants have no effect on IgG avidity (Huo et al. 2015) .", [["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["mice", "ORGANISM", 37, 41], ["VLPs", "CELL", 60, 64], ["VLPs", "ORGANISM", 153, 157], ["mice", "ORGANISM", 171, 175], ["IgG", "GENE_OR_GENE_PRODUCT", 253, 256], ["IgG", "PROTEIN", 28, 31], ["IgG", "PROTEIN", 253, 256], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 171, 175], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 171, 175], ["IgG", "TEST", 28, 31], ["a significantly higher avidity for VLPs", "PROBLEM", 118, 157], ["immunization route", "TREATMENT", 202, 220], ["adjuvants", "TREATMENT", 225, 234], ["IgG avidity", "PROBLEM", 253, 264]]], ["Some NoV VLPs candidates have shown efficacy in human trials (Atmar et al. 2011; Bernstein et al. 2015) .", [["NoV VLPs", "ORGANISM", 5, 13], ["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["VLPs", "OBSERVATION", 9, 13]]], ["As we known, the VP1, which can selfassemble into VLPs when expressed in sf9 cells use a recombinant baculovirus expression system (Jiang et al. 1992) .", [["sf9 cells", "ANATOMY", 73, 82], ["VP1", "GENE_OR_GENE_PRODUCT", 17, 20], ["VLPs", "GENE_OR_GENE_PRODUCT", 50, 54], ["sf9 cells", "CELL", 73, 82], ["VP1", "PROTEIN", 17, 20], ["sf9 cells", "CELL_LINE", 73, 82], ["baculovirus", "SPECIES", 101, 112], ["the VP1", "TEST", 13, 20], ["a recombinant baculovirus expression system", "TREATMENT", 87, 130]]], ["Therefore, in our research, GII.17 VLPs has been regarded as the most promising vaccine candidates.", [["GII.17 VLPs", "ORGANISM", 28, 39], ["GII.17 VLPs", "TREATMENT", 28, 39]]], ["They were intraperitoneally (i.p.) injected with the antigen mixture alongside an aluminum hydroxide adjuvant.Discussion and conclusionAmong the GII.17 VP1, the P region is further divided into the P1 and the P2 subregion.", [["intraperitoneally", "ANATOMY", 10, 27], ["aluminum hydroxide", "CHEMICAL", 82, 100], ["aluminum hydroxide", "CHEMICAL", 82, 100], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 82, 100], ["GII.17 VP1", "DNA", 145, 155], ["P region", "DNA", 161, 169], ["P1", "DNA", 198, 200], ["P2 subregion", "DNA", 209, 221], ["the antigen mixture", "TREATMENT", 49, 68], ["an aluminum hydroxide adjuvant", "TREATMENT", 79, 109], ["P1", "ANATOMY_MODIFIER", 198, 200], ["P2", "ANATOMY", 209, 211], ["subregion", "ANATOMY_MODIFIER", 212, 221]]], ["The P2 subregion is located at the outermost layer of the entire capsid, which is important for the binding of NoVs, as well as for antibody recognition (Tan et al. 2003) .", [["outermost layer", "ANATOMY", 35, 50], ["capsid", "ANATOMY", 65, 71], ["capsid", "CELLULAR_COMPONENT", 65, 71], ["NoVs", "GENE_OR_GENE_PRODUCT", 111, 115], ["P2 subregion", "DNA", 4, 16], ["NoVs", "PROTEIN", 111, 115], ["antibody recognition", "TEST", 132, 152], ["P2", "OBSERVATION_MODIFIER", 4, 6], ["subregion", "OBSERVATION_MODIFIER", 7, 16], ["outermost", "OBSERVATION_MODIFIER", 35, 44], ["layer", "OBSERVATION_MODIFIER", 45, 50], ["entire", "OBSERVATION_MODIFIER", 58, 64], ["capsid", "OBSERVATION", 65, 71]]], ["Regarding Escherichia coli, expression of P domain can lead to formation of a P-particle, 12-or 24-dimers, which contained all the elements required for receptor binding and are immunogenic in animal studies (Fang et al. 2013; Tamminen et al. 2012) .", [["Escherichia coli", "ORGANISM", 10, 26], ["24-dimers", "SIMPLE_CHEMICAL", 96, 105], ["P domain", "PROTEIN", 42, 50], ["Escherichia coli", "SPECIES", 10, 26], ["Escherichia coli", "SPECIES", 10, 26], ["Escherichia coli", "PROBLEM", 10, 26], ["expression of P domain", "PROBLEM", 28, 50], ["a P-particle", "TEST", 76, 88], ["receptor binding", "PROBLEM", 153, 169], ["animal studies", "TEST", 193, 207], ["Escherichia coli", "OBSERVATION", 10, 26]]], ["So to characterize the binding specificity of the GII.17 VP1 capsid protein assembled VLPs, in our study, we used rabbit sera against the GII.17 P domain.Discussion and conclusionDue to the lack of an animal model for human NoVs infection, the challenge study could not be conducted to assess the efficacy of immunization.", [["sera", "ANATOMY", 121, 125], ["NoVs infection", "DISEASE", 224, 238], ["rabbit", "ORGANISM", 114, 120], ["sera", "ORGANISM_SUBSTANCE", 121, 125], ["human", "ORGANISM", 218, 223], ["NoVs", "CANCER", 224, 228], ["GII.17 VP1 capsid protein", "PROTEIN", 50, 75], ["P domain", "DNA", 145, 153], ["rabbit", "SPECIES", 114, 120], ["human", "SPECIES", 218, 223], ["rabbit", "SPECIES", 114, 120], ["human", "SPECIES", 218, 223], ["our study", "TEST", 95, 104], ["rabbit sera", "TREATMENT", 114, 125], ["human NoVs infection", "PROBLEM", 218, 238], ["the challenge study", "TEST", 240, 259], ["immunization", "TREATMENT", 309, 321], ["infection", "OBSERVATION", 229, 238]]], ["Recently, B cells, as a cellular target of human NoVs, could be developed in the in vitro infection model (Jones et al. 2014 ).", [["B cells", "ANATOMY", 10, 17], ["cellular", "ANATOMY", 24, 32], ["NoVs", "ANATOMY", 49, 53], ["infection", "DISEASE", 90, 99], ["B cells", "CELL", 10, 17], ["cellular", "CELL", 24, 32], ["human", "ORGANISM", 43, 48], ["NoVs", "CELL", 49, 53], ["B cells", "CELL_TYPE", 10, 17], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["B cells", "PROBLEM", 10, 17], ["human NoVs", "PROBLEM", 43, 53]]], ["Prior to that, HBGAs are important receptors for NoV infection.", [["NoV infection", "DISEASE", 49, 62], ["HBGAs", "SIMPLE_CHEMICAL", 15, 20], ["NoV", "ORGANISM", 49, 52], ["HBGAs", "PROTEIN", 15, 20], ["HBGAs", "TEST", 15, 20], ["NoV infection", "PROBLEM", 49, 62], ["infection", "OBSERVATION", 53, 62]]], ["Also, the HBGAs-VLPs blocking assay was used as a surrogate method for the evaluation of NoVs neutralization in vitro.", [["HBGAs", "GENE_OR_GENE_PRODUCT", 10, 15], ["NoVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["HBGAs", "PROTEIN", 10, 15], ["NoVs", "PROTEIN", 89, 93], ["the HBGAs", "TEST", 6, 15], ["VLPs blocking assay", "TREATMENT", 16, 35], ["a surrogate method", "TREATMENT", 48, 66], ["the evaluation", "TEST", 71, 85], ["NoVs neutralization", "PROBLEM", 89, 108]]], ["HBGAs have been proposed as receptors for NoVs.", [["HBGAs", "GENE_OR_GENE_PRODUCT", 0, 5], ["NoVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["HBGAs", "PROTEIN", 0, 5], ["NoVs", "PROTEIN", 42, 46], ["HBGAs", "TEST", 0, 5], ["NoVs", "PROBLEM", 42, 46]]], ["Due to the different genotypes of NoVs, such as GI.3 and GII.2 did not bind to synthetic or salivary HBGAs, whereas GII.4 could bind to salivary HBGAs (Huo et al. 2015 (Huo et al. , 2016a .", [["salivary", "ANATOMY", 136, 144], ["NoVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["NoVs", "PROTEIN", 34, 38], ["NoVs", "PROBLEM", 34, 38], ["salivary HBGAs", "TEST", 92, 106], ["salivary HBGAs", "TEST", 136, 150], ["NoVs", "OBSERVATION", 34, 38]]], ["In our study, VLPs from capsid proteins of epidemic NoV GII.17 exhibited broader HBGA recognition, except for blood type O individuals, however, the reason, to explain this phenomenon is unknown.", [["blood", "ANATOMY", 110, 115], ["VLPs", "ORGANISM", 14, 18], ["NoV GII", "ORGANISM", 52, 59], ["HBGA", "CANCER", 81, 85], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["VLPs", "PROTEIN", 14, 18], ["capsid proteins", "PROTEIN", 24, 39], ["HBGA", "PROTEIN", 81, 85], ["NoV GII", "SPECIES", 52, 59], ["our study", "TEST", 3, 12], ["VLPs", "TREATMENT", 14, 18], ["broader HBGA recognition", "TEST", 73, 97], ["blood type O individuals", "PROBLEM", 110, 134], ["this phenomenon", "PROBLEM", 168, 183]]], ["A possible explanation could be sourced from a previously reported study, which found that the recombinant MxV (GII.3) VLPs demonstrated a degree of binding to salivary HBGAs from a blood type A individual (Huang et al. 2005) .Discussion and conclusionAt the same time, we used human saliva to evaluate the blockade assay.", [["salivary HBGAs", "ANATOMY", 160, 174], ["blood", "ANATOMY", 182, 187], ["MxV", "GENE_OR_GENE_PRODUCT", 107, 110], ["VLPs", "ORGANISM", 119, 123], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["human", "ORGANISM", 278, 283], ["saliva", "ORGANISM_SUBSTANCE", 284, 290], ["recombinant MxV", "PROTEIN", 95, 110], ["GII", "PROTEIN", 112, 115], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 278, 283], ["a previously reported study", "TEST", 45, 72], ["VLPs", "PROBLEM", 119, 123], ["salivary HBGAs", "PROBLEM", 160, 174], ["human saliva", "TREATMENT", 278, 290], ["the blockade assay", "TEST", 303, 321], ["possible explanation could", "UNCERTAINTY", 2, 28]]], ["Our results indicate that rabbit serum against GII.17 VLPs, blocked the binding of capsid protein assembled VLPs to salivary HBGAs from a blood type AB individuals.", [["serum", "ANATOMY", 33, 38], ["salivary HBGAs", "ANATOMY", 116, 130], ["blood", "ANATOMY", 138, 143], ["rabbit", "ORGANISM", 26, 32], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["salivary HBGAs", "CANCER", 116, 130], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["capsid protein", "PROTEIN", 83, 97], ["rabbit", "SPECIES", 26, 32], ["rabbit", "SPECIES", 26, 32], ["rabbit serum", "TEST", 26, 38], ["GII", "PROBLEM", 47, 50], ["capsid protein", "PROBLEM", 83, 97], ["salivary HBGAs", "TEST", 116, 130], ["a blood type AB individuals", "PROBLEM", 136, 163]]], ["The blocking rate reached up to 60%, whereas anti-PBS did not show such effects.", [["anti-PBS", "CHEMICAL", 45, 53], ["anti-PBS", "SIMPLE_CHEMICAL", 45, 53], ["anti-PBS", "PROTEIN", 45, 53], ["The blocking rate", "TEST", 0, 17]]], ["The discovery of new receptors or factors that promote the binding of GII.17 VLPs to HBGAs is key for monitoring the development of vaccine and vaccine efficacy evaluation.", [["HBGAs", "CHEMICAL", 85, 90], ["GII", "GENE_OR_GENE_PRODUCT", 70, 73], ["VLPs", "ORGANISM", 77, 81], ["HBGAs", "SIMPLE_CHEMICAL", 85, 90], ["vaccine", "TREATMENT", 132, 139], ["vaccine efficacy evaluation", "TEST", 144, 171], ["new", "OBSERVATION_MODIFIER", 17, 20]]], ["The data also suggested important information about the presence of other Considering the prevalence of GII.17, the NoVs vaccine should be urgently developed.", [["GII", "DISEASE", 104, 107], ["NoVs", "GENE_OR_GENE_PRODUCT", 116, 120], ["GII", "PROBLEM", 104, 107], ["the NoVs vaccine", "TREATMENT", 112, 128]]], ["Our results showed that GII.17 VLPs induced antibodies should be protective against in vivo NoV GII.17 infections.", [["infections", "DISEASE", 103, 113], ["VLPs", "ORGANISM", 31, 35], ["NoV GII", "ORGANISM", 92, 99], ["antibodies", "PROTEIN", 44, 54], ["NoV", "SPECIES", 92, 95], ["GII", "PROBLEM", 24, 27], ["VLPs induced antibodies", "TREATMENT", 31, 54], ["17 infections", "PROBLEM", 100, 113], ["GII", "OBSERVATION", 24, 27], ["infections", "OBSERVATION", 103, 113]]], ["Therefore, we identified GII.17 VLPs as a viable candidate.", [["VLPs", "ORGANISM", 32, 36], ["GII", "PROBLEM", 25, 28], ["GII", "OBSERVATION", 25, 28]]], ["NoVs vaccine represents a step forward in developing broad-spectrum, multivalent vaccines against acute viral gastroenteritis.", [["viral gastroenteritis", "DISEASE", 104, 125], ["NoVs vaccine", "TREATMENT", 0, 12], ["multivalent vaccines", "TREATMENT", 69, 89], ["acute viral gastroenteritis", "PROBLEM", 98, 125], ["viral gastroenteritis", "OBSERVATION", 104, 125]]]], "e3ee0c6aa51b073461bd09e06330c919687f925b": [["pandemic, the ability of the evidence synthesis model to meet the needs of stakeholders was challenged (1, 2) .", [["pandemic", "PROBLEM", 0, 8], ["synthesis model", "PROBLEM", 38, 53]]], ["Thousands of randomized controlled trials (RCTs) have been initiated during the pandemic, and their results are frequently rushed to publication or communicated through non-peer-reviewed preprints.", [["randomized controlled trials (RCTs", "TREATMENT", 13, 47]]]], "PMC3495767": [["BackgroundDespite the eradication of naturally occurring smallpox, the licensed smallpox vaccine is still administered to military personnel and first responders due to the threat of bioterrorism[1], as well as to individuals with potential exposure to monkeypox.", [["smallpox", "DISEASE", 57, 65], ["monkeypox", "DISEASE", 253, 262], ["monkeypox", "ORGANISM", 253, 262], ["smallpox", "TREATMENT", 57, 65], ["the licensed smallpox vaccine", "TREATMENT", 67, 96], ["monkeypox", "PROBLEM", 253, 262]]], ["In February 2008, the Centers for Diseases Control and Prevention (CDC) disposed of the last of its 12 million doses of Dryvax, the licensed first generation smallpox vaccine grown on the skin of calves.", [["skin", "ANATOMY", 188, 192], ["Dryvax", "CHEMICAL", 120, 126], ["Dryvax", "SIMPLE_CHEMICAL", 120, 126], ["smallpox", "ORGANISM", 158, 166], ["skin", "ORGAN", 188, 192], ["calves", "ORGANISM", 196, 202], ["calves", "SPECIES", 196, 202], ["Diseases Control", "TREATMENT", 34, 50], ["Dryvax", "TREATMENT", 120, 126], ["the licensed first generation smallpox vaccine", "TREATMENT", 128, 174], ["skin", "ANATOMY", 188, 192], ["calves", "ANATOMY", 196, 202]]], ["A new vaccine, ACAM2000, was licensed by the Food and Drug Administration in 2007 as a replacement.", [["ACAM2000", "CHEMICAL", 15, 23], ["A new vaccine", "TREATMENT", 0, 13], ["ACAM2000", "TREATMENT", 15, 23], ["a replacement", "TREATMENT", 85, 98]]], ["ACAM2000 is a replication-competent vaccinia virus clone derived from Dryvax and manufactured in large scale mammalian cell cultures.", [["cell cultures", "ANATOMY", 119, 132], ["ACAM2000", "CHEMICAL", 0, 8], ["Dryvax", "CHEMICAL", 70, 76], ["ACAM2000", "SIMPLE_CHEMICAL", 0, 8], ["vaccinia", "ORGANISM", 36, 44], ["cell cultures", "CELL", 119, 132], ["mammalian cell cultures", "CELL_LINE", 109, 132], ["vaccinia virus", "SPECIES", 36, 50], ["a replication", "TREATMENT", 12, 25], ["competent vaccinia virus clone", "TREATMENT", 26, 56], ["Dryvax", "TREATMENT", 70, 76], ["vaccinia virus", "OBSERVATION", 36, 50], ["large", "OBSERVATION_MODIFIER", 97, 102], ["mammalian cell cultures", "OBSERVATION", 109, 132]]], ["Efficacy was determined in a number of animal models and found to be non-inferior to Dryvax in eliciting an immunological response; however ACAM2000 has a similar safety profile when compared to Dryvax and introduces a level of risk for a small subset of individuals[2].", [["Dryvax", "CHEMICAL", 85, 91], ["ACAM2000", "CHEMICAL", 140, 148], ["Dryvax", "CHEMICAL", 195, 201], ["ACAM2000", "CHEMICAL", 140, 148], ["Dryvax", "SIMPLE_CHEMICAL", 85, 91], ["ACAM2000", "SIMPLE_CHEMICAL", 140, 148], ["Dryvax", "TREATMENT", 85, 91], ["Dryvax", "TREATMENT", 195, 201], ["a small subset of individuals", "PROBLEM", 237, 266], ["small", "OBSERVATION_MODIFIER", 239, 244]]], ["These complications may be severe and life-threatening.", [["These complications", "PROBLEM", 0, 19], ["severe", "OBSERVATION_MODIFIER", 27, 33]]], ["Severe adverse events following vaccination may include eczema vaccinatum (EV) in patients with atopic dermatitis and certain other skin conditions, and progressive vaccinia (PV) in immunocompromised patients[3-6].BackgroundVaccinia Immune Globulin Intravenous (Human) (VIGIV), a polyclonal antibody preparation manufactured from plasma of vaccinia-immunized donors, is the only licensed therapy for smallpox vaccine complications.", [["skin", "ANATOMY", 132, 136], ["plasma", "ANATOMY", 330, 336], ["eczema vaccinatum", "DISEASE", 56, 73], ["atopic dermatitis", "DISEASE", 96, 113], ["vaccinia (PV)", "DISEASE", 165, 178], ["Globulin", "CHEMICAL", 240, 248], ["patients", "ORGANISM", 82, 90], ["skin", "ORGAN", 132, 136], ["vaccinia", "ORGANISM", 165, 173], ["patients", "ORGANISM", 200, 208], ["Human", "ORGANISM", 262, 267], ["plasma", "ORGANISM_SUBSTANCE", 330, 336], ["vaccinia", "ORGANISM", 340, 348], ["donors", "ORGANISM", 359, 365], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 200, 208], ["Human", "SPECIES", 262, 267], ["eczema vaccinatum", "SPECIES", 56, 73], ["PV", "SPECIES", 175, 177], ["Human", "SPECIES", 262, 267], ["Severe adverse events", "PROBLEM", 0, 21], ["vaccination", "TREATMENT", 32, 43], ["eczema vaccinatum", "PROBLEM", 56, 73], ["atopic dermatitis", "PROBLEM", 96, 113], ["certain other skin conditions", "PROBLEM", 118, 147], ["progressive vaccinia", "PROBLEM", 153, 173], ["BackgroundVaccinia Immune Globulin Intravenous (Human) (VIGIV)", "TREATMENT", 214, 276], ["a polyclonal antibody preparation", "TREATMENT", 278, 311], ["plasma of vaccinia", "TREATMENT", 330, 348], ["immunized donors", "TREATMENT", 349, 365], ["licensed therapy", "TREATMENT", 379, 395], ["smallpox vaccine complications", "TREATMENT", 400, 430], ["atopic dermatitis", "OBSERVATION", 96, 113], ["skin", "ANATOMY", 132, 136], ["progressive", "OBSERVATION_MODIFIER", 153, 164], ["vaccinia", "OBSERVATION", 165, 173]]], ["While no placebo-controlled clinical trials were performed with the currently available VIGIV product, the use of similar products has historically decreased mortality, from 100% to 50% for PV, and from 30-40% to 3-4% for EV (reviewed in[7]).", [["PV", "SPECIES", 190, 192], ["placebo", "TREATMENT", 9, 16], ["PV", "TEST", 190, 192], ["historically", "OBSERVATION_MODIFIER", 135, 147], ["decreased", "OBSERVATION_MODIFIER", 148, 157]]], ["In severe cases very high repeated doses of VIGIV have been used and in the context of widespread vaccination, VIGIV supply could be limiting[6,8].", [["VIGIV", "CHEMICAL", 44, 49], ["VIGIV", "CHEMICAL", 44, 49], ["VIGIV", "SIMPLE_CHEMICAL", 44, 49], ["VIGIV", "SIMPLE_CHEMICAL", 111, 116], ["VIGIV", "TREATMENT", 44, 49], ["severe", "OBSERVATION_MODIFIER", 3, 9]]], ["Enhancing the potency of licensed VIGIV is challenging in part because virus neutralizing assays for screening donor plasma are laborious, require live virus, and are subject to the variability typically encountered in biological assays.", [["plasma", "ANATOMY", 117, 123], ["VIGIV", "CHEMICAL", 34, 39], ["VIGIV", "SIMPLE_CHEMICAL", 34, 39], ["plasma", "ORGANISM_SUBSTANCE", 117, 123], ["virus neutralizing assays", "TEST", 71, 96], ["screening donor plasma", "TEST", 101, 123], ["live virus", "PROBLEM", 147, 157], ["potency", "OBSERVATION_MODIFIER", 14, 21]]], ["Binding assays to quantitate antibody levels are problematic in the absence of specific epitope binding information or in the context of polyclonal preparations that may contain a mixture of neutralizing and non-neutralizing antibodies, and are therefore typically supported by use of a plaque reduction neutralization assay[9].", [["plaque", "ANATOMY", 287, 293], ["plaque reduction", "DISEASE", 287, 303], ["non-neutralizing antibodies", "PROTEIN", 208, 235], ["Binding assays", "TEST", 0, 14], ["antibody levels", "TEST", 29, 44], ["polyclonal preparations", "TREATMENT", 137, 160], ["neutralizing and non-neutralizing antibodies", "PROBLEM", 191, 235], ["a plaque reduction neutralization assay", "TREATMENT", 285, 324], ["plaque", "OBSERVATION", 287, 293]]], ["Since immunogenicity is a critical consideration in vaccine development, structural understanding of critical viral protein epitopes would aid development of feasible assays capable of measuring important antibody specificities in donor plasma and VIGIV.BackgroundDuring the poxvirus infectious life cycle, approximately 1% of intracellular mature virions (IMV) are wrapped with additional membrane and exocytosed as extracellular enveloped virus (EEV) (reviewed in[10]).", [["donor plasma", "ANATOMY", 231, 243], ["intracellular", "ANATOMY", 327, 340], ["virions", "ANATOMY", 348, 355], ["IMV", "ANATOMY", 357, 360], ["membrane", "ANATOMY", 390, 398], ["extracellular", "ANATOMY", 417, 430], ["plasma", "ORGANISM_SUBSTANCE", 237, 243], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 327, 340], ["membrane", "CELLULAR_COMPONENT", 390, 398], ["extracellular enveloped virus", "ORGANISM", 417, 446], ["viral protein epitopes", "PROTEIN", 110, 132], ["IMV", "SPECIES", 357, 360], ["EEV", "SPECIES", 448, 451], ["critical viral protein epitopes", "TREATMENT", 101, 132], ["donor plasma", "TEST", 231, 243], ["intracellular mature virions", "TREATMENT", 327, 355], ["additional membrane", "TREATMENT", 379, 398], ["extracellular enveloped virus", "TREATMENT", 417, 446], ["poxvirus", "OBSERVATION_MODIFIER", 275, 283], ["infectious", "OBSERVATION_MODIFIER", 284, 294]]], ["While IMV may mediate host-to-host transmission[11,12], EEV are thought to be uniquely responsible for rapid spread of virus in vivo and present an important antibody target.", [["EEV", "GENE_OR_GENE_PRODUCT", 56, 59], ["IMV", "SPECIES", 6, 9], ["EEV", "SPECIES", 56, 59], ["EEV", "PROBLEM", 56, 59], ["rapid spread of virus", "PROBLEM", 103, 124], ["thought to be", "UNCERTAINTY", 64, 77], ["virus", "OBSERVATION", 119, 124], ["antibody target", "OBSERVATION", 158, 173]]], ["Antibody-mediated inhibition of EEV release from infected cells and blockade of EEV entry have been demonstrated[13-15].", [["cells", "ANATOMY", 58, 63], ["EEV", "CHEMICAL", 32, 35], ["EEV", "GENE_OR_GENE_PRODUCT", 32, 35], ["cells", "CELL", 58, 63], ["EEV", "GENE_OR_GENE_PRODUCT", 80, 83], ["EEV", "PROTEIN", 32, 35], ["infected cells", "CELL_TYPE", 49, 63], ["Antibody", "TEST", 0, 8], ["EEV release", "TREATMENT", 32, 43], ["infected cells", "PROBLEM", 49, 63], ["blockade of EEV entry", "TREATMENT", 68, 89], ["infected cells", "OBSERVATION", 49, 63]]], ["Passive immunization is more effective in polyclonal antibody preparations containing higher EEV antibody titers[16], and anti-EEV monoclonals provide protection in a mouse vaccinia intranasal challenge model[17].", [["anti-EEV monoclonals", "SIMPLE_CHEMICAL", 122, 142], ["mouse", "ORGANISM", 167, 172], ["vaccinia", "ORGANISM", 173, 181], ["EEV antibody", "PROTEIN", 93, 105], ["mouse", "SPECIES", 167, 172], ["EEV", "SPECIES", 93, 96], ["anti-EEV", "SPECIES", 122, 130], ["mouse", "SPECIES", 167, 172], ["Passive immunization", "TREATMENT", 0, 20], ["polyclonal antibody preparations", "TREATMENT", 42, 74], ["higher EEV antibody titers", "TREATMENT", 86, 112], ["anti-EEV monoclonals", "TREATMENT", 122, 142], ["a mouse vaccinia intranasal challenge model", "TREATMENT", 165, 208]]], ["Vaccination with EEV proteins can also elicit a protective immune response[18].", [["EEV", "GENE_OR_GENE_PRODUCT", 17, 20], ["EEV proteins", "PROTEIN", 17, 29], ["EEV", "SPECIES", 17, 20], ["Vaccination with EEV proteins", "TREATMENT", 0, 29]]], ["Unfortunately, in immunized individuals anti-EEV titers vary considerably and may decline over time post-vaccination[19,20].", [["individuals anti-EEV", "ORGANISM", 28, 48], ["anti-EEV", "SPECIES", 40, 48]]], ["Anti-EEV antibody levels are also variable among different VIG products (M. Kennedy and R. Fisher, unpublished data) suggesting that potency gains might be realized by selecting plasma of donors with more robust responses to EEV neutralizing surface determinants.", [["plasma", "ANATOMY", 178, 184], ["surface", "ANATOMY", 242, 249], ["Anti-EEV antibody", "GENE_OR_GENE_PRODUCT", 0, 17], ["plasma", "ORGANISM_SUBSTANCE", 178, 184], ["donors", "ORGANISM", 188, 194], ["Anti-EEV antibody", "PROTEIN", 0, 17], ["EEV neutralizing surface determinants", "PROTEIN", 225, 262], ["EEV", "SPECIES", 225, 228], ["Anti-EEV antibody levels", "TEST", 0, 24], ["potency gains", "PROBLEM", 133, 146], ["plasma of donors", "TREATMENT", 178, 194], ["EEV neutralizing surface", "TREATMENT", 225, 249], ["neutralizing surface", "OBSERVATION", 229, 249]]], ["However, identification and characterization of EEV neutralizing determinants is still incomplete and assays to measure EEV neutralizing activity are subject to a high degree of variability.BackgroundThe EEV envelope contains several viral proteins, including A56R[21,22], F13L[23,24], B5R[13,25], A36R[26], A34R[27,28], and A33R[29].", [["EEV", "GENE_OR_GENE_PRODUCT", 48, 51], ["EEV", "GENE_OR_GENE_PRODUCT", 120, 123], ["EEV", "GENE_OR_GENE_PRODUCT", 204, 207], ["A56R[21,22]", "GENE_OR_GENE_PRODUCT", 260, 271], ["F13L", "GENE_OR_GENE_PRODUCT", 273, 277], ["B5R", "GENE_OR_GENE_PRODUCT", 286, 289], ["A36R[26]", "GENE_OR_GENE_PRODUCT", 298, 306], ["EEV neutralizing determinants", "PROTEIN", 48, 77], ["viral proteins", "PROTEIN", 234, 248], ["A56R", "PROTEIN", 260, 264], ["EEV", "SPECIES", 120, 123], ["EEV neutralizing determinants", "PROBLEM", 48, 77], ["assays", "TEST", 102, 108], ["EEV neutralizing activity", "PROBLEM", 120, 145], ["a high degree of variability", "PROBLEM", 161, 189], ["The EEV envelope", "TEST", 200, 216], ["several viral proteins", "TEST", 226, 248], ["A56R", "TEST", 260, 264], ["F13L", "TEST", 273, 277], ["B5R", "TEST", 286, 289], ["A36R", "TEST", 298, 302], ["A34R", "TEST", 308, 312], ["A33R", "TEST", 325, 329], ["neutralizing", "OBSERVATION", 52, 64], ["neutralizing activity", "OBSERVATION", 124, 145], ["high degree", "OBSERVATION_MODIFIER", 163, 174], ["several", "OBSERVATION_MODIFIER", 226, 233], ["viral proteins", "OBSERVATION", 234, 248]]], ["Among those, B5[30] and A33[31] proteins are known neutralization or viral spread inhibition targets associated with the EEV membrane and/or infected cells.", [["EEV membrane", "ANATOMY", 121, 133], ["cells", "ANATOMY", 150, 155], ["A33[31", "SIMPLE_CHEMICAL", 24, 30], ["EEV membrane", "CELLULAR_COMPONENT", 121, 133], ["cells", "CELL", 150, 155], ["infected cells", "CELL_TYPE", 141, 155], ["B5", "TEST", 13, 15], ["A33", "TEST", 24, 27], ["known neutralization", "PROBLEM", 45, 65], ["viral spread inhibition targets", "PROBLEM", 69, 100], ["the EEV membrane", "PROBLEM", 117, 133], ["infected cells", "PROBLEM", 141, 155], ["neutralization", "OBSERVATION", 51, 65], ["EEV membrane", "OBSERVATION", 121, 133], ["infected cells", "OBSERVATION", 141, 155]]], ["The A33 protein appears to regulate EEV egress from cells and interacts with A36 to antagonize superinfection of neighboring cells, promoting more rapid long-distance dissemination[32-34].", [["cells", "ANATOMY", 52, 57], ["cells", "ANATOMY", 125, 130], ["A33", "GENE_OR_GENE_PRODUCT", 4, 7], ["EEV", "GENE_OR_GENE_PRODUCT", 36, 39], ["cells", "CELL", 52, 57], ["A36", "GENE_OR_GENE_PRODUCT", 77, 80], ["cells", "CELL", 125, 130], ["A33 protein", "PROTEIN", 4, 15], ["A36", "PROTEIN", 77, 80], ["neighboring cells", "CELL_TYPE", 113, 130], ["antagonize superinfection of neighboring cells", "PROBLEM", 84, 130], ["EEV egress", "OBSERVATION", 36, 46], ["neighboring cells", "OBSERVATION", 113, 130], ["more", "OBSERVATION_MODIFIER", 142, 146], ["rapid", "OBSERVATION_MODIFIER", 147, 152]]], ["Antibodies such as MAb-1G10 directed against A33 block comet formation in vitro and can protect against poxvirus challenge in vivo in passive transfer models[31,35-37].BackgroundMAb-1G10 was initially characterized as an A33-binding monoclonal antibody that could provide partial protection in vivo against an intranasal VACV-WR challenge in a mouse model, as well as block EV spread in cell culture[37].", [["cell", "ANATOMY", 387, 391], ["MAb-1G10", "CHEMICAL", 19, 27], ["BackgroundMAb-1G10", "CHEMICAL", 168, 186], ["BackgroundMAb-1G10", "CHEMICAL", 168, 186], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 19, 27], ["A33", "GENE_OR_GENE_PRODUCT", 45, 48], ["poxvirus", "ORGANISM", 104, 112], ["BackgroundMAb-1G10", "SIMPLE_CHEMICAL", 168, 186], ["A33", "SIMPLE_CHEMICAL", 221, 224], ["VACV-WR", "ORGANISM", 321, 328], ["mouse", "ORGANISM", 344, 349], ["cell", "CELL", 387, 391], ["MAb", "PROTEIN", 19, 22], ["1G10", "PROTEIN", 23, 27], ["A33", "PROTEIN", 45, 48], ["A33-binding monoclonal antibody", "PROTEIN", 221, 252], ["mouse", "SPECIES", 344, 349], ["poxvirus", "SPECIES", 104, 112], ["VACV", "SPECIES", 321, 325], ["mouse", "SPECIES", 344, 349], ["Antibodies", "TEST", 0, 10], ["MAb", "TEST", 19, 22], ["A33 block", "TREATMENT", 45, 54], ["poxvirus challenge", "TREATMENT", 104, 122], ["BackgroundMAb", "TEST", 168, 181], ["an A33-binding monoclonal antibody", "PROBLEM", 218, 252], ["an intranasal VACV", "TREATMENT", 307, 325], ["a mouse model", "TREATMENT", 342, 355], ["block EV spread", "PROBLEM", 368, 383], ["cell culture", "TEST", 387, 399]]], ["Although a disconnect between protective efficacy and antibody affinity has been demonstrated for antibodies raised against A33[35], A33 has been evaluated as part of an effort to identify epitopes which might be cross-protective against multiple pathogenic poxviruses[38].", [["A33", "CHEMICAL", 133, 136], ["A33[35", "ORGANISM", 124, 130], ["A33", "GENE_OR_GENE_PRODUCT", 133, 136], ["antibodies", "PROTEIN", 98, 108], ["A33", "PROTEIN", 133, 136], ["epitopes", "PROTEIN", 189, 197], ["a disconnect between protective efficacy", "PROBLEM", 9, 49], ["antibody affinity", "TEST", 54, 71], ["antibodies", "PROBLEM", 98, 108], ["A33", "PROBLEM", 124, 127], ["epitopes", "PROBLEM", 189, 197], ["multiple pathogenic poxviruses", "PROBLEM", 238, 268]]], ["This analysis showed that the \u03b2-mercaptoethanol sensitive MAb-1G10 epitope on vaccinia A33 was not present in the monkeypox A33 ortholog A35; the interpretation was that the MAb-1G10 binding epitope was conformational in nature.", [["\u03b2-mercaptoethanol", "CHEMICAL", 30, 47], ["\u03b2-mercaptoethanol", "CHEMICAL", 30, 47], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 30, 47], ["vaccinia A33", "ORGANISM", 78, 90], ["monkeypox A33", "ORGANISM", 114, 127], ["\u03b2-mercaptoethanol sensitive MAb-1G10 epitope", "PROTEIN", 30, 74], ["monkeypox A33 ortholog A35", "DNA", 114, 140], ["MAb-1G10 binding epitope", "PROTEIN", 174, 198], ["vaccinia A33", "SPECIES", 78, 90], ["monkeypox A33", "SPECIES", 114, 127], ["This analysis", "TEST", 0, 13], ["the \u03b2-mercaptoethanol sensitive MAb", "TREATMENT", 26, 61], ["vaccinia A33", "TREATMENT", 78, 90], ["the MAb", "TEST", 170, 177]]], ["Binding of MAb-1G10 to the monkeypox A35 protein could be restored by single-residue exchanges at positions 117, 118, and 120 changing the monkeypox sequence to the vaccinia sequence.", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 11, 19], ["monkeypox", "ORGANISM", 27, 36], ["A35", "GENE_OR_GENE_PRODUCT", 37, 40], ["vaccinia", "ORGANISM", 165, 173], ["MAb", "PROTEIN", 11, 14], ["1G10", "PROTEIN", 15, 19], ["monkeypox A35 protein", "PROTEIN", 27, 48], ["vaccinia sequence", "DNA", 165, 182], ["Binding of MAb", "TEST", 0, 14]]], ["Based on this information, residues 117\u2013120 were implicated as core residues forming the MAb-1G10 epitope.", [["\u2013120", "AMINO_ACID", 39, 43], ["MAb-1G10 epitope", "PROTEIN", 89, 105], ["residues", "TEST", 27, 35], ["the MAb", "TREATMENT", 85, 92]]], ["The importance of this region was reinforced by crystallographic data from a fragment of the ectodomain of A33 (residues 98\u2013185)[39].", [["ectodomain", "PROTEIN", 93, 103], ["A33", "PROTEIN", 107, 110]]], ["A dimeric, \u03b2-strand rich structural model of vaccinia A33 with structural similarity with C-type lectins was proposed.", [["vaccinia A33", "ORGANISM", 45, 57], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 90, 104], ["vaccinia A33", "PROTEIN", 45, 57], ["C-type lectins", "PROTEIN", 90, 104], ["vaccinia A33", "SPECIES", 45, 57], ["vaccinia A33", "TREATMENT", 45, 57], ["C-type lectins", "TREATMENT", 90, 104]]], ["The described structure featured 5 \u03b2-strands and 2 \u03b1-helices stabilized by 2 intramolecular disulfide bonds (C100-C109 and C126-C180).", [["C100-C109 and C126-C180", "CHEMICAL", 109, 132], ["disulfide", "CHEMICAL", 92, 101], ["C100-C109", "CHEMICAL", 109, 118], ["C126-C180", "CHEMICAL", 123, 132], ["2 \u03b1-helices", "SIMPLE_CHEMICAL", 49, 60], ["2 intramolecular disulfide bonds", "SIMPLE_CHEMICAL", 75, 107], ["C100-C109", "SIMPLE_CHEMICAL", 109, 118], ["C126-C180", "SIMPLE_CHEMICAL", 123, 132], ["2 intramolecular disulfide bonds", "TEST", 75, 107], ["C100", "TEST", 109, 113], ["C126", "TEST", 123, 127], ["disulfide bonds", "OBSERVATION", 92, 107]]], ["Residues 117\u2013120 were mapped to a surface-exposed edge on the proposed monomer structure, well removed from the dimer and proposed ligand-binding interfaces.BackgroundTo provide additional characterization of the epitope involved in cell to cell spread of vaccinia, we considered whether additional residues might influence MAb-1G10 binding in the context of the vaccinia A33 protein.", [["surface", "ANATOMY", 34, 41], ["cell", "ANATOMY", 233, 237], ["cell", "ANATOMY", 241, 245], ["cell", "CELL", 233, 237], ["cell", "CELL", 241, 245], ["vaccinia", "ORGANISM", 256, 264], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 324, 332], ["vaccinia", "ORGANISM", 363, 371], ["A33", "GENE_OR_GENE_PRODUCT", 372, 375], ["dimer", "PROTEIN", 112, 117], ["MAb", "PROTEIN", 324, 327], ["1G10", "PROTEIN", 328, 332], ["vaccinia A33 protein", "PROTEIN", 363, 383], ["vaccinia A33", "SPECIES", 363, 375], ["Residues", "TEST", 0, 8], ["the epitope", "PROBLEM", 209, 220], ["vaccinia", "TREATMENT", 256, 264], ["additional residues", "PROBLEM", 288, 307], ["MAb", "TEST", 324, 327], ["the vaccinia A33 protein", "TREATMENT", 359, 383], ["edge", "OBSERVATION_MODIFIER", 50, 54], ["monomer structure", "OBSERVATION", 71, 88], ["binding interfaces", "OBSERVATION", 138, 156]]], ["In this study, we screened a random peptide phage display library to find peptides specifically bound by MAb-1G10.", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 105, 113], ["MAb", "PROTEIN", 105, 108], ["1G10", "PROTEIN", 109, 113], ["this study", "TEST", 3, 13], ["a random peptide phage", "TREATMENT", 27, 49], ["MAb", "TEST", 105, 108]]], ["A conformationally constrained consensus motif of seven residues was analyzed against available A33 sequence and structural information to generate an epitope model, which was tested and confirmed by an alanine site directed mutagenesis approach.", [["alanine", "CHEMICAL", 203, 210], ["alanine", "CHEMICAL", 203, 210], ["alanine", "AMINO_ACID", 203, 210], ["A33 sequence", "DNA", 96, 108], ["A conformationally constrained consensus motif of seven residues", "PROBLEM", 0, 64], ["an epitope model", "TREATMENT", 148, 164], ["an alanine site directed mutagenesis approach", "TREATMENT", 200, 245]]], ["The results demonstrated that the negatively charged D115 is required for MAb-1G10 binding, and helps establish the minimum epitope core for MAb-1G10 binding in the intact vaccinia A33 protein.", [["D115", "CHEMICAL", 53, 57], ["D115", "SIMPLE_CHEMICAL", 53, 57], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 74, 82], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 141, 149], ["vaccinia", "ORGANISM", 172, 180], ["A33", "GENE_OR_GENE_PRODUCT", 181, 184], ["D115", "PROTEIN", 53, 57], ["MAb", "PROTEIN", 74, 77], ["1G10", "PROTEIN", 78, 82], ["MAb", "PROTEIN", 141, 144], ["1G10", "PROTEIN", 145, 149], ["vaccinia A33 protein", "PROTEIN", 172, 192], ["vaccinia A33", "SPECIES", 172, 184], ["MAb", "TREATMENT", 74, 77], ["MAb", "TREATMENT", 141, 144]]], ["Our data also confirm that residue L118 contributes to epitope formation, in agreement with previous observations.", [["L118", "CHEMICAL", 35, 39], ["L118", "AMINO_ACID", 35, 39], ["Our data", "TEST", 0, 8], ["residue L118", "PROBLEM", 27, 39], ["epitope formation", "PROBLEM", 55, 72], ["epitope formation", "OBSERVATION", 55, 72]]], ["Our study shows that an unbiased mapping strategy utilizing random peptide display technology can effectively map linear and conformational epitopes involved in facilitating cell to cell spread of vaccinia.", [["cell", "ANATOMY", 174, 178], ["cell", "ANATOMY", 182, 186], ["vaccinia", "DISEASE", 197, 205], ["cell", "CELL", 174, 178], ["cell", "CELL", 182, 186], ["vaccinia", "ORGANISM", 197, 205], ["Our study", "TEST", 0, 9], ["an unbiased mapping strategy", "TEST", 21, 49], ["conformational epitopes", "PROBLEM", 125, 148], ["vaccinia", "PROBLEM", 197, 205], ["cell", "OBSERVATION", 174, 178], ["cell", "OBSERVATION", 182, 186], ["spread", "OBSERVATION_MODIFIER", 187, 193], ["vaccinia", "OBSERVATION", 197, 205]]], ["This work also expands understanding of an important orthopoxvirus epitope, which may be exploited to improve and inform therapies for vaccinia and potentially smallpox.Screening of random peptide libraries ::: ResultsIn considering the aligned sequences of poxvirus A33 homologs (Figure1), we noted more subtle patterns of alternating highly-charged residues and hydrophobic stretches, and the striking heterogeneity of charged residues in the proposed region of the MAb-1G10 epitope.", [["vaccinia", "DISEASE", 135, 143], ["smallpox", "DISEASE", 160, 168], ["vaccinia", "ORGANISM", 135, 143], ["poxvirus", "ORGANISM", 258, 266], ["A33", "GENE_OR_GENE_PRODUCT", 267, 270], ["Figure1", "GENE_OR_GENE_PRODUCT", 281, 288], ["MAb-1G10 epitope", "GENE_OR_GENE_PRODUCT", 468, 484], ["orthopoxvirus epitope", "PROTEIN", 53, 74], ["poxvirus A33 homologs", "PROTEIN", 258, 279], ["Figure1", "PROTEIN", 281, 288], ["hydrophobic stretches", "PROTEIN", 364, 385], ["MAb-1G10 epitope", "PROTEIN", 468, 484], ["an important orthopoxvirus epitope", "TREATMENT", 40, 74], ["therapies", "TREATMENT", 121, 130], ["vaccinia", "TREATMENT", 135, 143], ["poxvirus A33 homologs", "TREATMENT", 258, 279], ["hydrophobic stretches", "PROBLEM", 364, 385], ["charged residues", "PROBLEM", 421, 437], ["the MAb", "TREATMENT", 464, 471], ["hydrophobic stretches", "OBSERVATION", 364, 385], ["charged residues", "OBSERVATION", 421, 437], ["MAb", "ANATOMY", 468, 471]]], ["If non-convalent interactions among charged and hydrophobic residues influence regional conformation, then the context of the MAb-1G10 epitope (for example, presentation of the epitope in a monkeypox A35 versus vaccinia A33 backbone) might yield different epitope mapping information.", [["vaccinia A33", "ORGANISM", 211, 223], ["MAb", "PROTEIN", 126, 129], ["1G10 epitope", "PROTEIN", 130, 142], ["epitope", "PROTEIN", 177, 184], ["non-convalent interactions", "PROBLEM", 3, 29], ["hydrophobic residues influence regional conformation", "PROBLEM", 48, 100], ["the MAb", "TREATMENT", 122, 129], ["the epitope", "PROBLEM", 173, 184], ["a monkeypox A35", "TREATMENT", 188, 203], ["vaccinia A33 backbone", "TREATMENT", 211, 232]]], ["On this basis we decided to pursue additional characterization of the MAb-1G10 epitope.", [["MAb-1G10 epitope", "PROTEIN", 70, 86], ["the MAb", "TREATMENT", 66, 73]]], ["To obtain unbiased information on the conformationally distinct epitope interacting with MAb-1G10, a disulfide-constrained heptapeptide library screening approach was used.", [["disulfide", "CHEMICAL", 101, 110], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 89, 97], ["MAb", "PROTEIN", 89, 92], ["1G10", "PROTEIN", 93, 97], ["MAb", "TREATMENT", 89, 92], ["a disulfide-constrained heptapeptide library screening approach", "TREATMENT", 99, 162]]], ["In this approach, the randomized peptide segment is flanked by paired cysteines, which are oxidized during phage assembly to present the peptide as a taut loop at the N-terminus of the minor phage coat protein PIII.", [["cysteines", "CHEMICAL", 70, 79], ["N", "CHEMICAL", 167, 168], ["N-terminus", "PROTEIN", 167, 177], ["minor phage coat protein", "PROTEIN", 185, 209], ["PIII", "PROTEIN", 210, 214], ["the randomized peptide segment", "TREATMENT", 18, 48], ["paired cysteines", "PROBLEM", 63, 79], ["a taut loop", "PROBLEM", 148, 159], ["cysteines", "OBSERVATION", 70, 79], ["oxidized", "OBSERVATION_MODIFIER", 91, 99], ["minor phage", "ANATOMY", 185, 196], ["protein PIII", "OBSERVATION", 202, 214]]], ["Ten MAb-1G10 binding peptides were isolated from the conformational library screening, none of which contain vaccinia virus A33 sequence (Figure2A).", [["vaccinia virus A33", "ORGANISM", 109, 127], ["vaccinia virus A33 sequence", "DNA", 109, 136], ["vaccinia virus", "SPECIES", 109, 123], ["vaccinia virus A33", "SPECIES", 109, 127], ["Ten MAb", "TEST", 0, 7], ["the conformational library screening", "TEST", 49, 85]]], ["Two consensus motifs were identified: CXXY(F)NEPL(F)C, and CXXXWPF(H)EC.", [["EC", "ANATOMY", 69, 71], ["F)C", "GENE_OR_GENE_PRODUCT", 50, 53], ["CXXXWPF(H)EC", "GENE_OR_GENE_PRODUCT", 59, 71], ["consensus motifs", "DNA", 4, 20], ["CXXXWPF(H)EC", "CELL_LINE", 59, 71], ["Two consensus motifs", "TEST", 0, 20]]], ["Biotinylated peptide mimics were subsequently constructed to verify MAb-1G10 binding in a solid-phase assay (Figure2B).", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 68, 76], ["MAb", "PROTEIN", 68, 71], ["1G10", "PROTEIN", 72, 76], ["Biotinylated peptide mimics", "TREATMENT", 0, 27], ["MAb", "TEST", 68, 71], ["a solid-phase assay", "TEST", 88, 107]]], ["Strong interaction of MAb-1G10 with one of the peptides (RF2-1), containing the CXXY(F)NEPL(F)C motif, was confirmed in the ELISA based assay (Figure3A).", [["MAb-1G10", "CHEMICAL", 22, 30], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 22, 30], ["RF2-1", "GENE_OR_GENE_PRODUCT", 57, 62], ["F)C", "GENE_OR_GENE_PRODUCT", 92, 95], ["MAb", "PROTEIN", 22, 25], ["1G10", "PROTEIN", 26, 30], ["CXXY(F)NEPL(F)C motif", "DNA", 80, 101], ["MAb", "TEST", 22, 25]]], ["We observed that N-ethylmaleimide treatment of reduced peptide RF2-1 blocked MAb-1G10 binding (Figure3B), suggesting that intact disulfide bonds were important for epitope conformation.", [["N-ethylmaleimide", "CHEMICAL", 17, 33], ["N-ethylmaleimide", "CHEMICAL", 17, 33], ["disulfide", "CHEMICAL", 129, 138], ["N-ethylmaleimide", "SIMPLE_CHEMICAL", 17, 33], ["RF2-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 77, 85], ["Figure3B", "SIMPLE_CHEMICAL", 95, 103], ["1G10", "PROTEIN", 81, 85], ["Figure3B", "PROTEIN", 95, 103], ["N-ethylmaleimide treatment", "TREATMENT", 17, 43], ["reduced peptide RF2", "TREATMENT", 47, 66], ["MAb", "TEST", 77, 80], ["intact disulfide bonds", "PROBLEM", 122, 144], ["epitope conformation", "PROBLEM", 164, 184], ["intact", "OBSERVATION", 122, 128], ["disulfide bonds", "OBSERVATION", 129, 144]]], ["A second pass of library screening was undertaken to determine if additional consensus motifs might be obtained.", [["consensus motifs", "DNA", 77, 93], ["library screening", "TEST", 17, 34]]], ["The second screen utilized a phage library in which linear dodecapeptides were presented at the N-terminus of phage coat protein PIII.", [["N", "CHEMICAL", 96, 97], ["dodecapeptides", "GENE_OR_GENE_PRODUCT", 59, 73], ["phage coat protein PIII", "GENE_OR_GENE_PRODUCT", 110, 133], ["N-terminus", "PROTEIN", 96, 106], ["phage coat protein PIII", "PROTEIN", 110, 133], ["The second screen", "TEST", 0, 17], ["a phage library", "TREATMENT", 27, 42], ["linear dodecapeptides", "TREATMENT", 52, 73], ["phage coat protein PIII", "TREATMENT", 110, 133], ["protein PIII", "OBSERVATION", 121, 133]]], ["Two MAb-1G10 binding peptides were obtained by screening the linear peptide library, neither of which contained viral sequence and both containing a consensus CEPLC motif (Figure2A).", [["viral sequence", "DNA", 112, 126], ["consensus CEPLC motif", "DNA", 149, 170], ["Two MAb", "TEST", 0, 7], ["screening the linear peptide library", "TEST", 47, 83], ["viral sequence", "TEST", 112, 126], ["viral", "OBSERVATION", 112, 117]]], ["A comparison of peptide sequences obtained from the 2 library screens suggested that the conformationally constrained CEPLC sequence was likely to be functionally identical to the minimal core MAb-1G10 epitope.Molecular modeling of the MAb-1G10 epitope ::: ResultsWhile the CELPC sequence is not present in vaccinia A33, we reasoned that the conformation of the constrained CELPC motif might be identifiable in the folded A33 protein.", [["vaccinia A33", "ORGANISM", 307, 319], ["CELPC", "GENE_OR_GENE_PRODUCT", 374, 379], ["A33", "GENE_OR_GENE_PRODUCT", 422, 425], ["CEPLC sequence", "DNA", 118, 132], ["minimal core MAb-1G10 epitope", "PROTEIN", 180, 209], ["MAb", "PROTEIN", 236, 239], ["1G10 epitope", "PROTEIN", 240, 252], ["CELPC sequence", "DNA", 274, 288], ["CELPC motif", "DNA", 374, 385], ["A33 protein", "PROTEIN", 422, 433], ["vaccinia A33", "SPECIES", 307, 319], ["A comparison of peptide sequences", "TEST", 0, 33], ["the 2 library screens", "TEST", 48, 69], ["the conformationally constrained CEPLC sequence", "PROBLEM", 85, 132], ["the MAb", "TEST", 232, 239], ["the CELPC sequence", "TEST", 270, 288], ["the constrained CELPC motif", "TREATMENT", 358, 385], ["minimal", "OBSERVATION_MODIFIER", 180, 187]]], ["A molecular model of the short consensus CELPC peptide was constructed (Figure4A) as an aid in identifying potential MAb-1G10 binding regions in the intact A33 molecule.", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 117, 125], ["MAb-1G10 binding regions", "DNA", 117, 141], ["A33 molecule", "PROTEIN", 156, 168], ["potential MAb", "TREATMENT", 107, 120], ["intact", "OBSERVATION_MODIFIER", 149, 155], ["A33 molecule", "OBSERVATION", 156, 168]]], ["For this, the molecular coordinates of two loops with (pdbid 3DXQ, sequence C(177)DPLC(181)) and without (pdbid 1M6B, C(304)GGLC(308)) disulphide bonds were extracted.", [["disulphide", "CHEMICAL", 135, 145], ["sequence C", "TEST", 67, 77], ["DPLC", "TEST", 82, 86], ["pdbid", "TEST", 106, 111], ["GGLC", "TEST", 124, 128], ["disulphide bonds", "PROBLEM", 135, 151], ["loops", "ANATOMY_MODIFIER", 43, 48]]], ["Although both structures are loops, the presence or absence of the disulphide bond prescribes a different topology for these sequences.", [["disulphide", "CHEMICAL", 67, 77], ["these sequences", "TEST", 119, 134], ["loops", "OBSERVATION", 29, 34]]], ["To better visualize the difference, we \u201cmutated\u201d the CGGLC sequence in silico to the phage consensus sequence (CEPLC) using Pymol and subsequently undertook energy minimization of this model for 5000 steps in vacuum using CHARMM field.", [["Pymol", "CHEMICAL", 124, 129], ["CGGLC sequence", "DNA", 53, 67], ["phage consensus sequence", "DNA", 85, 109], ["this model", "TREATMENT", 180, 190]]], ["The resulting model showed the disulfide bonded CEPLC peptide featuring an 11.7 angstrom distance between the charged glutamate side chain and the hydrophobic leucine residue, whereas in the reduced loop the similar distance (aspartate-leucine) was only 6.9 angstroms.", [["glutamate", "CHEMICAL", 118, 127], ["leucine", "CHEMICAL", 159, 166], ["aspartate", "CHEMICAL", 226, 235], ["leucine", "CHEMICAL", 236, 243], ["disulfide", "CHEMICAL", 31, 40], ["glutamate", "CHEMICAL", 118, 127], ["leucine", "CHEMICAL", 159, 166], ["aspartate", "CHEMICAL", 226, 235], ["leucine", "CHEMICAL", 236, 243], ["CEPLC peptide", "SIMPLE_CHEMICAL", 48, 61], ["leucine residue", "AMINO_ACID", 159, 174], ["aspartate-leucine", "SIMPLE_CHEMICAL", 226, 243], ["charged glutamate side chain", "PROTEIN", 110, 138], ["the disulfide bonded CEPLC peptide", "PROBLEM", 27, 61], ["the charged glutamate side chain", "TREATMENT", 106, 138], ["the hydrophobic leucine residue", "PROBLEM", 143, 174], ["disulfide bonded", "OBSERVATION", 31, 47], ["11.7 angstrom", "OBSERVATION_MODIFIER", 75, 88], ["hydrophobic leucine residue", "OBSERVATION", 147, 174], ["reduced", "OBSERVATION_MODIFIER", 191, 198], ["loop", "OBSERVATION_MODIFIER", 199, 203], ["similar", "OBSERVATION_MODIFIER", 208, 215], ["distance", "OBSERVATION_MODIFIER", 216, 224], ["6.9 angstroms", "OBSERVATION", 254, 267]]], ["First, reducing the disulphide bond would reduce the binding of the phage peptide to MAb-1G10 antibody by virtue of altering the conformation of the loop and second, and most importantly, the mature A33 molecule must contain in its surface residues similar to E and L at a similar relative position as the consensus phage peptide.", [["surface", "ANATOMY", 232, 239], ["disulphide", "CHEMICAL", 20, 30], ["MAb-1G10 antibody", "GENE_OR_GENE_PRODUCT", 85, 102], ["A33", "GENE_OR_GENE_PRODUCT", 199, 202], ["MAb", "PROTEIN", 85, 88], ["1G10 antibody", "PROTEIN", 89, 102], ["mature A33 molecule", "PROTEIN", 192, 211], ["E and L", "PROTEIN", 260, 267], ["the disulphide bond", "PROBLEM", 16, 35], ["MAb", "TEST", 85, 88], ["the mature A33 molecule", "PROBLEM", 188, 211], ["disulphide bond", "OBSERVATION", 20, 35], ["mature", "OBSERVATION_MODIFIER", 192, 198], ["A33 molecule", "OBSERVATION", 199, 211]]], ["Probing the published structure of A33 for a surface-exposed region with a distance between charged and hydrophobic residues similar to the CEPLC peptide yielded a possible match at residues D115 and L118 (Figure4B), which are separated by 11.4 angstroms in the structure model of the A33 protein[39].", [["surface", "ANATOMY", 45, 52], ["A33", "CHEMICAL", 35, 38], ["A33", "GENE_OR_GENE_PRODUCT", 35, 38], ["A33", "PROTEIN", 35, 38], ["Figure4B", "PROTEIN", 206, 214], ["A33 protein", "PROTEIN", 285, 296], ["a surface-exposed region", "TREATMENT", 43, 67], ["hydrophobic residues", "PROBLEM", 104, 124], ["the CEPLC peptide", "TEST", 136, 153], ["hydrophobic residues", "OBSERVATION", 104, 124]]], ["However, given the results from heptapeptide phage display, we could not rule out an alternative possibility that more complex interactions among D115, Y178, and N125 might influence the shape of the MAb-1G10 epitope by long range hydrogen bonding interactions (Figure4C).Confirmation of critical MAb-1G10 residues by alanine scanning ::: ResultsAn alanine scanning technique was used to determine if either of these hypotheses regarding the MAb-1G10 epitope structure might be correct.", [["alanine", "CHEMICAL", 318, 325], ["alanine", "CHEMICAL", 349, 356], ["D115, Y178, and N125", "CHEMICAL", 146, 166], ["hydrogen", "CHEMICAL", 231, 239], ["alanine", "CHEMICAL", 318, 325], ["alanine", "CHEMICAL", 349, 356], ["D115", "GENE_OR_GENE_PRODUCT", 146, 150], ["Y178", "GENE_OR_GENE_PRODUCT", 152, 156], ["N125", "GENE_OR_GENE_PRODUCT", 162, 166], ["alanine", "AMINO_ACID", 318, 325], ["alanine", "AMINO_ACID", 349, 356], ["MAb", "GENE_OR_GENE_PRODUCT", 442, 445], ["MAb-1G10 epitope", "PROTEIN", 200, 216], ["MAb", "PROTEIN", 442, 445], ["heptapeptide phage", "TREATMENT", 32, 50], ["the MAb", "TREATMENT", 196, 203], ["critical MAb", "TREATMENT", 288, 300], ["alanine scanning", "TEST", 318, 334], ["ResultsAn alanine scanning technique", "TEST", 339, 375], ["the MAb", "TREATMENT", 438, 445], ["1G10 epitope structure", "TREATMENT", 446, 468]]], ["To accomplish this, the ectodomain of wild type A33 (residues 59\u2013186) was expressed in E. coli as a His-tagged recombinant protein, isolated from inclusion bodies, and refolded on an affinity purification column.", [["residues 59\u2013186", "CHEMICAL", 53, 68], ["His", "CHEMICAL", 100, 103], ["A33", "GENE_OR_GENE_PRODUCT", 48, 51], ["E. coli", "ORGANISM", 87, 94], ["ectodomain", "PROTEIN", 24, 34], ["wild type A33", "PROTEIN", 38, 51], ["His-tagged recombinant protein", "PROTEIN", 100, 130], ["E. coli", "SPECIES", 87, 94], ["E. coli", "SPECIES", 87, 94], ["E. coli", "PROBLEM", 87, 94], ["tagged recombinant protein", "PROBLEM", 104, 130], ["an affinity purification column", "TREATMENT", 180, 211], ["E. coli", "OBSERVATION", 87, 94]]], ["To confirm the process of protein refolding, the native, soluble A33 protein was also generated from E. coli cytosolic fractions for comparative purposes.", [["cytosolic fractions", "ANATOMY", 109, 128], ["A33", "GENE_OR_GENE_PRODUCT", 65, 68], ["E. coli", "ORGANISM", 101, 108], ["A33 protein", "PROTEIN", 65, 76], ["E. coli", "SPECIES", 101, 108], ["E. coli", "SPECIES", 101, 108], ["protein refolding", "TREATMENT", 26, 43], ["soluble A33 protein", "TEST", 57, 76], ["E. coli cytosolic fractions", "PROBLEM", 101, 128], ["comparative purposes", "TEST", 133, 153], ["coli cytosolic fractions", "OBSERVATION", 104, 128]]], ["Binding to MAb-1G10 was found comparable by ELISA and immunoprecipitation (Figure5A and B), as well as to another anti-A33 MAb 10F10 by ELISA[38].", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 11, 19], ["MAb", "PROTEIN", 11, 14], ["1G10", "PROTEIN", 15, 19], ["anti-A33 MAb 10F10", "PROTEIN", 114, 132], ["MAb", "TEST", 11, 14], ["ELISA", "TEST", 44, 49], ["immunoprecipitation", "TEST", 54, 73], ["Figure5A", "TEST", 75, 83]]], ["Since protein recovery yields were much higher for the proteins isolated from inclusion bodies, we chose to utilize refolded recombinant proteins for further characterization.", [["refolded recombinant proteins", "PROTEIN", 116, 145], ["further characterization", "TEST", 150, 174]]], ["We used site directed mutagenesis to prepare a series of A33 variants in which alanine residues were individually substituted for D115, Y116, Q117, L118, N125, and E129.", [["alanine", "CHEMICAL", 79, 86], ["alanine", "CHEMICAL", 79, 86], ["D115, Y116, Q117, L118, N125, and E129", "CHEMICAL", 130, 168], ["A33", "GENE_OR_GENE_PRODUCT", 57, 60], ["alanine", "AMINO_ACID", 79, 86], ["site directed mutagenesis", "TREATMENT", 8, 33], ["A33 variants", "TREATMENT", 57, 69], ["alanine residues", "TEST", 79, 95], ["D115", "TREATMENT", 130, 134]]], ["In addition, a series of double alanine substitution A33 variants and a quadruple alanine substitution A33 variant were constructed.", [["alanine", "CHEMICAL", 32, 39], ["alanine", "CHEMICAL", 82, 89], ["alanine", "CHEMICAL", 32, 39], ["alanine", "CHEMICAL", 82, 89], ["alanine", "AMINO_ACID", 32, 39], ["alanine", "AMINO_ACID", 82, 89], ["double alanine substitution A33 variants", "TREATMENT", 25, 65], ["a quadruple alanine substitution A33 variant", "TREATMENT", 70, 114]]], ["All of these were successfully expressed in E. coli with similar efficiency and purity as compared to E. coli expressed wild type recombinant A33 (rA33; Supplemental Figure2).", [["E. coli", "ORGANISM", 44, 51], ["E. coli", "ORGANISM", 102, 109], ["recombinant A33", "ORGANISM", 130, 145], ["A33", "PROTEIN", 142, 145], ["E. coli", "SPECIES", 44, 51], ["E. coli", "SPECIES", 102, 109], ["E. coli", "SPECIES", 44, 51], ["E. coli", "SPECIES", 102, 109], ["E. coli", "PROBLEM", 44, 51], ["similar efficiency", "PROBLEM", 57, 75], ["E. coli", "PROBLEM", 102, 109], ["Supplemental Figure2)", "TREATMENT", 153, 174], ["E. coli", "OBSERVATION", 44, 51], ["efficiency", "OBSERVATION_MODIFIER", 65, 75]]], ["MAb-1G10 binding was disrupted by mutations at positions 115 or 118, suggesting that these residues are critical in the MAb-1G10 epitope.", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 0, 8], ["MAb", "PROTEIN", 0, 3], ["1G10", "PROTEIN", 4, 8], ["MAb-1G10 epitope", "PROTEIN", 120, 136], ["these residues", "PROBLEM", 85, 99], ["the MAb", "TREATMENT", 116, 123]]], ["In contrast, alanine substitutions at residues 116, 117, 120, 125, and 129 did not prevent interaction with MAb-1G10.Confirming the MAb-1G10 epitope using an in vitro functional test ::: ResultsInhibition of EEV spread can be functionally evaluated in vitro using an established method in which EEVs released from infected cells rapidly form satellite plaques, commonly referred to as the comet assay.", [["cells", "ANATOMY", 323, 328], ["satellite plaques", "ANATOMY", 342, 359], ["alanine", "CHEMICAL", 13, 20], ["alanine", "CHEMICAL", 13, 20], ["alanine", "AMINO_ACID", 13, 20], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 108, 116], ["EEV", "SIMPLE_CHEMICAL", 208, 211], ["EEVs", "GENE_OR_GENE_PRODUCT", 295, 299], ["cells", "CELL", 323, 328], ["satellite plaques", "PATHOLOGICAL_FORMATION", 342, 359], ["MAb", "PROTEIN", 108, 111], ["1G10", "PROTEIN", 112, 116], ["MAb-1G10 epitope", "PROTEIN", 132, 148], ["EEVs", "PROTEIN", 295, 299], ["infected cells", "CELL_TYPE", 314, 328], ["alanine substitutions at residues", "TEST", 13, 46], ["MAb", "TEST", 108, 111], ["the MAb", "TREATMENT", 128, 135], ["EEV spread", "PROBLEM", 208, 218], ["infected cells", "PROBLEM", 314, 328], ["satellite plaques", "PROBLEM", 342, 359], ["the comet assay", "TEST", 385, 400], ["EEV", "OBSERVATION", 208, 211], ["infected cells", "OBSERVATION", 314, 328], ["satellite", "OBSERVATION_MODIFIER", 342, 351], ["plaques", "OBSERVATION", 352, 359]]], ["Addition of MAb-1G10 to the supernatant following adsorption of virus to target cells blocked the development of satellite plaques in a dose-dependent manner, with most comets blocked at 12.5 \u03bcg/ml (Figure6).", [["supernatant", "ANATOMY", 28, 39], ["cells", "ANATOMY", 80, 85], ["satellite plaques", "ANATOMY", 113, 130], ["MAb-1G10", "CHEMICAL", 12, 20], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 12, 20], ["cells", "CELL", 80, 85], ["satellite plaques", "PATHOLOGICAL_FORMATION", 113, 130], ["MAb", "PROTEIN", 12, 15], ["1G10", "PROTEIN", 16, 20], ["target cells", "CELL_TYPE", 73, 85], ["MAb", "TREATMENT", 12, 15], ["virus", "TREATMENT", 64, 69], ["satellite plaques", "PROBLEM", 113, 130], ["satellite", "OBSERVATION_MODIFIER", 113, 122], ["plaques", "OBSERVATION", 123, 130]]], ["To demonstrate functional relevance of our assays, we tested the ability of our phage and recombinant protein preparations to interfere with the comet neutralizing capacity of MAb-1G10.", [["MAb-1G10", "CHEMICAL", 176, 184], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 176, 184], ["MAb", "PROTEIN", 176, 179], ["1G10", "PROTEIN", 180, 184], ["our assays", "TEST", 39, 49], ["our phage", "TREATMENT", 76, 85], ["recombinant protein preparations", "TREATMENT", 90, 122], ["MAb", "TEST", 176, 179]]], ["When phage expressing the CELPC consensus motif (Figure6) were included in the comet assay along with MAb-1G10 , satellite plaques were restored, demonstrating that MAb-1G10 activity had been abolished.", [["satellite plaques", "ANATOMY", 113, 130], ["CELPC", "GENE_OR_GENE_PRODUCT", 26, 31], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 102, 110], ["satellite plaques", "PATHOLOGICAL_FORMATION", 113, 130], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 165, 173], ["CELPC consensus motif", "DNA", 26, 47], ["Figure6", "DNA", 49, 56], ["MAb", "PROTEIN", 102, 105], ["1G10", "PROTEIN", 106, 110], ["MAb", "PROTEIN", 165, 168], ["1G10", "PROTEIN", 169, 173], ["the comet assay", "TEST", 75, 90], ["MAb", "TEST", 102, 105], ["satellite plaques", "PROBLEM", 113, 130], ["MAb", "TEST", 165, 168], ["plaques", "OBSERVATION", 123, 130]]], ["Conversely, when A33 variant proteins containing D115A or L118A mutations were added to the comet assay along with MAb-1G10 , there was no effect on MAb-1G10 comet-neutralizing activity, confirming the loss of a functional MAb-1G10 epitope in these A33 mutant proteins (Figure7).", [["D115A", "GENE_OR_GENE_PRODUCT", 49, 54], ["L118A", "GENE_OR_GENE_PRODUCT", 58, 63], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 115, 123], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 149, 157], ["A33 mutant", "ORGANISM", 249, 259], ["A33 variant proteins", "PROTEIN", 17, 37], ["D115A", "PROTEIN", 49, 54], ["MAb", "PROTEIN", 115, 118], ["1G10", "PROTEIN", 119, 123], ["1G10", "PROTEIN", 153, 157], ["MAb", "PROTEIN", 223, 226], ["1G10 epitope", "PROTEIN", 227, 239], ["A33 mutant proteins", "PROTEIN", 249, 268], ["Figure7", "PROTEIN", 270, 277], ["the comet assay", "TEST", 88, 103], ["MAb", "TEST", 115, 118], ["MAb", "TEST", 149, 152], ["a functional MAb", "TREATMENT", 210, 226], ["1G10 epitope", "TREATMENT", 227, 239], ["no", "UNCERTAINTY", 136, 138]]], ["Addition of Y116A or Q117A variant A33 proteins had no effect on MAb-1G10 activity in the comet assay (data not shown).", [["Y116A", "GENE_OR_GENE_PRODUCT", 12, 17], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 65, 73], ["Y116A", "PROTEIN", 12, 17], ["A33 proteins", "PROTEIN", 35, 47], ["MAb", "PROTEIN", 65, 68], ["1G10", "PROTEIN", 69, 73], ["MAb", "TEST", 65, 68], ["the comet assay", "TEST", 86, 101]]], ["Interestingly, A33 containing a S120A mutation retained some ability to interact with 1G10 (Figure7).DiscussionWe used a randomized peptide library screen to evaluate the A33 comet inhibiting epitope recognized by monoclonal antibody MAb-1G10.", [["S120A", "GENE_OR_GENE_PRODUCT", 32, 37], ["Figure7", "GENE_OR_GENE_PRODUCT", 92, 99], ["A33", "GENE_OR_GENE_PRODUCT", 171, 174], ["A33", "PROTEIN", 15, 18], ["S120A", "PROTEIN", 32, 37], ["1G10", "PROTEIN", 86, 90], ["Figure7", "PROTEIN", 92, 99], ["A33 comet inhibiting epitope", "PROTEIN", 171, 199], ["monoclonal antibody MAb", "PROTEIN", 214, 237], ["1G10", "PROTEIN", 238, 242], ["a S120A mutation", "PROBLEM", 30, 46], ["a randomized peptide library screen", "TEST", 119, 154], ["monoclonal antibody MAb", "TEST", 214, 237]]], ["Phage technology offers the opportunity to explore the interactive determinants of proteins without preexisting assumptions about the context of the interactions.", [["Phage technology", "TREATMENT", 0, 16]]], ["In this case, the conformationally constrained peptide sequence identified in our library screening was successfully matched with a putative surface-exposed region of vaccinia A33 previously implicated in MAb-1G10 binding.", [["surface", "ANATOMY", 141, 148], ["vaccinia A33", "ORGANISM", 167, 179], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 205, 213], ["vaccinia A33", "PROTEIN", 167, 179], ["MAb", "PROTEIN", 205, 208], ["1G10", "PROTEIN", 209, 213], ["vaccinia A33", "SPECIES", 167, 179], ["the conformationally constrained peptide sequence", "PROBLEM", 14, 63], ["our library screening", "TEST", 78, 99], ["vaccinia A33", "TREATMENT", 167, 179], ["surface", "OBSERVATION_MODIFIER", 141, 148], ["vaccinia", "OBSERVATION", 167, 175]]], ["However, our analysis implicated a new upstream residue, D115, in MAb-1G10 binding.", [["D115", "SIMPLE_CHEMICAL", 57, 61], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 66, 74], ["MAb", "PROTEIN", 66, 69], ["1G10", "PROTEIN", 70, 74], ["our analysis", "TEST", 9, 21], ["a new upstream residue", "PROBLEM", 33, 55]]], ["As this residue is completely conserved among members of the Orthopoxvirus genus, its role in MAb-1G10 binding was not considered in previous studies.DiscussionBlocking in vivo dissemination of vaccinia virus is an important approach to controlling complications of vaccination in at risk individuals.", [["vaccinia virus", "DISEASE", 194, 208], ["Orthopoxvirus genus", "ORGANISM", 61, 80], ["MAb-1G10", "GENE_OR_GENE_PRODUCT", 94, 102], ["vaccinia virus", "ORGANISM", 194, 208], ["MAb", "PROTEIN", 94, 97], ["1G10", "PROTEIN", 98, 102], ["vaccinia virus", "SPECIES", 194, 208], ["previous studies", "TEST", 133, 149], ["vaccinia virus", "TREATMENT", 194, 208], ["vaccination", "TREATMENT", 266, 277], ["vaccinia virus", "OBSERVATION", 194, 208]]], ["Poxvirus spread within the host is accelerated by the double-enveloped EEV, which are propelled by actin tails and released prior to target cell lysis[40].", [["cell", "ANATOMY", 140, 144], ["Poxvirus", "GENE_OR_GENE_PRODUCT", 0, 8], ["EEV", "GENE_OR_GENE_PRODUCT", 71, 74], ["actin", "GENE_OR_GENE_PRODUCT", 99, 104], ["cell", "CELL", 140, 144], ["actin tails", "PROTEIN", 99, 110], ["Poxvirus spread", "PROBLEM", 0, 15], ["target cell lysis", "TREATMENT", 133, 150], ["EEV", "OBSERVATION", 71, 74]]], ["A33 is one of the proteins presented on the EEV surface[41] and deletion of the A33R gene in vaccinia virus reduces disease in an experimental infection model due to inefficient cell-to-cell spread[34].", [["EEV surface", "ANATOMY", 44, 55], ["cell", "ANATOMY", 178, 182], ["cell", "ANATOMY", 186, 190], ["infection", "DISEASE", 143, 152], ["A33", "GENE_OR_GENE_PRODUCT", 0, 3], ["EEV", "GENE_OR_GENE_PRODUCT", 44, 47], ["A33R", "GENE_OR_GENE_PRODUCT", 80, 84], ["vaccinia virus", "ORGANISM", 93, 107], ["cell", "CELL", 178, 182], ["cell", "CELL", 186, 190], ["A33", "PROTEIN", 0, 3], ["A33R gene", "DNA", 80, 89], ["vaccinia virus", "SPECIES", 93, 107], ["the A33R gene", "TREATMENT", 76, 89], ["vaccinia virus reduces disease", "PROBLEM", 93, 123], ["an experimental infection model", "PROBLEM", 127, 158], ["inefficient cell", "PROBLEM", 166, 182], ["vaccinia virus", "OBSERVATION", 93, 107], ["infection", "OBSERVATION", 143, 152]]], ["A33 has also been shown to interact through its cytoplasmic and transmembrane regions with A36[42], and these EEV proteins together may enhance long-range viral dissemination while limiting superinfection of nearby cells[32].", [["cytoplasmic", "ANATOMY", 48, 59], ["transmembrane", "ANATOMY", 64, 77], ["cells", "ANATOMY", 215, 220], ["A33", "CHEMICAL", 0, 3], ["A33", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasmic", "ORGANISM_SUBSTANCE", 48, 59], ["transmembrane", "CELLULAR_COMPONENT", 64, 77], ["EEV", "GENE_OR_GENE_PRODUCT", 110, 113], ["cells", "CELL", 215, 220], ["A33", "PROTEIN", 0, 3], ["cytoplasmic and transmembrane regions", "PROTEIN", 48, 85], ["EEV proteins", "PROTEIN", 110, 122], ["nearby cells", "CELL_TYPE", 208, 220], ["these EEV proteins", "TEST", 104, 122], ["long-range viral dissemination", "PROBLEM", 144, 174], ["superinfection of nearby cells", "PROBLEM", 190, 220]]], ["Vaccine-induced or passively transferred anti-A33 antibodies can mediate protection against lethal orthopoxvirus disease in animal models[31,35-37].", [["orthopoxvirus disease", "DISEASE", 99, 120], ["anti-A33 antibodies", "GENE_OR_GENE_PRODUCT", 41, 60], ["anti-A33 antibodies", "PROTEIN", 41, 60], ["anti-A33", "SPECIES", 41, 49], ["orthopoxvirus", "SPECIES", 99, 112], ["Vaccine", "TREATMENT", 0, 7], ["anti-A33 antibodies", "TREATMENT", 41, 60], ["lethal orthopoxvirus disease", "PROBLEM", 92, 120]]], ["Because A33 is a critical component of vaccinia virulence, neutralizing strategies which target this protein may be particularly effective and thus require appropriate potency assays.DiscussionAnti-EEV antibody responses are without exception important for prophylaxis and treatment of poxviruses in animal models.", [["A33", "GENE_OR_GENE_PRODUCT", 8, 11], ["vaccinia", "ORGANISM", 39, 47], ["poxviruses", "ORGANISM", 286, 296], ["A33", "PROTEIN", 8, 11], ["vaccinia", "SPECIES", 39, 47], ["vaccinia virulence", "PROBLEM", 39, 57], ["neutralizing strategies", "TREATMENT", 59, 82], ["DiscussionAnti-EEV antibody responses", "TEST", 183, 220], ["prophylaxis", "TREATMENT", 257, 268], ["treatment", "TREATMENT", 273, 282], ["poxviruses", "TREATMENT", 286, 296], ["vaccinia virulence", "OBSERVATION", 39, 57]]], ["However, serological assessment of anti-EEV antibodies in human smallpox vaccine studies or as a component of passive antibody therapy has been limited.", [["smallpox", "DISEASE", 64, 72], ["anti-EEV antibodies", "GENE_OR_GENE_PRODUCT", 35, 54], ["human", "ORGANISM", 58, 63], ["anti-EEV antibodies", "PROTEIN", 35, 54], ["human", "SPECIES", 58, 63], ["anti-EEV", "SPECIES", 35, 43], ["human", "SPECIES", 58, 63], ["serological assessment", "TEST", 9, 31], ["anti-EEV antibodies", "TREATMENT", 35, 54], ["human smallpox vaccine studies", "TEST", 58, 88], ["passive antibody therapy", "TREATMENT", 110, 134]]], ["In part this is due to use of well-established PRNT assays, which measure anti-IMV but not anti-EEV activity.", [["anti-IMV", "GENE_OR_GENE_PRODUCT", 74, 82], ["anti-EEV", "GENE_OR_GENE_PRODUCT", 91, 99], ["PRNT", "PROTEIN", 47, 51], ["anti-EEV", "PROTEIN", 91, 99], ["PRNT assays", "TEST", 47, 58]]], ["Measuring EEV activity has proven challenging due to the fragile nature of the viral envelope[41] and the infectious nature of both EEV and IMV forms of the virus.", [["EEV", "GENE_OR_GENE_PRODUCT", 10, 13], ["EEV", "CANCER", 132, 135], ["EEV", "SPECIES", 132, 135], ["IMV", "SPECIES", 140, 143], ["the fragile nature", "PROBLEM", 53, 71], ["the viral envelope", "PROBLEM", 75, 93], ["the virus", "PROBLEM", 153, 162], ["infectious", "OBSERVATION", 106, 116]]], ["The comet inhibition assay for EEV antibodies is useful for research studies, but is difficult to validate, and does not provide a robust quantititative result.", [["EEV antibodies", "GENE_OR_GENE_PRODUCT", 31, 45], ["EEV antibodies", "PROTEIN", 31, 45], ["EEV", "SPECIES", 31, 34], ["The comet inhibition assay", "TEST", 0, 26], ["EEV antibodies", "TEST", 31, 45], ["research studies", "TEST", 60, 76]]], ["The importance of measuring anti-EEV antibodies is underscored by observations that anti-B5 and anti-A33 antibody levels are variable in polyclonal VIGIV preparations using research tests (Fisher and Kennedy, unpublished).", [["anti-EEV antibodies", "GENE_OR_GENE_PRODUCT", 28, 47], ["anti-B5", "SIMPLE_CHEMICAL", 84, 91], ["anti-A33 antibody", "GENE_OR_GENE_PRODUCT", 96, 113], ["anti-EEV antibodies", "PROTEIN", 28, 47], ["anti-B5", "PROTEIN", 84, 91], ["anti-A33 antibody", "PROTEIN", 96, 113], ["VIGIV", "SPECIES", 148, 153], ["measuring anti-EEV antibodies", "TEST", 18, 47], ["anti-B5", "TEST", 84, 91], ["anti-A33 antibody levels", "TEST", 96, 120], ["polyclonal VIGIV preparations", "TREATMENT", 137, 166], ["research tests", "TEST", 173, 187]]], ["Binding assays such as ELISAs offer several advantages in terms of reproducibility, speed, and robustness; however to be truly predictive of potency the assay should be specific for a known neutralizing epitope (or epitopes).", [["neutralizing epitope", "PROTEIN", 190, 210], ["epitopes", "PROTEIN", 215, 223], ["Binding assays", "TEST", 0, 14], ["a known neutralizing epitope", "PROBLEM", 182, 210]]], ["The current study provides thorough characterization of an A33 conformational comet inhibiting epitope and links the epitope to a viral spread assay.", [["A33 conformational comet inhibiting epitope", "PROTEIN", 59, 102], ["The current study", "TEST", 0, 17], ["thorough characterization", "TEST", 27, 52], ["an A33 conformational comet inhibiting epitope", "PROBLEM", 56, 102], ["the epitope", "PROBLEM", 113, 124], ["a viral spread assay", "PROBLEM", 128, 148]]], ["Peptide mimics reflecting the MAb-1G10 binding epitope can be tested in a robust solid phase assay format.", [["MAb-1G10 binding epitope", "PROTEIN", 30, 54], ["Peptide mimics", "PROBLEM", 0, 14], ["the MAb", "TREATMENT", 26, 33], ["1G10 binding epitope", "TREATMENT", 34, 54]]], ["Further development and optimization of an assay for evaluation of VIGIV products is currently underway.", [["VIGIV products", "PROTEIN", 67, 81], ["an assay", "TEST", 40, 48], ["evaluation", "TEST", 53, 63], ["VIGIV products", "TREATMENT", 67, 81]]], ["Additionally, such methods could be used to efficiently screen plasma of vaccinated donors for inclusion in plasma pools used to manufacture VIGIV, or for convalescent plasma intended for therapy in the event of a smallpox outbreak.DiscussionTo be comprehensive, an optimal anti-EEV assay should include more than one EEV epitope for assessment unless presence of 1G10-like antibodies is shown to be a more general marker for robust anti-EEV responses.", [["plasma", "ANATOMY", 63, 69], ["plasma", "ANATOMY", 108, 114], ["plasma", "ANATOMY", 168, 174], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["donors", "ORGANISM", 84, 90], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["plasma", "ORGANISM_SUBSTANCE", 168, 174], ["1G10", "GENE_OR_GENE_PRODUCT", 364, 368], ["anti-EEV", "CANCER", 433, 441], ["EEV epitope", "PROTEIN", 318, 329], ["1G10", "PROTEIN", 364, 368], ["antibodies", "PROTEIN", 374, 384], ["anti-EEV", "PROTEIN", 433, 441], ["VIGIV", "SPECIES", 141, 146], ["vaccinated donors", "TREATMENT", 73, 90], ["plasma pools", "TEST", 108, 120], ["convalescent plasma", "TREATMENT", 155, 174], ["therapy", "TREATMENT", 188, 195], ["a smallpox outbreak", "PROBLEM", 212, 231], ["an optimal anti-EEV assay", "TEST", 263, 288], ["assessment", "TEST", 334, 344], ["1G10-like antibodies", "PROBLEM", 364, 384], ["smallpox", "OBSERVATION", 214, 222]]], ["A limitation to this broader approach is lack of detailed structural information for other important target EEV proteins such as B5.", [["EEV", "GENE_OR_GENE_PRODUCT", 108, 111], ["B5", "GENE_OR_GENE_PRODUCT", 129, 131], ["EEV proteins", "PROTEIN", 108, 120], ["B5", "PROTEIN", 129, 131]]], ["In the absence of such data, validation of peptides identified in a random display approach is more challenging.", [["peptides", "PROBLEM", 43, 51]]], ["Another consideration is accurately reflecting or providing a correlation to effector mechanisms such as complement or Fc receptor involvement[17,43].", [["Fc receptor", "GENE_OR_GENE_PRODUCT", 119, 130], ["Fc receptor", "PROTEIN", 119, 130]]], ["Our future studies will include structural analysis of key vaccinia-neutralizing targets to support random peptide library screening efforts, as well as evaluating neutralizing epitope/effector mechanism interactions.DiscussionThe risks of serious side effects from current live attenuated vaccinia virus vaccines provide the impetus for renewed efforts to develop safer and effective alternatives.", [["vaccinia", "ORGANISM", 59, 67], ["vaccinia virus", "ORGANISM", 290, 304], ["vaccinia virus", "SPECIES", 290, 304], ["Our future studies", "TEST", 0, 18], ["structural analysis", "TEST", 32, 51], ["key vaccinia", "TREATMENT", 55, 67], ["neutralizing targets", "TREATMENT", 68, 88], ["random peptide library screening", "TEST", 100, 132], ["neutralizing epitope/effector mechanism interactions", "TREATMENT", 164, 216], ["serious side effects", "PROBLEM", 240, 260], ["current live attenuated vaccinia virus vaccines", "TREATMENT", 266, 313], ["safer and effective alternatives", "TREATMENT", 365, 397]]], ["So far approaches to develop safe smallpox vaccines have ranged from the study of highly attenuated live vaccinia viruses[44-46] to use of alphavirus replicon vectors expressing vaccinia genes[47] to subunit vaccines delivered either as DNA plasmids[31,48] or purified proteins[49,50].", [["vaccinia viruses", "ORGANISM", 105, 121], ["alphavirus", "ORGANISM", 139, 149], ["vaccinia", "ORGANISM", 178, 186], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["vaccinia genes", "DNA", 178, 192], ["DNA plasmids", "DNA", 237, 249], ["purified proteins", "PROTEIN", 260, 277], ["vaccinia viruses", "SPECIES", 105, 121], ["safe smallpox vaccines", "TREATMENT", 29, 51], ["the study", "TEST", 69, 78], ["vaccinia viruses", "PROBLEM", 105, 121], ["alphavirus replicon vectors", "TREATMENT", 139, 166], ["subunit vaccines", "TREATMENT", 200, 216], ["DNA plasmids", "TEST", 237, 249], ["purified proteins", "TEST", 260, 277]]], ["An alternative approach to vaccine design is the use of molecules that mimic the immunogenic element of interest.", [["An alternative approach to vaccine", "TREATMENT", 0, 34]]], ["For example, peptide mimics coupled with carrier proteins or presented as polymers have been developed for cancer, anti-allergic and contraceptive vaccines[51,52].", [["cancer", "ANATOMY", 107, 113], ["cancer", "DISEASE", 107, 113], ["cancer", "CANCER", 107, 113], ["carrier proteins", "PROTEIN", 41, 57], ["peptide mimics", "PROBLEM", 13, 27], ["carrier proteins", "PROBLEM", 41, 57], ["cancer", "PROBLEM", 107, 113], ["anti-allergic and contraceptive vaccines", "TREATMENT", 115, 155]]], ["Interestingly, peptide mimics need not have similarity to any linear sequence of the antigen but rely on the use of conformation dependent epitopes to stimulate antibodies that will cross-react with the target antigen.ConclusionsThese results confirm L118 as a component of the MAb-1G10 binding epitope, and further identify D115 as an essential residue.", [["L118", "SIMPLE_CHEMICAL", 251, 255], ["D115", "GENE_OR_GENE_PRODUCT", 325, 329], ["conformation dependent epitopes", "PROTEIN", 116, 147], ["antibodies", "PROTEIN", 161, 171], ["target antigen", "PROTEIN", 203, 217], ["L118", "PROTEIN", 251, 255], ["MAb-1G10 binding epitope", "PROTEIN", 278, 302], ["D115", "PROTEIN", 325, 329], ["any linear sequence of the antigen", "PROBLEM", 58, 92], ["conformation dependent epitopes", "TREATMENT", 116, 147], ["the MAb", "TREATMENT", 274, 281], ["an essential residue", "PROBLEM", 333, 353], ["essential", "OBSERVATION_MODIFIER", 336, 345], ["residue", "OBSERVATION", 346, 353]]], ["By defining the minimum conformational structure, as well as the conformational arrangement of a short peptide sequence recognized by MAb-1G10, these results introduce the possibility of designing small molecule mimics that may interfere with the function of A33 in vivo.", [["MAb-1G10", "GENE_OR_GENE_PRODUCT", 134, 142], ["A33", "GENE_OR_GENE_PRODUCT", 259, 262], ["MAb", "PROTEIN", 134, 137], ["1G10", "PROTEIN", 138, 142], ["A33", "PROTEIN", 259, 262], ["a short peptide sequence", "PROBLEM", 95, 119], ["MAb", "TEST", 134, 137], ["small molecule mimics", "PROBLEM", 197, 218], ["A33 in vivo", "TREATMENT", 259, 270]]], ["Our current study demonstrates how an interdisciplinary approach integrating conformational peptide display, structure mapping, and a biologically relevant assay provides a more complete characterization of an important vaccinia epitope.", [["vaccinia", "ORGANISM", 220, 228], ["vaccinia epitope", "PROTEIN", 220, 236], ["Our current study", "TEST", 0, 17], ["structure mapping", "TEST", 109, 126], ["an important vaccinia epitope", "PROBLEM", 207, 236], ["vaccinia epitope", "OBSERVATION", 220, 236]]], ["Our findings suggest an additional option for vaccine subunit development, the possibility of using streamlined assays to assess anti-EEV vaccine responses, and provide a path towards improved potency evaluation of passive immune therapies for human orthopoxvirus disease.Virus stocks, antibodies and cells ::: Methods and materialsThe IHDJ strain of vaccinia virus was obtained from the laboratory of Bernard Moss (NIAID) and passaged once through Vero E6 cells (ATCC).", [["cells", "ANATOMY", 301, 306], ["Vero E6 cells", "ANATOMY", 449, 462], ["ATCC", "ANATOMY", 464, 468], ["orthopoxvirus disease", "DISEASE", 250, 271], ["human", "ORGANISM", 244, 249], ["Virus", "ORGANISM", 272, 277], ["cells", "CELL", 301, 306], ["IHDJ strain", "ORGANISM", 336, 347], ["vaccinia virus", "ORGANISM", 351, 365], ["Vero E6 cells", "CELL", 449, 462], ["ATCC", "CELL", 464, 468], ["antibodies", "PROTEIN", 286, 296], ["Vero E6 cells", "CELL_LINE", 449, 462], ["ATCC", "CELL_LINE", 464, 468], ["human", "SPECIES", 244, 249], ["vaccinia virus", "SPECIES", 351, 365], ["anti-EEV", "SPECIES", 129, 137], ["human", "SPECIES", 244, 249], ["vaccinia virus", "SPECIES", 351, 365], ["Vero E6", "SPECIES", 449, 456], ["an additional option", "TREATMENT", 21, 41], ["vaccine", "TREATMENT", 46, 53], ["streamlined assays", "TEST", 100, 118], ["anti-EEV vaccine", "TREATMENT", 129, 145], ["potency evaluation", "TEST", 193, 211], ["passive immune therapies", "TREATMENT", 215, 239], ["human orthopoxvirus disease", "PROBLEM", 244, 271], ["Virus stocks", "TEST", 272, 284], ["The IHDJ strain of vaccinia virus", "PROBLEM", 332, 365], ["Vero E6 cells", "TREATMENT", 449, 462], ["vaccinia virus", "OBSERVATION", 351, 365], ["Bernard Moss", "OBSERVATION", 402, 414]]], ["Vero E6 cells were maintained in cDMEM (Dubelco\u2019s minimal essential media containing 10% fetal bovine serum, 4.5 mg/mL D-glucose, 110 \u03bcg/mL sodium pyruvate, 100 \u03bcM nonessential amino acids, 100 U/mL penicillin/streptomycin, and 0.25 \u03bcg/mL amphotericin) and infected at a low MOI (0.2) for 1 hour at 37\u00b0C, and were then incubated at 37\u00b0C and monitored for cytopathic effect daily.", [["Vero E6 cells", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 89, 107], ["D-glucose", "CHEMICAL", 119, 128], ["sodium pyruvate", "CHEMICAL", 140, 155], ["amino acids", "CHEMICAL", 177, 188], ["penicillin", "CHEMICAL", 199, 209], ["streptomycin", "CHEMICAL", 210, 222], ["amphotericin", "CHEMICAL", 239, 251], ["D-glucose", "CHEMICAL", 119, 128], ["sodium pyruvate", "CHEMICAL", 140, 155], ["amino acids", "CHEMICAL", 177, 188], ["penicillin", "CHEMICAL", 199, 209], ["streptomycin", "CHEMICAL", 210, 222], ["amphotericin", "CHEMICAL", 239, 251], ["Vero E6 cells", "CELL", 0, 13], ["bovine", "ORGANISM", 95, 101], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["D-glucose", "SIMPLE_CHEMICAL", 119, 128], ["sodium", "SIMPLE_CHEMICAL", 140, 146], ["pyruvate", "SIMPLE_CHEMICAL", 147, 155], ["amino acids", "AMINO_ACID", 177, 188], ["penicillin", "SIMPLE_CHEMICAL", 199, 209], ["streptomycin", "SIMPLE_CHEMICAL", 210, 222], ["amphotericin", "SIMPLE_CHEMICAL", 239, 251], ["C", "GENE_OR_GENE_PRODUCT", 335, 336], ["Vero E6 cells", "CELL_LINE", 0, 13], ["bovine", "SPECIES", 95, 101], ["Vero E6", "SPECIES", 0, 7], ["bovine", "SPECIES", 95, 101], ["Vero E6 cells", "PROBLEM", 0, 13], ["minimal essential media", "TREATMENT", 50, 73], ["fetal bovine serum", "TREATMENT", 89, 107], ["glucose", "TEST", 121, 128], ["sodium pyruvate", "TREATMENT", 140, 155], ["nonessential amino acids", "TREATMENT", 164, 188], ["penicillin", "TREATMENT", 199, 209], ["streptomycin", "TREATMENT", 210, 222], ["amphotericin", "TREATMENT", 239, 251], ["cytopathic effect", "PROBLEM", 355, 372], ["E6 cells", "OBSERVATION", 5, 13]]], ["On day 3 postinfection, cells and cell culture supernatant were removed to centrifuge tubes and spun for 15 minutes at 2000 \u00d7 g at 4\u00b0C in an Eppendorf Model 5404R centrifuge equipped with a swinging bucket rotor.", [["cells", "ANATOMY", 24, 29], ["cell culture supernatant", "ANATOMY", 34, 58], ["tubes", "ANATOMY", 86, 91], ["cells", "CELL", 24, 29], ["cell", "CELL", 34, 38], ["postinfection", "PROBLEM", 9, 22], ["cells", "PROBLEM", 24, 29], ["cell culture supernatant", "TEST", 34, 58], ["centrifuge tubes", "TREATMENT", 75, 91], ["a swinging bucket rotor", "TREATMENT", 188, 211]]], ["The resulting cell pellets were resuspended in cold cDMEM, processed with a chilled Dounce homogenizer, and clarified by centrifugation at 1000 \u00d7 g for 10 minutes at 4\u00b0C. The supernatant was disrupted using a cup horn sonicator for 4 cycles each composed of 30 seconds at 90% power, 50% duty cycle followed by 60 seconds on ice.", [["cell", "ANATOMY", 14, 18], ["supernatant", "ANATOMY", 175, 186], ["cell", "CELL", 14, 18], ["The resulting cell pellets", "PROBLEM", 0, 26], ["a cup horn sonicator", "TREATMENT", 207, 227], ["cell pellets", "OBSERVATION", 14, 26]]], ["Aliquots were removed to check sterility and viral titer, and the remainder aliquoted and frozen at -80\u00b0C. The MAb-1G10 hybridoma was grown in BD Cell Monoclonal Antibody Medium (Fisher).", [["Aliquots", "ANATOMY", 0, 8], ["Cell", "ANATOMY", 146, 150], ["Aliquots", "ORGANISM_SUBSTANCE", 0, 8], ["MAb", "GENE_OR_GENE_PRODUCT", 111, 114], ["BD Cell", "CELL", 143, 150], ["MAb-1G10 hybridoma", "CELL_LINE", 111, 129], ["Aliquots", "TREATMENT", 0, 8], ["viral titer", "TEST", 45, 56], ["The MAb", "TREATMENT", 107, 114], ["1G10 hybridoma", "TREATMENT", 115, 129], ["BD Cell", "OBSERVATION_MODIFIER", 143, 150], ["Monoclonal Antibody", "OBSERVATION", 151, 170]]], ["Hybridoma supernatant was applied to a protein A affinity column (GE Healthcare) and after extensive washes with PBS, the bound antibody was eluted with 0.1M glycine pH 2.5 and immediately neutralized with 1M Tris-HCl (pH 8.0).Epitope mapping by randomized peptide phage display library ::: Methods and materialsSelection of peptides from random peptide phage display libraries (PhD-C7C and PhD-12; New England Biolabs, Beverly, MA) was described previously[9].", [["supernatant", "ANATOMY", 10, 21], ["glycine", "CHEMICAL", 158, 165], ["1M Tris-HCl", "CHEMICAL", 206, 217], ["glycine", "CHEMICAL", 158, 165], ["1M Tris-HCl", "CHEMICAL", 206, 217], ["Tris-HCl", "SIMPLE_CHEMICAL", 209, 217], ["Hybridoma", "SPECIES", 0, 9], ["Hybridoma supernatant", "TREATMENT", 0, 21], ["a protein A affinity column", "TREATMENT", 37, 64], ["extensive washes with PBS", "TREATMENT", 91, 116], ["the bound antibody", "TEST", 118, 136], ["glycine pH", "TEST", 158, 168], ["1M Tris", "TREATMENT", 206, 213], ["pH", "TEST", 219, 221], ["Epitope mapping", "TREATMENT", 227, 242], ["peptides", "TEST", 325, 333], ["random peptide phage", "TEST", 339, 359]]], ["Briefly, 2 \u00d7 1010 phages were incubated with MAb-1G10 monoclonal antibody /protein G mixtures for 20 min at room temperature.", [["MAb-1G10 monoclonal antibody", "PROTEIN", 45, 73], ["protein G", "PROTEIN", 75, 84], ["MAb", "TEST", 45, 48], ["monoclonal antibody /protein G mixtures", "TREATMENT", 54, 93]]], ["After eight washings with 0.05 M Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl and 0.05% Tween 20, the phages were eluted from the complex with 0.1 M HCl for 8 min at room temperature and neutralized with 1 M Tris-HCl (pH 9.0).", [["Tris-HCl", "CHEMICAL", 33, 41], ["NaCl", "CHEMICAL", 76, 80], ["HCl", "CHEMICAL", 152, 155], ["Tris-HCl", "CHEMICAL", 211, 219], ["Tris-HCl", "CHEMICAL", 33, 41], ["NaCl", "CHEMICAL", 76, 80], ["Tween 20", "CHEMICAL", 91, 99], ["HCl", "CHEMICAL", 152, 155], ["Tris-HCl", "CHEMICAL", 211, 219], ["Tris-HCl", "SIMPLE_CHEMICAL", 33, 41], ["Tris-HCl", "SIMPLE_CHEMICAL", 211, 219], ["0.05 M Tris-HCl buffer", "TREATMENT", 26, 48], ["pH", "TEST", 50, 52], ["0.15 M NaCl", "TREATMENT", 69, 80], ["the phages", "TREATMENT", 101, 111], ["pH", "TEST", 221, 223]]], ["The eluted phages were then amplified in the host strain ER2738 and precipitated with 25% PEG/4 M NaCl.", [["PEG", "CHEMICAL", 90, 93], ["NaCl", "CHEMICAL", 98, 102], ["PEG", "CHEMICAL", 90, 93], ["NaCl", "CHEMICAL", 98, 102], ["ER2738", "SIMPLE_CHEMICAL", 57, 63], ["The eluted phages", "TREATMENT", 0, 17], ["25% PEG/4 M NaCl", "TREATMENT", 86, 102]]], ["After three additional rounds of selection of amplified phages, DNA from well-separated plaques was sequenced, and the corresponding peptide sequence was then deduced from the DNA sequence.Structural analysis ::: Methods and materialsMolecular coordinates for the A33 protein [PDB: 3K7B] used in structural analysis and modeling were obtained from the Protein Data Bank[53] then visualized and analyzed using Pymol (PyMOL Molecular Graphics System, Version 1.1r1, Schr\u00f6dinger, LLC).", [["plaques", "ANATOMY", 88, 95], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["plaques", "PATHOLOGICAL_FORMATION", 88, 95], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["Pymol", "SIMPLE_CHEMICAL", 409, 414], ["amplified phages", "DNA", 46, 62], ["DNA sequence", "DNA", 176, 188], ["A33 protein", "PROTEIN", 264, 275], ["3K7B", "PROTEIN", 282, 286], ["selection of amplified phages", "TREATMENT", 33, 62], ["DNA from well-separated plaques", "PROBLEM", 64, 95], ["the corresponding peptide sequence", "TEST", 115, 149], ["the DNA sequence", "TEST", 172, 188], ["the A33 protein", "TEST", 260, 275], ["PDB", "TEST", 277, 280], ["structural analysis", "TEST", 296, 315], ["Version", "TEST", 449, 456], ["plaques", "OBSERVATION", 88, 95], ["LLC", "ANATOMY", 477, 480]]], ["To model the structure of the consensus positive phage display peptide, the structural database was queried using BLAST for short sequences containing two cysteines separated by three amino acids (CXXXC).", [["amino acids", "CHEMICAL", 184, 195], ["cysteines", "CHEMICAL", 155, 164], ["amino acids", "CHEMICAL", 184, 195], ["CXXXC", "CHEMICAL", 197, 202], ["amino acids", "AMINO_ACID", 184, 195], ["CXXXC", "PROTEIN", 197, 202], ["short sequences", "TEST", 124, 139], ["two cysteines", "TREATMENT", 151, 164], ["three amino acids", "TREATMENT", 178, 195]]], ["The structures returned from the search were examined for the presence or absence of disulphide bonds and for local conformation.", [["disulphide", "CHEMICAL", 85, 95], ["disulphide bonds", "PROBLEM", 85, 101], ["disulphide bonds", "OBSERVATION", 85, 101]]], ["If different the sequence extracted from the database was altered to the sequence of phage display peptide, energy minimized using CHARMM[54] and then compared with the possible locus of the MAb-1G10 epitope.Protein expression and purification ::: Methods and materialsBriefly, the DNA sequence encoding the residues from 59 to 186 of wild type A33 was amplified by PCR from vaccinia virus Western Reserve strain[55].", [["DNA", "CELLULAR_COMPONENT", 282, 285], ["A33", "GENE_OR_GENE_PRODUCT", 345, 348], ["vaccinia virus", "ORGANISM", 375, 389], ["MAb-1G10 epitope", "PROTEIN", 191, 207], ["DNA sequence", "DNA", 282, 294], ["vaccinia virus", "SPECIES", 375, 389], ["the MAb", "TEST", 187, 194], ["the DNA sequence", "TEST", 278, 294], ["wild type A33", "PROBLEM", 335, 348], ["PCR", "TEST", 366, 369]]], ["To facilitate protein purification and refolding, a His tag and peptide linker were introduced into the N terminal region of the rA33 construct.", [["His", "CHEMICAL", 52, 55], ["N", "CHEMICAL", 104, 105], ["rA33", "GENE_OR_GENE_PRODUCT", 129, 133], ["His tag", "PROTEIN", 52, 59], ["N terminal region", "PROTEIN", 104, 121], ["rA33 construct", "DNA", 129, 143], ["protein purification", "TREATMENT", 14, 34], ["refolding", "TREATMENT", 39, 48], ["a His tag and peptide linker", "TREATMENT", 50, 78], ["terminal", "ANATOMY_MODIFIER", 106, 114], ["region", "ANATOMY_MODIFIER", 115, 121]]], ["Finally, the PCR product was cloned into pET28 (BD Bioscience).", [["pET28", "PROTEIN", 41, 46], ["the PCR product", "TEST", 9, 24]]], ["Utilizing this construct as a template, plasmids encoding A33 containing the desired mutations were constructed using a kit for site directed mutagenesis (New England Biolabs) according to manufacturer\u2019s instructions using primers described in Table1.", [["plasmids", "ANATOMY", 40, 48], ["A33", "GENE_OR_GENE_PRODUCT", 58, 61], ["plasmids", "DNA", 40, 48], ["A33", "DNA", 58, 61], ["Table1", "DNA", 244, 250], ["this construct", "TREATMENT", 10, 24], ["a template, plasmids encoding A33", "TREATMENT", 28, 61], ["the desired mutations", "TREATMENT", 73, 94], ["a kit", "TREATMENT", 118, 123], ["site directed mutagenesis", "TREATMENT", 128, 153], ["New England Biolabs)", "TREATMENT", 155, 175]]], ["The accuracy of the resulting constructs was verified by DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["DNA sequencing", "TEST", 57, 71]]], ["E. coli strain BL21-DE3 was transformed with the resulting plasmids, cultured at 37\u00b0C to an OD600 value of approximately 0.4, and then induced with 0.2 mM IPTG for 4 hours.", [["plasmids", "ANATOMY", 59, 67], ["IPTG", "CHEMICAL", 155, 159], ["IPTG", "CHEMICAL", 155, 159], ["E. coli", "ORGANISM", 0, 7], ["BL21-DE3", "GENE_OR_GENE_PRODUCT", 15, 23], ["DE3", "PROTEIN", 20, 23], ["plasmids", "DNA", 59, 67], ["E. coli strain BL21", "SPECIES", 0, 19], ["E. coli", "SPECIES", 0, 7], ["BL21-DE3", "SPECIES", 15, 23], ["E. coli strain BL21", "TEST", 0, 19], ["the resulting plasmids", "PROBLEM", 45, 67], ["0.2 mM IPTG", "TREATMENT", 148, 159], ["coli strain BL21", "OBSERVATION", 3, 19], ["plasmids", "OBSERVATION", 59, 67]]], ["Bacteria were collected by centrifugation for 15 minutes at 5500 \u00d7 g.", [["Bacteria", "CELL", 0, 8], ["Bacteria", "PROBLEM", 0, 8]]], ["The resulting cell pellet was washed with PBS, resuspended in 1 mg/mL lysozyme in PBS, incubated at room temperature for 1 hour, then subjected to sonication on ice for three cycles of 5 minutes each.", [["cell pellet", "ANATOMY", 14, 25], ["cell", "CELL", 14, 18], ["lysozyme", "PROTEIN", 70, 78], ["The resulting cell pellet", "TREATMENT", 0, 25], ["PBS", "TREATMENT", 42, 45], ["ice", "TREATMENT", 161, 164], ["cell pellet", "OBSERVATION", 14, 25]]], ["Alternatively, bacteria were resuspended in 50 mM Tris, 50 mM NaCl, 10 mM EDTA, pH 8.0 and lysed with a French press.", [["NaCl", "CHEMICAL", 62, 66], ["Tris", "CHEMICAL", 50, 54], ["NaCl", "CHEMICAL", 62, 66], ["EDTA", "CHEMICAL", 74, 78], ["EDTA", "SIMPLE_CHEMICAL", 74, 78], ["bacteria", "PROBLEM", 15, 23], ["Tris", "TEST", 50, 54], ["pH", "TEST", 80, 82], ["a French press", "TREATMENT", 102, 116], ["bacteria", "OBSERVATION_MODIFIER", 15, 23]]], ["Inclusion bodies were collected by centrifugation at 18000 \u00d7 g for 30 minutes, washed with PBS/0.5% Triton X-100, solubilized overnight in 6 M guanidine, 20 mM Tris, 5 mM DTT, pH 8.0 and then incubated with Ni-NTA agarose beads for 2 hours at room temperature.", [["bodies", "ANATOMY", 10, 16], ["Triton X-100", "CHEMICAL", 100, 112], ["Ni-NTA", "CHEMICAL", 207, 213], ["guanidine", "CHEMICAL", 143, 152], ["Tris", "CHEMICAL", 160, 164], ["DTT", "CHEMICAL", 171, 174], ["Ni-NTA", "CHEMICAL", 207, 213], ["Triton X-100", "SIMPLE_CHEMICAL", 100, 112], ["guanidine", "SIMPLE_CHEMICAL", 143, 152], ["DTT", "SIMPLE_CHEMICAL", 171, 174], ["PBS", "TREATMENT", 91, 94], ["guanidine", "TREATMENT", 143, 152], ["20 mM Tris", "TREATMENT", 154, 164], ["pH", "TEST", 176, 178], ["Ni-NTA agarose beads", "TREATMENT", 207, 227]]], ["The beads were loaded onto a Econo-pac column (Biorad) and washed with 3 column volumes of 6 M guanidine.", [["beads", "ANATOMY", 4, 9], ["guanidine", "CHEMICAL", 95, 104], ["guanidine", "CHEMICAL", 95, 104], ["The beads", "TREATMENT", 0, 9], ["a Econo-pac column", "TREATMENT", 27, 45], ["3 column volumes", "TREATMENT", 71, 87], ["guanidine", "TREATMENT", 95, 104]]], ["Protein folding was facilitated by washes with a decreasing concentration of guanidine (6 M, 4 M, 2 M, 1 M), and a final wash with PBS.", [["guanidine", "CHEMICAL", 77, 86], ["guanidine", "CHEMICAL", 77, 86], ["guanidine", "SIMPLE_CHEMICAL", 77, 86], ["Protein folding", "PROBLEM", 0, 15], ["a decreasing concentration of guanidine", "TREATMENT", 47, 86], ["a final wash with PBS", "TREATMENT", 113, 134]]], ["The refolded proteins were eluted from the column with 250 mM inidazole in PBS, pH 8.0 and dialyzed against PBS at 4\u00b0C with extensive buffer changes.", [["inidazole", "CHEMICAL", 62, 71], ["inidazole", "CHEMICAL", 62, 71], ["inidazole", "SIMPLE_CHEMICAL", 62, 71], ["refolded proteins", "PROTEIN", 4, 21], ["The refolded proteins", "TREATMENT", 0, 21], ["250 mM inidazole in PBS", "TREATMENT", 55, 78], ["pH", "TEST", 80, 82], ["PBS", "TEST", 108, 111], ["extensive buffer changes", "PROBLEM", 124, 148], ["extensive", "OBSERVATION_MODIFIER", 124, 133], ["buffer changes", "OBSERVATION", 134, 148]]], ["The protein solution was then clarified by centrifugation at 18000 \u00d7 g and the resulting supernatant snap-frozen in liquid nitrogen and stored at -80\u00b0C.Protein expression and purification ::: Methods and materialsTo express and purify soluble recombinant A33 proteins from E.coli, the protein was expressed in BL21(DE3) at 18\u00b0C in the presence of 5% glycerol and 2.5% ethanol.", [["supernatant", "ANATOMY", 89, 100], ["glycerol", "CHEMICAL", 350, 358], ["ethanol", "CHEMICAL", 368, 375], ["nitrogen", "CHEMICAL", 123, 131], ["glycerol", "CHEMICAL", 350, 358], ["ethanol", "CHEMICAL", 368, 375], ["A33", "GENE_OR_GENE_PRODUCT", 255, 258], ["E.coli", "GENE_OR_GENE_PRODUCT", 273, 279], ["BL21", "CELL", 310, 314], ["DE3", "CELL", 315, 318], ["glycerol", "SIMPLE_CHEMICAL", 350, 358], ["ethanol", "SIMPLE_CHEMICAL", 368, 375], ["A33 proteins", "PROTEIN", 255, 267], ["E.coli", "PROTEIN", 273, 279], ["BL21", "PROTEIN", 310, 314], ["E.coli", "SPECIES", 273, 279], ["BL21", "SPECIES", 310, 314], ["The protein solution", "TREATMENT", 0, 20], ["frozen in liquid nitrogen", "TREATMENT", 106, 131], ["E.coli", "PROBLEM", 273, 279], ["the protein", "TEST", 281, 292], ["5% glycerol", "TREATMENT", 347, 358]]], ["The soluble fraction containing A33 was adsorbed onto Talon affinity resin, loaded into an Eco-Pak column and refolded on the column using the method described above.", [["A33", "CHEMICAL", 32, 35], ["A33", "SIMPLE_CHEMICAL", 32, 35], ["The soluble fraction", "TREATMENT", 0, 20], ["Talon affinity resin", "TREATMENT", 54, 74], ["an Eco-Pak column", "TREATMENT", 88, 105], ["Pak column", "OBSERVATION", 95, 105], ["column", "ANATOMY", 126, 132]]], ["Purity of the proteins was assessed on SDS-PAGE gels (Invitrogen) stained with GelCode Blue (Pierce) or by HPLC analysis with a Zobax GF250 size exclusion column.Peptide synthesis ::: Methods and materialsSynthetic phage peptide mimics RF2-1:ACTSYNEPLCGGGSAK-(C6-biotin) and RF2-5:ACGDDWPHECGGGSAK-(C6-biotin) were made by standard 9-fluorenylmethoxy carbonyl chemistry and purified by HPLC (Center for Biologics Evaluation and Research Facility for Biotechnology Resources, US Food and Drug Administration, Rockville, MD).", [["RF2-5:ACGDDWPHECGGGSAK-(C6-biotin", "CHEMICAL", 275, 308], ["9-fluorenylmethoxy carbonyl", "CHEMICAL", 332, 359], ["GelCode Blue", "CHEMICAL", 79, 91], ["biotin", "CHEMICAL", 263, 269], ["RF2-5:ACGDDWPHECGGGSAK-(C6-biotin", "CHEMICAL", 275, 308], ["9-fluorenylmethoxy carbonyl", "CHEMICAL", 332, 359], ["GelCode Blue", "SIMPLE_CHEMICAL", 79, 91], ["RF2-1", "SIMPLE_CHEMICAL", 236, 241], ["ACTSYNEPLCGGGSAK-(C6-biotin", "SIMPLE_CHEMICAL", 242, 269], ["RF2-5", "SIMPLE_CHEMICAL", 275, 280], ["ACGDDWPHECGGGSAK-(C6-biotin", "SIMPLE_CHEMICAL", 281, 308], ["9-fluorenylmethoxy carbonyl", "SIMPLE_CHEMICAL", 332, 359], ["the proteins", "TEST", 10, 22], ["SDS", "TEST", 39, 42], ["HPLC analysis", "TEST", 107, 120], ["a Zobax GF250 size exclusion column", "TREATMENT", 126, 161], ["Methods and materialsSynthetic phage peptide", "TEST", 184, 228], ["RF2", "TEST", 236, 239], ["ACTSYNEPLCGGGSAK", "TEST", 242, 258], ["C6-biotin)", "TEST", 260, 270], ["RF2", "TEST", 275, 278], ["ACGDDWPHECGGGSAK", "TEST", 281, 297], ["C6-biotin)", "TREATMENT", 299, 309], ["Biologics Evaluation", "TEST", 403, 423], ["size", "OBSERVATION_MODIFIER", 140, 144], ["exclusion column", "OBSERVATION", 145, 161]]], ["Peptides were confirmed to have the expected molecular weight by matrix-assisted laser desorption ionization-time-of-flight mass spectroscopy.", [["matrix-assisted laser desorption ionization", "TREATMENT", 65, 108], ["flight mass spectroscopy", "TEST", 117, 141]]], ["Reduced peptides were generated as previously described[56].", [["Reduced peptides", "PROBLEM", 0, 16], ["peptides", "OBSERVATION", 8, 16]]], ["Briefly, the peptide was dissolved in 0.1 M phosphate buffer (pH7.0) and incubated with 20 fold of molar excess of both tris(2-carboxyethyl)phosphine (TCEP) and N-Ethylmaleimide (NEM) at room temperature for 2 h.", [["phosphate", "CHEMICAL", 44, 53], ["tris(2-carboxyethyl)phosphine", "CHEMICAL", 120, 149], ["TCEP", "CHEMICAL", 151, 155], ["N-Ethylmaleimide", "CHEMICAL", 161, 177], ["NEM", "CHEMICAL", 179, 182], ["phosphate", "CHEMICAL", 44, 53], ["tris(2-carboxyethyl)phosphine", "CHEMICAL", 120, 149], ["TCEP", "CHEMICAL", 151, 155], ["N-Ethylmaleimide", "CHEMICAL", 161, 177], ["NEM", "CHEMICAL", 179, 182], ["tris(2-carboxyethyl)phosphine", "SIMPLE_CHEMICAL", 120, 149], ["TCEP", "SIMPLE_CHEMICAL", 151, 155], ["N-Ethylmaleimide", "SIMPLE_CHEMICAL", 161, 177], ["NEM", "SIMPLE_CHEMICAL", 179, 182], ["0.1 M phosphate buffer", "TREATMENT", 38, 60], ["molar excess of both tris(2-carboxyethyl)phosphine (TCEP", "TREATMENT", 99, 155], ["N-Ethylmaleimide (NEM", "TREATMENT", 161, 182]]], ["Peptide solutions were stored at -80\u00b0C until use.ELISAs ::: Methods and materials96-well polystyrene plates (Corning) were coated with rA33 proteins (10 \u03bcg/ml, 100 \u03bcl per well) in PBS overnight at 4\u00b0C, and unbound rA33 was removed with saline containing 0.5% Tween 20 (PBS-T).", [["polystyrene", "CHEMICAL", 89, 100], ["Tween 20", "CHEMICAL", 259, 267], ["rA33", "SIMPLE_CHEMICAL", 214, 218], ["saline", "SIMPLE_CHEMICAL", 236, 242], ["rA33 proteins", "PROTEIN", 135, 148], ["Peptide solutions", "TREATMENT", 0, 17], ["Methods and materials", "TREATMENT", 60, 81], ["well polystyrene plates", "TREATMENT", 84, 107], ["rA33 proteins", "TREATMENT", 135, 148], ["saline", "TREATMENT", 236, 242]]], ["Non-specific protein binding was blocked with 5% nonfat dry milk in PBS-T.", [["milk", "ANATOMY", 60, 64], ["milk", "ORGANISM_SUBSTANCE", 60, 64], ["Non-specific protein binding", "PROBLEM", 0, 28], ["protein binding", "OBSERVATION", 13, 28]]], ["Serial dilutions of MAb-1G10 in blocking buffer were added to wells and incubated for 1 h at 37\u00b0C. Wells were washed 4 times in PBS-T before addition of horseradish peroxidase (HRP) -conjugated anti-mouse secondary antibody (Roche Diagnostics) diluted in blocking buffer.", [["MAb-1G10", "CHEMICAL", 20, 28], ["MAb-1G10", "SIMPLE_CHEMICAL", 20, 28], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 153, 175], ["HRP", "SIMPLE_CHEMICAL", 177, 180], ["MAb", "PROTEIN", 20, 23], ["1G10", "PROTEIN", 24, 28], ["horseradish peroxidase (HRP) -conjugated anti-mouse secondary antibody", "PROTEIN", 153, 223], ["horseradish", "SPECIES", 153, 164], ["Serial dilutions of MAb", "TREATMENT", 0, 23], ["blocking buffer", "TREATMENT", 32, 47], ["horseradish peroxidase", "TREATMENT", 153, 175], ["conjugated anti-mouse secondary antibody (Roche Diagnostics)", "TREATMENT", 183, 243], ["blocking buffer", "TREATMENT", 255, 270]]], ["After 1 h incubation, plates were washed 4 times prior to application of soluble HRP substrate (BM Blue, Roche Diagnostics) for 30 min.", [["HRP substrate", "SIMPLE_CHEMICAL", 81, 94], ["1 h incubation", "TREATMENT", 6, 20], ["plates", "TREATMENT", 22, 28], ["soluble HRP substrate (BM Blue", "TREATMENT", 73, 103]]], ["The reaction was stopped by adding 1M sulfuric acid, and absorbance at 450 nm was determined using a plate reader (Molecular Devices).", [["1M sulfuric acid", "CHEMICAL", 35, 51], ["sulfuric acid", "CHEMICAL", 38, 51], ["1M sulfuric acid", "SIMPLE_CHEMICAL", 35, 51], ["The reaction", "PROBLEM", 0, 12], ["1M sulfuric acid", "TREATMENT", 35, 51], ["absorbance", "TREATMENT", 57, 67], ["a plate reader (Molecular Devices", "TREATMENT", 99, 132]]], ["For detection of antibody binding to biotinylated peptides, peptides diluted in phosphate buffer were added to wells of streptavidin-coated 96-well plates (Thermo Scientific), plates incubated overnight at 4\u00b0C, and bound antibody detected as described above.Immunoprecipitation analysis ::: Methods and materialsTo prepare antibody-conjugated beads, antibody dilutions were incubated with protein A Dynal magnetic beads (Invitrogen) according to manufacturer\u2019s instructions overnight, then treated with excess BS3 crosslinking agent at room temperature for 30 minutes.", [["phosphate", "CHEMICAL", 80, 89], ["BS3", "CHEMICAL", 510, 513], ["phosphate", "CHEMICAL", 80, 89], ["BS3", "CHEMICAL", 510, 513], ["phosphate buffer", "SIMPLE_CHEMICAL", 80, 96], ["streptavidin", "SIMPLE_CHEMICAL", 120, 132], ["BS3", "SIMPLE_CHEMICAL", 510, 513], ["antibody", "PROTEIN", 323, 331], ["antibody binding", "PROBLEM", 17, 33], ["biotinylated peptides", "TREATMENT", 37, 58], ["peptides", "TREATMENT", 60, 68], ["phosphate buffer", "TREATMENT", 80, 96], ["streptavidin", "TEST", 120, 132], ["bound antibody", "TEST", 215, 229], ["Immunoprecipitation analysis", "TEST", 258, 286], ["antibody-conjugated beads", "TREATMENT", 323, 348], ["antibody dilutions", "TEST", 350, 368], ["protein A Dynal magnetic beads", "TREATMENT", 389, 419], ["excess BS3 crosslinking agent", "TREATMENT", 503, 532]]], ["Crosslinking was quenched by incubating with 1 M Tris buffer.", [["Tris", "CHEMICAL", 49, 53], ["1 M Tris buffer", "TREATMENT", 45, 60]]], ["Unbound antibody was removed by incubation with 0.1 M glycine buffer (pH 2.5), followed by three times washing in PBS-T buffer.", [["glycine", "CHEMICAL", 54, 61], ["glycine", "CHEMICAL", 54, 61], ["Unbound antibody", "TEST", 0, 16], ["0.1 M glycine buffer", "TREATMENT", 48, 68]]], ["5 \u03bcg of each rA33 protein was incubated with 200 \u03bcl of antibody-conjugated beads for 1 hour at room temperature with consistent rotation.", [["rA33", "GENE_OR_GENE_PRODUCT", 13, 17], ["rA33 protein", "PROTEIN", 13, 25], ["antibody", "PROTEIN", 55, 63], ["antibody-conjugated beads", "TREATMENT", 55, 80]]], ["After extensive washing in PBS-T, the bound rA33 proteins were eluted by using 0.1M glycine (pH 2.5).", [["glycine", "CHEMICAL", 84, 91], ["glycine", "CHEMICAL", 84, 91], ["rA33", "GENE_OR_GENE_PRODUCT", 44, 48], ["glycine", "SIMPLE_CHEMICAL", 84, 91], ["rA33 proteins", "PROTEIN", 44, 57], ["PBS", "TEST", 27, 30], ["the bound rA33 proteins", "TEST", 34, 57], ["pH", "TEST", 93, 95]]], ["Eluted proteins were analyzed by SDS-PAGE and detected by staining with GelCode Blue (Pierce).Comet inhibition assay ::: Methods and materialsConfluent monolayers of Vero E6 cells in six-well cell culture plates (Corning) were infected with the IHD-J strain of VACV at 50\u2013100 pfu per well in 0.2 mL cDMEM.", [["monolayers", "ANATOMY", 152, 162], ["Vero E6 cells", "ANATOMY", 166, 179], ["cell", "ANATOMY", 192, 196], ["GelCode Blue", "CHEMICAL", 72, 84], ["Confluent monolayers", "CELL", 142, 162], ["Vero E6 cells", "CELL", 166, 179], ["cell", "CELL", 192, 196], ["VACV", "ORGANISM", 261, 265], ["Vero E6 cells", "CELL_LINE", 166, 179], ["Vero E6", "SPECIES", 166, 173], ["VACV", "SPECIES", 261, 265], ["Eluted proteins", "TEST", 0, 15], ["Methods and materials", "TREATMENT", 121, 142], ["Vero E6 cells", "TREATMENT", 166, 179], ["VACV", "TREATMENT", 261, 265], ["Confluent", "OBSERVATION_MODIFIER", 142, 151], ["monolayers", "OBSERVATION_MODIFIER", 152, 162], ["Vero E6 cells", "OBSERVATION", 166, 179], ["well cell", "OBSERVATION_MODIFIER", 187, 196]]], ["One well was left uninfected as a sham control.", [["a sham control", "TREATMENT", 32, 46], ["left", "ANATOMY_MODIFIER", 13, 17], ["uninfected", "OBSERVATION", 18, 28]]], ["After incubation for 1 h at 37\u00b0C, the media was removed, and cells were washed twice with 2 mL PBS.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["the media", "TREATMENT", 34, 43], ["2 mL PBS", "TREATMENT", 90, 98]]], ["Virus-only wells received 2mL cDMEM, and virus + MAb wells received 2 mL cDMEM containing MAb-1G10 at 12.5 \u03bcg/mL.", [["cDMEM", "CHEMICAL", 73, 78], ["MAb-1G10", "CHEMICAL", 90, 98], ["Virus", "ORGANISM", 0, 5], ["MAb-1G10", "SIMPLE_CHEMICAL", 90, 98], ["Virus", "PROBLEM", 0, 5], ["virus + MAb wells", "TREATMENT", 41, 58], ["MAb", "TREATMENT", 90, 93]]], ["Test wells received 2 mL cDMEM containing 12.5 \u03bcg/mL MAb-1G10 in combination with concentrations of A33 proteins ranging from 0.1-10 times molar excess over the monoclonal antibody.", [["cDMEM", "CHEMICAL", 25, 30], ["MAb-1G10", "CHEMICAL", 53, 61], ["MAb-1G10", "SIMPLE_CHEMICAL", 53, 61], ["A33 proteins", "PROTEIN", 100, 112], ["monoclonal antibody", "PROTEIN", 161, 180], ["A33 proteins", "TEST", 100, 112], ["the monoclonal antibody", "TEST", 157, 180], ["monoclonal antibody", "OBSERVATION", 161, 180]]], ["Some experiments utilized purified phage instead of A33 proteins.", [["A33", "GENE_OR_GENE_PRODUCT", 52, 55], ["A33 proteins", "PROTEIN", 52, 64], ["purified phage", "TREATMENT", 26, 40], ["A33 proteins", "TREATMENT", 52, 64]]], ["Plates were placed in a CO2 incubator maintained at 37\u00b0C for 46 hours, and comets visualized by staining the monolayers with 0.13% crystal violet in 5% ethanol/3% neutral buffered formalin prior to imaging.Bioinformatics and statistical analysis ::: Methods and materialsData was obtained from the NIAID Virus Pathogen Database and Analysis Resource (ViPR) online through the web site athttp://www.viprbrc.org (http://www.viprbrc.org) and from the Viral Bioinformatics Resource Center (VBRC;http://www.vbrc.org) and was aligned and visualized using multiple sequence alignment tools available at these websites.", [["monolayers", "ANATOMY", 109, 119], ["crystal violet", "CHEMICAL", 131, 145], ["ethanol", "CHEMICAL", 152, 159], ["CO2", "CHEMICAL", 24, 27], ["ethanol", "CHEMICAL", 152, 159], ["formalin", "CHEMICAL", 180, 188], ["monolayers", "CELL", 109, 119], ["ethanol", "SIMPLE_CHEMICAL", 152, 159], ["formalin", "SIMPLE_CHEMICAL", 180, 188], ["a CO2 incubator", "TREATMENT", 22, 37], ["0.13% crystal violet", "TREATMENT", 125, 145], ["3% neutral buffered formalin", "TREATMENT", 160, 188], ["imaging", "TEST", 198, 205], ["statistical analysis", "TEST", 225, 245], ["Methods and materialsData", "TEST", 250, 275], ["VBRC", "TEST", 486, 490], ["multiple sequence alignment tools", "TEST", 549, 582]]], ["Statistical analysis was performed using Prism 5 (GraphPad Software).", [["Statistical analysis", "TEST", 0, 20], ["Prism", "TEST", 41, 46]]], ["All experiments were performed in duplicate unless otherwise noted.Competing interestsThe authors declare that they have no competing interests.Authors\u2019 contributionsYH and YG generated recombinant A33 proteins, performed ELISA and Western blot analyses.", [["A33", "GENE_OR_GENE_PRODUCT", 198, 201], ["recombinant A33 proteins", "PROTEIN", 186, 210], ["All experiments", "TEST", 0, 15], ["ELISA", "TEST", 222, 227], ["blot analyses", "TEST", 240, 253]]], ["PZ and ES performed random peptide phage mapping and molecular modeling of the resulting peptides.", [["PZ", "CHEMICAL", 0, 2], ["PZ", "SIMPLE_CHEMICAL", 0, 2], ["random peptide phage mapping", "TREATMENT", 20, 48]]], ["SC performed EEV spread assays and performed ELISAs with the recombinant proteins.", [["recombinant proteins", "PROTEIN", 61, 81], ["EEV spread assays", "TEST", 13, 30], ["the recombinant proteins", "TREATMENT", 57, 81]]], ["JER, MK, and DES participated in the design of the study and provided critical review of the manuscript.", [["MK", "CHEMICAL", 5, 7], ["DES", "CHEMICAL", 13, 16], ["the study", "TEST", 47, 56]]], ["RWF conceived the study and participated in its design and coordination.", [["the study", "TEST", 14, 23]]]], "111d4191f8924434532860e3d1c33bc4583874ff": [["deficiency of angiotensin-(1-7), as the latter is also anti-inflammatory and antithrombotic.", [["angiotensin-(1-7)", "CHEMICAL", 14, 31], ["angiotensin-(1-7", "SIMPLE_CHEMICAL", 14, 30], ["deficiency of angiotensin", "PROBLEM", 0, 25], ["antithrombotic", "TREATMENT", 77, 91], ["angiotensin", "OBSERVATION", 14, 25], ["anti-inflammatory", "OBSERVATION_MODIFIER", 55, 72]]], ["The net effect of such processes is not only a predisposition to SARS-CoV-2 infection in pregnancy, but also to such complications in pregnancy as systemic hypertension and preeclampsia.", [["SARS", "DISEASE", 65, 69], ["infection", "DISEASE", 76, 85], ["hypertension", "DISEASE", 156, 168], ["preeclampsia", "DISEASE", 173, 185], ["CoV-2", "ORGANISM", 70, 75], ["SARS-CoV", "SPECIES", 65, 73], ["such processes", "PROBLEM", 18, 32], ["SARS", "PROBLEM", 65, 69], ["CoV", "PROBLEM", 70, 73], ["2 infection in pregnancy", "PROBLEM", 74, 98], ["such complications in pregnancy", "PROBLEM", 112, 143], ["systemic hypertension", "PROBLEM", 147, 168], ["preeclampsia", "PROBLEM", 173, 185], ["net effect", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 76, 85], ["systemic", "OBSERVATION_MODIFIER", 147, 155], ["hypertension", "OBSERVATION", 156, 168], ["preeclampsia", "OBSERVATION", 173, 185]]]], "131276fce5681acc1232981163627299ba9d662c": [["Hong Kong is one of the richest cities in the world with an impressive GDP of USD 46,000, but with a large Gini coefficient of 0.537, and thus the issue of poverty deserves special attention.", [["impressive", "OBSERVATION_MODIFIER", 60, 70], ["large", "OBSERVATION_MODIFIER", 101, 106]]], ["The poverty line in Hong Kong is set at 50% of the medianBackgroundUntil 1997, Hong Kong was a British colony for more than 150 years (since 1842).", [["The poverty line", "TREATMENT", 0, 16], ["poverty line", "OBSERVATION", 4, 16]]], ["The social security system in Hong Kong was shaped by the laissez-faire philosophy under the previous colonial regime.", [["the previous colonial regime", "TREATMENT", 89, 117]]], ["Only the very needy and vulnerable families would receive support by the government.", [["very", "OBSERVATION_MODIFIER", 9, 13], ["needy", "OBSERVATION", 14, 19]]], ["Thus, Hong Kong's welfare system was perceived as a typical example of the residual model of welfare, which views the government welfare provision only as a last resort.", [["Hong Kong's welfare system", "TREATMENT", 6, 32]]], ["The laissez-faire philosophy and residual welfare model were also compatible with Chinese Confucian values, which emphasize filial piety, respect for older people, love for one's family, self-restraint, shouldering collective responsibility, mutual help, and so on.", [["people", "ORGANISM", 156, 162], ["people", "SPECIES", 156, 162], ["The laissez", "TREATMENT", 0, 11], ["residual welfare model", "PROBLEM", 33, 55], ["Chinese Confucian values", "PROBLEM", 82, 106], ["self-restraint", "TREATMENT", 187, 201], ["faire philosophy", "OBSERVATION", 12, 28]]], ["Under the principle of \"one country, two systems\", Hong Kong has enjoyed a high degree of autonomy and is responsible for its domestic affairs including tax system.", [["tax", "PROTEIN", 153, 156], ["high degree", "OBSERVATION_MODIFIER", 75, 86], ["autonomy", "OBSERVATION", 90, 98]]], ["The HKSAR government does not have to contribute any revenue towards the Central Government.", [["Central Government", "OBSERVATION", 73, 91]]], ["Since 1997, the government experienced 6 years of budget deficit, from 1998-1999 to [2004] [2005] , which was related to the 1997 Asian financial crisis and the 2003 Severe Acute Respiratory Syndrome (SARS) epidemic.", [["Acute Respiratory Syndrome", "DISEASE", 173, 199], ["SARS", "DISEASE", 201, 205], ["budget deficit", "PROBLEM", 50, 64], ["Severe Acute Respiratory Syndrome", "PROBLEM", 166, 199], ["epidemic", "PROBLEM", 207, 215], ["Severe", "OBSERVATION_MODIFIER", 166, 172], ["Acute", "OBSERVATION_MODIFIER", 173, 178], ["Respiratory Syndrome", "OBSERVATION", 179, 199]]], ["During this period, the low-income group suffered most from the two economic shocks.", [["low", "OBSERVATION_MODIFIER", 24, 27]]], ["The rising social welfare needs of low-income families greatly increased government spending, and consequently new social policies to expand and diversify the social welfare system had to be suspended [10] .BackgroundThe Comprehensive Social Security Assistance (CSSA) is the most important welfare program in Hong Kong.", [["rising", "OBSERVATION_MODIFIER", 4, 10]]], ["The applications of CSSA have to go through income and assets means tests.", [["CSSA", "CANCER", 20, 24], ["CSSA", "TREATMENT", 20, 24], ["assets means tests", "TEST", 55, 73]]], ["In the first year (i.e., 1993), the number of CSSA cases was 91,362 and the number of CSSA recipients was 121,060.", [["CSSA", "DISEASE", 46, 50], ["CSSA", "CANCER", 46, 50], ["CSSA cases", "TEST", 46, 56]]], ["The number of cases rapidly increased and reached a peak in the year 2005 (of 298,011); since then, it has steadily declined to 232,134 in 2017.", [["rapidly", "OBSERVATION_MODIFIER", 20, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["The number of recipients had a similar trend, with a dramatic increase in the years of 1997 of , 1998 of , 2002 of , and 2003 of .", [["recipients", "ORGANISM", 14, 24], ["number", "OBSERVATION_MODIFIER", 4, 10], ["similar", "OBSERVATION_MODIFIER", 31, 38], ["trend", "OBSERVATION_MODIFIER", 39, 44], ["dramatic", "OBSERVATION_MODIFIER", 53, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["Under the principle of \"one country, two systems\", Hong Kong has enjoyed a high degree of autonomy and is responsible for its domestic affairs including tax system.", [["tax", "PROTEIN", 153, 156], ["high degree", "OBSERVATION_MODIFIER", 75, 86], ["autonomy", "OBSERVATION", 90, 98]]], ["The HKSAR government does not have to contribute any revenue towards the Central Government.", [["Central Government", "OBSERVATION", 73, 91]]], ["Since 1997, the government experienced 6 years of budget deficit, from 1998-1999 to 2004-2005, which was related to the 1997 Asian financial crisis and the 2003 Severe Acute Respiratory Syndrome (SARS) epidemic.", [["Acute Respiratory Syndrome", "DISEASE", 168, 194], ["SARS", "DISEASE", 196, 200], ["budget deficit", "PROBLEM", 50, 64], ["Severe Acute Respiratory Syndrome", "PROBLEM", 161, 194], ["epidemic", "PROBLEM", 202, 210], ["Severe", "OBSERVATION_MODIFIER", 161, 167], ["Acute", "OBSERVATION_MODIFIER", 168, 173], ["Respiratory Syndrome", "OBSERVATION", 174, 194]]], ["During this period, the low-income group suffered most from the two economic shocks.", [["low", "OBSERVATION_MODIFIER", 24, 27]]], ["The rising social welfare needs of low-income families greatly increased government spending, and consequently new social policies to expand and diversify the social welfare system had to be suspended [10] .BackgroundThe Comprehensive Social Security Assistance (CSSA) is the most important welfare program in Hong Kong.", [["rising", "OBSERVATION_MODIFIER", 4, 10]]], ["The applications of CSSA have to go through income and assets means tests.", [["CSSA", "CANCER", 20, 24], ["CSSA", "TREATMENT", 20, 24], ["assets means tests", "TEST", 55, 73]]], ["In the first year (i.e., 1993), the number of CSSA cases was 91,362 and the number of CSSA recipients was 121,060.", [["CSSA", "DISEASE", 46, 50], ["CSSA", "CANCER", 46, 50], ["CSSA cases", "TEST", 46, 56]]], ["The number of cases rapidly increased and reached a peak in the year 2005 (of 298,011); since then, it has steadily declined to 232,134 in 2017.", [["rapidly", "OBSERVATION_MODIFIER", 20, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["The number of recipients had a similar trend, with a dramatic increase in the years of 1997 of , 1998 of , 2002 of , and 2003 of .", [["recipients", "ORGANISM", 14, 24], ["number", "OBSERVATION_MODIFIER", 4, 10], ["similar", "OBSERVATION_MODIFIER", 31, 38], ["trend", "OBSERVATION_MODIFIER", 39, 44], ["dramatic", "OBSERVATION_MODIFIER", 53, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["In 1997 of and 1998 , when the Asian financial crisis struck Hong Kong, the number of recipients had increased by 59,239 and 86,000, respectively.", [["recipients", "ORGANISM", 86, 96], ["increased", "OBSERVATION_MODIFIER", 101, 110]]], ["1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Number of CSSA cases and recipientsBackgroundYear case recipients Figure 2 shows the age composition of the recipients.", [["recipients", "ORGANISM", 233, 243]]], ["As shown, in 1993, those aged 60 and above accounted for almost 60% of recipients, whereas those aged 15-59 and under 15 occupied about 25% and 15%, respectively.", [["recipients", "ORGANISM", 71, 81]]], ["The proportion of recipients aged 0-59 initially rose continuously, reaching about 66% in 2004; since then, it has started to decline and the proportion was about 50% in 2017.", [["recipients", "ORGANISM", 18, 28]]], ["As the population continues to age rapidly due to low fertility and long life expectancy, the proportion of recipients aged 60 and above is expected to increase.", [["recipients", "ORGANISM", 108, 118], ["low fertility", "PROBLEM", 50, 63], ["low fertility", "OBSERVATION", 50, 63]]], ["Res. Public Health 2020, 17, 1305 4 of 15 Figure 2 shows the age composition of the recipients.", [["recipients", "ORGANISM", 84, 94]]], ["As shown, in 1993, those aged 60 and above accounted for almost 60% of recipients, whereas those aged 15-59 and under 15 occupied about 25% and 15%, respectively.", [["recipients", "ORGANISM", 71, 81]]], ["The proportion of recipients aged 0-59 initially rose continuously, reaching about 66% in 2004; since then, it has started to decline and the proportion was about 50% in 2017.", [["recipients", "ORGANISM", 18, 28]]], ["As the population continues to age rapidly due to low fertility and long life expectancy, the proportion of recipients aged 60 and above is expected to increase.", [["recipients", "ORGANISM", 108, 118], ["low fertility", "PROBLEM", 50, 63], ["low fertility", "OBSERVATION", 50, 63]]], ["Such a large share of spending on CSSA and its rate of increase have become a concern for the Hong Kong government, especially in the years of the Asian financial crisis and SARS epidemic, Such a large share of spending on CSSA and its rate of increase have become a concern for the Hong Kong government, especially in the years of the Asian financial crisis and SARS epidemic, Such a large share of spending on CSSA and its rate of increase have become a concern for the Hong Kong government, especially in the years of the Asian financial crisis and SARS epidemic, when the budget turned to a deficit.", [["SARS", "DISEASE", 174, 178], ["SARS", "DISEASE", 363, 367], ["SARS", "DISEASE", 552, 556], ["CSSA", "TREATMENT", 34, 38], ["the Asian financial crisis", "PROBLEM", 143, 169], ["SARS epidemic", "PROBLEM", 174, 187], ["CSSA", "TREATMENT", 223, 227], ["SARS epidemic", "PROBLEM", 363, 376], ["CSSA", "TREATMENT", 412, 416], ["SARS epidemic", "PROBLEM", 552, 565], ["a deficit", "PROBLEM", 593, 602], ["large", "OBSERVATION_MODIFIER", 7, 12], ["large", "OBSERVATION_MODIFIER", 196, 201], ["large", "OBSERVATION_MODIFIER", 385, 390]]], ["The government did take steps to control the expenditure on CSSA and balance their budget by reducing the value of CSSA payments and the number of recipients.", [["CSSA payments", "TREATMENT", 115, 128]]], ["Theoretically, reducing the number of recipients can be achieved either by preventing people from entering the CSSA system or helping them leave the system.", [["recipients", "ORGANISM", 38, 48], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["The \"entering approach\" often influences a relatively larger number of the population at risk of poverty, preventing \"potential candidates\" from falling into CSSA with more universal measures.", [["poverty", "DISEASE", 97, 104], ["falling into CSSA", "PROBLEM", 145, 162], ["relatively", "OBSERVATION_MODIFIER", 43, 53], ["larger", "OBSERVATION_MODIFIER", 54, 60]]], ["The universal measures often include minimum wage, universal health insurance, subsidized education, public housing, and so on, from which both CSSA recipients and non-CSSA people can benefit [13] .", [["people", "ORGANISM", 173, 179], ["people", "SPECIES", 173, 179]]], ["Under these schemes, any Hong Kong permanent resident aged 18 and above was eligible to get a lump-sum payment of HKD 6000 and HKD 4000 in 2011 and 2019, respectively.", [["HKD", "PROBLEM", 114, 117]]], ["In contrast, the \"leaving approach\" is more likely to affect a relative smaller group of people that are unemployed, in low-paid work, or single parents, helping them get out of the system with more focused measures.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["more likely", "UNCERTAINTY", 39, 50], ["smaller", "OBSERVATION_MODIFIER", 72, 79]]], ["The focused measures include single parent allowance, transportation subsidy for low-income families, job training programs for the unemployed, and so on [13] .BackgroundThe Hong Kong government seemed to have adopted an \"entering approach\" in the 2000s, but the specific means of preventing people from entering was controversial.", [["people", "ORGANISM", 292, 298], ["people", "SPECIES", 292, 298]]], ["This revision was mainly driven by concerns about the budget shortfall [14] .", [["This revision", "TREATMENT", 0, 13], ["revision", "OBSERVATION", 5, 13]]], ["This created a psychological hurdle for those physically able adults and made them turn away from CSSA voluntarily.", [["CSSA", "CANCER", 98, 102]]], ["Wong (2000) [9] argued that the image of \"laziness\" and \"dependency\" constructed (whether intentionally or unintentionally) for the CSSA recipients actually reflected \"a failure rather than a success in fighting against poverty\".", [["laziness", "DISEASE", 42, 50], ["the CSSA recipients", "PROBLEM", 128, 147], ["a failure", "PROBLEM", 168, 177]]], ["The CSSA is meant to provide timely help for those needy families such that they still can receive the necessary financial support while looking for employment.", [["financial support", "TREATMENT", 113, 130]]], ["It does not mean to create some dependence on the system, and those seeking help should not be stigmatized.", [["some dependence on the system", "PROBLEM", 27, 56], ["some", "OBSERVATION_MODIFIER", 27, 31], ["dependence", "OBSERVATION", 32, 42]]], ["Furthermore, it is always the children from CSSA families who would need more support to break up intergenerational poverty.BackgroundMeanwhile, it should be emphasized that \"welfare dependency\" is a very common problem that many social security systems would face or try to avoid [15] [16] [17] .", [["poverty", "DISEASE", 116, 123], ["children", "ORGANISM", 30, 38], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 281, 295], ["children", "SPECIES", 30, 38]]], ["When the incentives to take and sustain jobs are not strong enough, people would continue claiming benefits from the social security system as they are often more secure and attractive than employment; thus, it would create a culture of \"dependency\", \"laziness\", or \"worklessness\", leading to \"excessive and ineffective public expenditure\", as well as \"persistent and prevalent poverty\" [17] .", [["laziness", "DISEASE", 252, 260], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["a culture", "TEST", 224, 233], ["\"dependency\"", "PROBLEM", 237, 249], ["laziness", "PROBLEM", 252, 260], ["\"excessive and ineffective public expenditure\"", "PROBLEM", 293, 339]]], ["To reduce such \"welfare dependency\", an effective \"leaving approach\" may help to incentivize CSSA recipients to return to and survive in the labor market.", [["CSSA recipients", "TREATMENT", 93, 108]]], ["Very few studies have provided evidence for the \"entering approach\".", [["Very few studies", "TEST", 0, 16]]], ["Furthermore, without reducing the CSSA payment and restricting the eligibility, is there any better way to control the expenditure on CSSA?", [["the CSSA payment", "TREATMENT", 30, 46]]], ["Which group of people and in what approach should the government intervene so that the number of recipients can be effectively reduced?", [["people", "ORGANISM", 15, 21], ["recipients", "ORGANISM", 97, 107], ["people", "SPECIES", 15, 21]]], ["Specifically, by modelling the dynamics of the CSSA system in a Markov chain process and performing an elasticity analysis, we aimed to identify the potential target group and the group-specific approaches.", [["an elasticity analysis", "TEST", 100, 122]]], ["The findings can shed some light on how to enhance and optimize the social security system in Hong Kong.Data and MethodThe data required for the analysis included (1) the age-specific number of people who entered the CSSA system during 2014-2015, (2) the age-specific number of people who left the system during 2014-2015, (3) the age-specific population in 2014, and (4) the number of births by mothers in terms of age group in 2014.", [["people", "ORGANISM", 194, 200], ["people", "ORGANISM", 278, 284], ["people", "SPECIES", 194, 200], ["people", "SPECIES", 278, 284], ["the analysis", "TEST", 141, 153]]], ["On the basis of these data, we estimated the age-specific transition probabilities; that is, the probabilities of leaving CSSA and the probability of entering CSSA.", [["CSSA", "DISEASE", 159, 163]]], ["All of the data are from the Hong Kong Census and Statistics Department (HKC&SD).Data and MethodWe modelled the dynamic of people moving in and out of the CSSA system using a stochastic process (Markov chain process).", [["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129]]], ["This method has been increasingly used in labor economics and demographic research, especially in evaluating social policies [19] [20] [21] [22] [23] .", [["[19] [20] [21] [22]", "CHEMICAL", 125, 144], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 125, 149], ["demographic research", "TEST", 62, 82]]], ["Let x t be the proportion of CSSA recipients in the total population at time t.", [["Let", "GENE_OR_GENE_PRODUCT", 0, 3], ["CSSA recipients", "TREATMENT", 29, 44]]], ["Therefore, we can simply formulate the inflow and outflow of CSSA recipients in Equation (1).Data and Methodwhere A is a 2 \u00d7 2 matrix,Data and MethodThe proportion of CSSA recipients in the total population, x t+1 , can be reduced either through reducing the probability of entering CSSA, p t , or through increasing the probability of leaving CSSA, q t .", [["CSSA recipients", "TREATMENT", 61, 76], ["CSSA recipients", "TREATMENT", 167, 182]]], ["To investigate whether the former or the latter approach is more effective in reducing the number of CSSA recipients is of great importance to policymakers.Data and MethodIn order to answer this question, we introduced the concept of elasticity.", [["CSSA recipients", "TREATMENT", 101, 116]]], ["Elasticity is originally a concept in economics.", [["Elasticity", "DISEASE", 0, 10]]], ["The concept of elasticity has recently been adopted by some scholars to evaluate the targeting of policies, for example the targeting of family polices in Singapore, Taiwan, and Australia [21] [22] [23] .", [["elasticity", "OBSERVATION", 15, 25]]], ["The larger the elasticity, the more influential the parameter to x t+1 .", [["larger", "OBSERVATION_MODIFIER", 4, 10], ["elasticity", "OBSERVATION_MODIFIER", 15, 25]]], ["The elasticity with respect to p t and q t can be formulated as follows:Data and Method(2)Data and MethodBy comparing the absolute values of \u03b4 p t and \u03b4 q t , we will know whether the \"entering\" or \"leaving\" approach is more effective in reducing the number of CSSA recipients in a certain year.Data and MethodIn reality, the probability of leaving or entering the CSSA system often varies across different age and socioeconomic groups.", [["the absolute values", "TEST", 118, 137]]], ["As the data of CSSA recipients by socioeconomic status is not available, we cannot include the socioeconomic groups in our analysis.", [["CSSA recipients", "TREATMENT", 15, 30], ["our analysis", "TEST", 119, 131]]], ["Let xData and MethodIn this study, we restricted our attention to those aged below 60, because those CSSA recipients aged 60 and above have a high chance of leaving the CSSA system due to death.", [["death", "DISEASE", 188, 193], ["recipients", "ORGANISM", 106, 116], ["MethodIn this study", "TEST", 14, 33], ["death", "PROBLEM", 188, 193]]], ["According to the rules under the CSSA system, the newborns of a CSSA recipient will become CSSA recipients directly.", [["newborns", "ORGANISM", 50, 58], ["a CSSA recipient", "TREATMENT", 62, 78], ["CSSA recipients", "TREATMENT", 91, 106]]], ["On the basis of the assumptions that the birth rates of the CSSA recipients and non-CSSA people are the same, and that the births are from women aged 15-49, x (0) t and y (0) t can be formulated by Equation (5).Data and Methodare the corresponding age-specific birth rates at time t.", [["CSSA recipients", "ORGANISM", 60, 75], ["people", "ORGANISM", 89, 95], ["women", "ORGANISM", 139, 144], ["people", "SPECIES", 89, 95], ["women", "SPECIES", 139, 144]]], ["The goal of our analysis was to investigate which group should be targeted and in which approach of \"leaving\" or \"entering\", so that the overall proportion of CSSA recipients can have the largest reduction.", [["CSSA", "ORGANISM", 159, 163], ["recipients", "ORGANISM", 164, 174], ["our analysis", "TEST", 12, 24], ["CSSA recipients", "TREATMENT", 159, 174], ["largest", "OBSERVATION_MODIFIER", 188, 195], ["reduction", "OBSERVATION_MODIFIER", 196, 205]]], ["Let X denote the overall proportion of the CSSA recipients in the population aged under 60, which can be calculated from the following formula:Data and Methodwhere w (i) t refers to the proportion of the age group i in the total population aged under 60 at time t, and 59 i=0 wData and Methodt was estimated on the basis of the age-specific population in 2014 from HKC&SD.", [["Let X", "GENE_OR_GENE_PRODUCT", 0, 5], ["Let X", "DNA", 0, 5], ["the CSSA recipients", "TREATMENT", 39, 58], ["Methodt", "TEST", 286, 293]]], ["Equations (9) and (10) were used to estimate the probability and the mean time.Pr(leaving at agei) = 1 \u2212 1 \u2212 q (i) t 1 \u2212 q (i+1) t \u00b7 \u00b7 \u00b7 1 \u2212 q (59) t (9) Mean time = 1 \u00d7 q (i) t + 2 \u00d7 q (i+1) t \u00d7 1 \u2212 q (i) t + \u00b7 \u00b7 \u00b7 +(60 \u2212 i) \u00d7 q (59) t \u00d7 1 \u2212 q (58) t \u00b7 \u00b7 \u00b7 1 \u2212 q (i) t(10)ResultsThe estimated age-specific probabilities of entering and leaving the CSSA system are shown in Table 1 .", [["Equations", "TEST", 0, 9], ["\u00b7", "TEST", 135, 136], ["Mean time", "TEST", 154, 163], ["t", "TEST", 176, 177], ["\u00d7", "TEST", 194, 195], ["t", "TEST", 206, 207], ["The estimated age", "TEST", 280, 297]]], ["The probability of leaving was found to be much higher than the probability of entering across all the ages.", [["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["Except for the two youngest age groups, the probability of leaving CSSA declines with the increase of age, indicating the increasing difficulty of raising their income above the level of the threshold.", [["CSSA declines", "PROBLEM", 67, 80], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["increasing", "OBSERVATION_MODIFIER", 122, 132], ["difficulty", "OBSERVATION", 133, 143]]], ["On one hand, this declining trend may be due to the fact that the family size will increase with people's age, and thus it would become more difficult to move all the family members out of the CSSA system.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103], ["size", "OBSERVATION_MODIFIER", 73, 77]]], ["On the other hand, previous research shows that in Hong Kong, as men and women get older, particularly after age 30, upward mobility of earnings declines while downward mobility of earnings increases [25] .", [["men", "ORGANISM", 65, 68], ["women", "ORGANISM", 73, 78], ["men", "SPECIES", 65, 68], ["women", "SPECIES", 73, 78]]], ["Workers in the lowest income quintile are more likely to be trapped at the bottom, experiencing no earning mobility [25, 26] .", [["trapped", "OBSERVATION", 60, 67]]], ["Parents of children aged 10-19 are more likely to be older, in the 40s and 50s, and that is probably why the leaving probability of the 10-19 age group is lower and very close to that of the 40-49 and 50-59 age groups.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]], ["Regarding the probability of entering CSSA, the 0-9 and 10-19 age groups were found to be at the highest level-much higher than the other age groups.", [["CSSA", "TEST", 38, 42], ["higher", "OBSERVATION_MODIFIER", 116, 122]]], ["Once their parents' incomes fall below the threshold level of CSSA, they become CSSA recipients directly.", [["CSSA recipients", "TREATMENT", 80, 95]]], ["Hence, these young people are indirectly entering the CSSA system.", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25]]], ["Table 2 shows the probability of a CSSA recipient first exiting the system before age 60 and the mean duration of staying in the system.", [["a CSSA recipient", "TREATMENT", 33, 49]]], ["There was a significant decline in the probability of first exit after age 30.", [["a significant decline", "PROBLEM", 10, 31], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["decline", "OBSERVATION_MODIFIER", 24, 31]]], ["This is very consistent with the age pattern shown in Table 1 .", [["very consistent with", "UNCERTAINTY", 8, 28]]], ["The probability dropped to 0.73 for those aged 50 and 0.48 for those aged 55.", [["The probability", "TEST", 0, 15]]], ["Regarding the mean time of staying in the system, children under age 15 were found to have the longest duration.", [["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58]]], ["On the basis of the age-specific probability of entering and leaving CSSA, we performed the elasticity analysis.", [["the elasticity analysis", "TEST", 88, 111]]], ["The results (in absolute values) are shown in Table 3 increased by 0.1, the overall proportion of CSSA recipients would decrease by 0.0012 (= 0.012 \u00d7 0.1).", [["CSSA recipients", "TREATMENT", 98, 113], ["decrease", "OBSERVATION_MODIFIER", 120, 128]]], ["From these results, it seems that preventing people aged 20-29 from entering the CSSA system has a larger impact; that is, the \"entering\" approach would be more effective in reducing the number of CSSA recipients in 2014.ResultsHowever, it should be noted that it is impossible and unrealistic to achieve a decrease of 0.1 in pResultsis only 0.0015 and a decrease of 0.1 will make it negative. in reducing the number of CSSA recipients; for the 10-19 and 20-29 age group, helping the CSSA recipients leave the system will have a larger impact (see the last column in Table 3 ).", [["people", "ORGANISM", 45, 51], ["recipients", "ORGANISM", 489, 499], ["people", "SPECIES", 45, 51], ["CSSA recipients", "TREATMENT", 197, 212], ["CSSA recipients", "TREATMENT", 420, 435], ["the CSSA recipients", "TREATMENT", 480, 499], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["impact", "OBSERVATION", 106, 112], ["decrease", "OBSERVATION_MODIFIER", 307, 315], ["negative", "OBSERVATION", 384, 392], ["number", "OBSERVATION_MODIFIER", 410, 416], ["CSSA recipients", "OBSERVATION", 420, 435]]], ["In sum, these results suggest that targeting the age group of 30-49 through the \"entering approach\" would lead to the greatest reduction in the number of CSSA recipients, as aiming at this group would also effectively prevent those aged 0-9 from entering the CSSA system.DiscussionsThis study investigated the targeting of the social security system in Hong Kong by evaluating the CSSA scheme, which is the fundamental welfare program.", [["CSSA recipients", "TREATMENT", 154, 169], ["This study", "TEST", 282, 292], ["greatest", "OBSERVATION_MODIFIER", 118, 126], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["CSSA recipients", "OBSERVATION", 154, 169]]], ["We have made use of the Markov chain process to model the dynamics-the inflow and outflow-of the CSSA system.", [["the Markov chain process", "TREATMENT", 20, 44], ["inflow", "ANATOMY_MODIFIER", 71, 77], ["outflow", "ANATOMY_MODIFIER", 82, 89]]], ["The results have revealed that the largest elasticity was in the 0-9 age group, meaning that targeting children at this age will lead to a largest decrease in the number of CSSA recipients.", [["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["a largest decrease", "PROBLEM", 137, 155], ["CSSA recipients", "TREATMENT", 173, 188], ["largest", "OBSERVATION_MODIFIER", 35, 42], ["elasticity", "OBSERVATION_MODIFIER", 43, 53], ["largest", "OBSERVATION_MODIFIER", 139, 146], ["decrease", "OBSERVATION_MODIFIER", 147, 155]]], ["Currently, child poverty is a serious issue in Hong Kong.", [["poverty", "DISEASE", 17, 24]]], ["In 2017, before government intervention, the poverty rate among children aged below 18 was about 23.1%, much higher than many other developed societies [2,27].", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["government intervention", "TREATMENT", 16, 39], ["the poverty rate", "TEST", 41, 57]]], ["As child poverty often results from parents' low income and unemployment, policies that support households with children would be desirable.", [["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120]]], ["More precisely speaking, the results suggest that targeting those aged 30-49 with children by decreasing the risk of entering CSSA would have the largest impact on the number of CSSA recipients.DiscussionsStudies on child poverty in Hong Kong have found that family structure is a strong predictor.", [["CSSA", "DISEASE", 126, 130], ["children", "ORGANISM", 82, 90], ["CSSA", "CANCER", 126, 130], ["children", "SPECIES", 82, 90], ["CSSA recipients", "TREATMENT", 178, 193], ["largest", "OBSERVATION_MODIFIER", 146, 153]]], ["It was found that children from immigrant families are more likely to live below the poverty line in Hong Kong due to low education of parents, high unemployment rate of mothers, and low payment of parents' jobs [28] .", [["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26]]], ["Moreover, children living with single parents have high risk of poverty; the poverty gap between children with single parents and children with two parents has been widening in recent decades [29] .", [["poverty", "DISEASE", 64, 71], ["children", "ORGANISM", 10, 18], ["children", "ORGANISM", 97, 105], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 10, 18], ["children", "SPECIES", 97, 105], ["children", "SPECIES", 130, 138], ["widening", "OBSERVATION_MODIFIER", 165, 173]]], ["Poverty is found to have a significant impact on children's psychological well-being-in Hong Kong, children in poverty have reported lower levels of self-esteem and more depressive symptoms, and they are more likely to live in public housing which is often more crowded, having poor hygiene and lack of facilities [31] .", [["Poverty", "DISEASE", 0, 7], ["depressive symptoms", "DISEASE", 170, 189], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 99, 107], ["more depressive symptoms", "PROBLEM", 165, 189], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["As shown in Table 3 , the elasticity to the probability of leaving in the 20-29 age group \u03b4 q (20\u221229) t was 0.109, meaning that given 1% increase in the probability of leaving (i.e., an increase of 1% \u00d7 0.2103), the proportion of CSSA recipients would reduce by 0.109%.DiscussionsThe elasticity to the probability of entering the group \u03b4 p (20\u221229) t \u00d7 was 0.04, meaning that given a 1% decrease in the probability of entering (i.e., a decrease of 1% \u00d7 0.0015), the proportion of CSSA recipients would reduce by 0.04%.", [["CSSA recipients", "TREATMENT", 230, 245], ["CSSA recipients", "TREATMENT", 479, 494]]], ["As shown in Figure 5 , the elasticities of the leaving probabilities decline with age, implying that the \"leaving approach\" is more effective in younger age groups than in older groups, as the employability of young people is much higher than their older counterparts and earning a salary through employment is the most effective way to leave the CSSA system.", [["people", "ORGANISM", 216, 222], ["people", "SPECIES", 216, 222]]], ["The elasticities of entering probabilities also showed a decreasing trend over ages, although the 20-29 and 50-59 age groups had the lowest elasticities.", [["decreasing", "OBSERVATION_MODIFIER", 57, 67], ["trend", "OBSERVATION_MODIFIER", 68, 73], ["lowest elasticities", "OBSERVATION", 133, 152]]], ["This means that the \"entering approach\" for these two groups is relatively less effective than in other age groups.", [["less", "OBSERVATION_MODIFIER", 75, 79], ["effective", "OBSERVATION_MODIFIER", 80, 89]]], ["The age pattern of the elasticities showed that targeting younger age groups would make a larger difference than targeting older groups.", [["larger", "OBSERVATION_MODIFIER", 90, 96]]], ["Furthermore, elasticities of entering probabilities were larger than leaving probabilities in the 0-9, 30-39, and 40-49 age groups, whereas the opposite pattern was shown in the 10-19 and 20-29 age group.", [["larger", "OBSERVATION_MODIFIER", 57, 63]]], ["These findings inform us that for the 0-9, 30-39, and 40-49 age group, preventing them from entering the CSSA system would be more effective in reducing the number of CSSA recipients; for the 10-19 and 20-29 age group, helping the CSSA recipients leave the system will have a larger impact (see the last column in Table 3 ).", [["recipients", "ORGANISM", 236, 246], ["CSSA recipients", "TREATMENT", 167, 182], ["the CSSA recipients", "TREATMENT", 227, 246]]], ["In sum, these results suggest that targeting the age group of 30-49 through the \"entering approach\" would lead to the greatest reduction in the number of CSSA recipients, as aiming at this group would also effectively prevent those aged 0-9 from entering the CSSA system.DiscussionsThis study investigated the targeting of the social security system in Hong Kong by evaluating the CSSA scheme, which is the fundamental welfare program.", [["CSSA recipients", "TREATMENT", 154, 169], ["This study", "TEST", 282, 292], ["greatest", "OBSERVATION_MODIFIER", 118, 126], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["CSSA recipients", "OBSERVATION", 154, 169]]], ["We have made use of the Markov chain process to model the dynamics-the inflow and outflow-of the CSSA system.", [["the Markov chain process", "TREATMENT", 20, 44], ["inflow", "ANATOMY_MODIFIER", 71, 77], ["outflow", "ANATOMY_MODIFIER", 82, 89]]], ["The results have revealed that the largest elasticity was in the 0-9 age group, meaning that targeting children at this age will lead to a largest decrease in the number of CSSA recipients.", [["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["a largest decrease", "PROBLEM", 137, 155], ["CSSA recipients", "TREATMENT", 173, 188], ["largest", "OBSERVATION_MODIFIER", 35, 42], ["elasticity", "OBSERVATION_MODIFIER", 43, 53], ["largest", "OBSERVATION_MODIFIER", 139, 146], ["decrease", "OBSERVATION_MODIFIER", 147, 155]]], ["Currently, child poverty is a serious issue in Hong Kong.", [["poverty", "DISEASE", 17, 24]]], ["In 2017, before government intervention, the poverty rate among children aged below 18 was about 23.1%, much higher than many other developed societies [2, 27] .", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["government intervention", "TREATMENT", 16, 39], ["the poverty rate", "TEST", 41, 57]]], ["As child poverty often results from parents' low income and unemployment, policies that support households with children would be desirable.", [["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120]]], ["More precisely speaking, the results suggest that targeting those aged 30-49 with children by decreasing the risk of entering CSSA would have the largest impact on the number of CSSA recipients.DiscussionsStudies on child poverty in Hong Kong have found that family structure is a strong predictor.", [["CSSA", "DISEASE", 126, 130], ["children", "ORGANISM", 82, 90], ["CSSA", "CANCER", 126, 130], ["children", "SPECIES", 82, 90], ["CSSA recipients", "TREATMENT", 178, 193], ["largest", "OBSERVATION_MODIFIER", 146, 153]]], ["It was found that children from immigrant families are more likely to live below the poverty line in Hong Kong due to low education of parents, high unemployment rate of mothers, and low payment of parents' jobs [28] .", [["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26]]], ["Moreover, children living with single parents have high risk of poverty; the poverty gap between children with single parents and children with two parents has been widening in recent decades [29] .", [["poverty", "DISEASE", 64, 71], ["children", "ORGANISM", 10, 18], ["children", "ORGANISM", 97, 105], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 10, 18], ["children", "SPECIES", 97, 105], ["children", "SPECIES", 130, 138], ["widening", "OBSERVATION_MODIFIER", 165, 173]]], ["Poverty is found to have a significant impact on children's psychological well-being-in Hong Kong, children in poverty have reported lower levels of self-esteem and more depressive symptoms, and they are more likely to live in public housing which is often more crowded, having poor hygiene and lack of facilities [31] .", [["Poverty", "DISEASE", 0, 7], ["depressive symptoms", "DISEASE", 170, 189], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 99, 107], ["more depressive symptoms", "PROBLEM", 165, 189], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["Food insecurity, as well as limited educational opportunities and learning resources would have a negative impact on the development of children from poor families, creating intergenerational poverty in Hong Kong [32] .", [["children", "ORGANISM", 136, 144], ["children", "SPECIES", 136, 144]]], ["Therefore, it is very important to identify the reasons of falling into the CSSA system and barriers to exit among households with children.DiscussionsSingle parenthood, unemployment, and low-earnings are the major reasons for physically-able adults becoming CSSA recipients.", [["children", "ORGANISM", 131, 139], ["adults", "ORGANISM", 243, 249], ["children", "SPECIES", 131, 139], ["CSSA recipients", "TREATMENT", 259, 274]]], ["The latest poverty study in 2017 shows that poverty among those who are working was only 4.9% in comparison to 14.7% in the general community [2].", [["poverty", "DISEASE", 44, 51], ["The latest poverty study", "TEST", 0, 24]]], ["Providing jobs and enhancing job earnings for the age group of 30-49 would effectively reduce the number of CSSA recipients.", [["CSSA recipients", "TREATMENT", 108, 123]]], ["The Hong Kong government has initiated the Public Transport Fare Subsidy Scheme to enhance people's ability to look for employment across districts [33] .", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97]]], ["The government also provides additional support for families-especially single-parent families-to work part-time and look after their children after work.", [["children", "ORGANISM", 134, 142], ["children", "SPECIES", 134, 142]]], ["Of course, the employment remuneration conditions should be improved so that working parents can earn enough to support the family without the need of CSSA.", [["CSSA", "CANCER", 151, 155], ["CSSA", "TREATMENT", 151, 155]]], ["In many western countries, the minimum wage is substantially higher (e.g., USD 13.3 in Australia, USD 10.3 in the United Kingdom), despite the fact that Hong Kong's GDP per capita of USD 49,000 actually ranks higher.", [["GDP", "CHEMICAL", 165, 168], ["GDP", "SIMPLE_CHEMICAL", 165, 168]]], ["It is found that for the 10-29 age groups, policies that aim to help people leave CSSA will be more effective than policies that aim to prevent people from entering CSSA.", [["CSSA", "DISEASE", 165, 169], ["people", "ORGANISM", 69, 75], ["people", "ORGANISM", 144, 150], ["people", "SPECIES", 69, 75], ["people", "SPECIES", 144, 150], ["CSSA", "TREATMENT", 82, 86]]], ["According to the Hong Kong Poverty Situation Report 2017, the unemployment rate among the young people 15-29 is relatively higher than the general population.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["the unemployment rate", "TEST", 58, 79]]], ["By upgrading working skills of young CSSA recipients, young adults can enhance their employability and secure jobs with better earnings, so that they can support themselves without CSSA.", [["CSSA", "DISEASE", 181, 185], ["adults", "ORGANISM", 60, 66]]], ["Diversifying the economic and working opportunities is also of great importance in improving the employability of our young people.", [["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130]]], ["The excessive rental cost in Hong Kong has been found to be a barrier for young people to start their own business.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["excessive", "OBSERVATION_MODIFIER", 4, 13], ["rental cost", "OBSERVATION", 14, 25]]], ["It is important for the government to provide initial support for these young entrepreneurs at the early stage of their career development.", [["initial support", "TREATMENT", 46, 61]]], ["Meanwhile, for the 30-59 age groups, policies that aim to prevent people from entering CSSA will be more effective than policies that aim to help people leave CSSA.", [["CSSA", "DISEASE", 159, 163], ["people", "ORGANISM", 66, 72], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 66, 72], ["people", "SPECIES", 146, 152]]], ["People of these ages often have other family members to care for, either young children or old parents, and sometimes both.", [["People", "ORGANISM", 0, 6], ["children", "ORGANISM", 79, 87], ["People", "SPECIES", 0, 6], ["children", "SPECIES", 79, 87]]], ["More often, they have jobs but the earnings are not adequate to cover the living expense of the whole family, and thus all members in the household become CSSA recipients.", [["CSSA recipients", "TREATMENT", 155, 170]]], ["In this case, policies that can increase the family income can prevent them from entering CSSA.", [["CSSA", "DISEASE", 90, 94]]], ["We should try to maintain or enhance the employability of these groups of people as a matter of importance.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80]]], ["Hong Kong still has one of the largest poverty gaps among the high income societies with a Gini coefficient of 0.54 [2] .", [["largest", "OBSERVATION_MODIFIER", 31, 38], ["high", "OBSERVATION_MODIFIER", 62, 66]]], ["The minimum hourly wage is HKD 37.5 (USD 4.8), which is one of the lowest in comparison to other OECD (i.e., The Organization for Economic Co-operation and Development) countries.", [["HKD", "TEST", 27, 30], ["USD", "TEST", 37, 40], ["Economic Co-operation", "TREATMENT", 130, 151], ["minimum", "OBSERVATION_MODIFIER", 4, 11]]], ["Currently, the Individual-based Work Incentive Transport Subsidy (I-WITS), to some extent, can help middle-aged adults broaden their horizons for better job opportunities across the whole territory [33] .", [["adults", "ORGANISM", 112, 118]]], ["In addition, the Working Family Allowance can provide extra income to households with children.", [["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94]]], ["It should be emphasized that the probability of entering and leaving CSSA, as well the elasticities with respect to these probabilities, should be monitored frequently and closely so that a more timely response can be in place to improve the efficiency of CSSA.DiscussionsIn spite of the positives, there are some limitations in this study.", [["CSSA", "DISEASE", 256, 260], ["CSSA", "TREATMENT", 69, 73], ["CSSA", "PROBLEM", 256, 260], ["this study", "TEST", 329, 339]]], ["Future research can assess the role of different socioeconomic subgroups in reducing the number of CSSA recipients, with better data access.", [["CSSA recipients", "TREATMENT", 99, 114]]], ["The number of female CSSA recipients was found to often be larger than male recipients, which is mainly the contribution of women's overrepresentation in the \"single-parent\" case under CSSA [34] .", [["recipients", "ORGANISM", 26, 36], ["women", "ORGANISM", 124, 129], ["women", "SPECIES", 124, 129], ["larger", "OBSERVATION_MODIFIER", 59, 65]]], ["For example, in 2017, 87.6% of single-parent recipients were female, most of whom were divorced or separated, in the age of 30-49 [35] .", [["recipients", "ORGANISM", 45, 55]]], ["However, due to a lack of gender-specific data, we were unable to examine whether the elasticities were different between men and women, and how big the difference was.", [["men", "ORGANISM", 122, 125], ["women", "ORGANISM", 130, 135], ["men", "SPECIES", 122, 125], ["women", "SPECIES", 130, 135]]], ["Third, we only restricted our analysis to those under age 60 and did not consider the elderly population due to limited information of the elderly people leaving CSSA because of death.", [["CSSA", "DISEASE", 162, 166], ["death", "DISEASE", 178, 183], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["death", "PROBLEM", 178, 183]]], ["Fourth, the Markov chain and elasticity analyses were based on several assumptions (e.g., assumption of the same birth rates between CSSA recipients and non-CSSA people), and consequently they did not fully model the exact dynamics of the CSSA system.", [["people", "SPECIES", 162, 168], ["elasticity analyses", "TEST", 29, 48], ["Markov chain", "OBSERVATION", 12, 24]]], ["However, this method is still a very useful tool to assess the targeting of the social security system and it can be further elaborated if more information about the CSSA recipients and employment data is available.ConclusionsThe propose model provides empirical evidence to identify the potential target groups of people that would lead to the largest reduction in the number of the CSSA recipients in the Hong Kong Social Security System.", [["people", "ORGANISM", 315, 321], ["people", "SPECIES", 315, 321], ["the CSSA recipients", "TREATMENT", 162, 181], ["employment data", "TEST", 186, 201], ["largest", "OBSERVATION_MODIFIER", 345, 352], ["reduction", "OBSERVATION_MODIFIER", 353, 362]]], ["This analytical method has also revealed whether policies would be more effective in preventing people from entering the CSSA system or helping them leave the CSSA scheme.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102]]], ["Poverty and income inequality have become one of the major causes of the recent months of social unrest in Hong Kong in 2019-2020.", [["Poverty", "DISEASE", 0, 7]]], ["The Government has been increasing its expenditure on welfare spending.", [["increasing", "OBSERVATION_MODIFIER", 24, 34]]], ["Our model can be used as a tool to examine its effectiveness of any poverty program with the aim to reduce the number of CSSA recipients.ConclusionsAuthor Contributions: Manuscript preparation and data analysis-M.C., B.K.S., K.F.L. and K.P.W.; leading the investigation as the PI for the project, critical review and final approval of the paper-P.Y. All authors have read and agreed to the published version of the manuscript.ConclusionsFunding: This research was funded by The Hong Kong Government: SPPR-12.", [["any poverty program", "TREATMENT", 64, 83], ["CSSA recipients", "TREATMENT", 121, 136], ["data analysis", "TEST", 197, 210], ["the investigation", "TEST", 252, 269]]]]}